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ABSTRACT 
 
Type two diabetes mellitus (T2D) is a significant cause of premature death and disability, accompanied 
with negative socio-economic impacts. This metabolic disorder is characterized by hyperglycaemia and 
defective insulin signalling. Long-term exposure to hyperglycaemia gives rise to altered fat metabolism 
and reactive oxygen species (ROS) generation. These precursors are central to the progression of 
dyslipidaemia and attenuated antioxidant (AO) response and detoxification system, respectively. Diabetic 
dyslipidaemia and oxidative stress (OS) are risk factors for the onset and progression of cardiovascular 
disease (CVD) and other diabetic complications. The treatment regimen for T2D comprises self-care and 
anti-diabetic drugs such as metformin. However, due to the lack of compliance to self-care 
recommendations and some undesirable side effects of metformin, there is the necessity for alternate 
therapy. 
 
Natural products have been used for the treatment of many disorders, including T2D. Trigonella foenum-
graecum commonly known as fenugreek is a plant that possesses anti-diabetic effects. These effects are 
attributed to its bioactive compound – 4-hydroxyisoleucine (4-OH-lle), which constitutes approximately 
80% of the bio-composition of the fenugreek seed. Despite these effects, biochemical and molecular 
effects of 4-OH-lle on insulin signalling, lipid metabolism, and ROS production is not well-documented. 
This study investigated the effects of 4-OH-lle in comparison to metformin and fenugreek seed extract 
(FSE) on hyperglycaemic human hepatoma (HepG2) cells and C57BL/6 male mice. Treatments were 
conducted under normoglycaemic and hyperglycaemic conditions as follows; control, 4-OH-lle (in vitro: 
100ng/ml; in vivo: 100mg/kg Body weight) metformin (in vitro: 20mM; in vivo: 20mg/kg Body weight) 
and FSE (in vitro: 100ng/ml; in vivo: 100mg/kg Body weight) treatment groups. The experiments 
included; blood glucose measurements, lipid profile analysis, spectrophotometric assays (in vitro), 
western blotting for protein expression and qPCR for mRNA expression.   
 
First, to validate the effects on insulin signalling and glucose sensing, glucose levels were measured with 
completion of an oral glucose tolerance test. 4-OH-lle treatment attenuated glucose levels, and elevated 
the mRNA levels of glycogen synthase (GS) and glucokinase (Gck). This was followed by the 
investigation of the protein and gene expression of insulin signalling regulators: insulin receptor β (IRβ), 
insulin receptor substrate 1 (IRS1), phosphorylated protein kinase B (pAkt), phosphorylated glycogen 
synthase kinase 3α/β (pGSK3α/β) and glucose transport 2 (GLUT2). In in vivo hyperglycaemia, 4-OH-lle 
increased the expression of the investigated proteins and genes. The results showed that 4-OH-lle was just 
as potent as MF, and FSE in stimulating the insulin signalling cascade. 
xvii 
 
Second, the effect of 4-OH-lle on dyslipidaemia was investigated by measuring mRNA levels of sterol 
regulatory binding element 1c (SREBP1c) and fatty acid synthase (FAS) – key factors in fatty acid 
metabolism. Both genes were up-regulated and correlated with the changes in triglyceride and cholesterol 
levels. Next the protein expression of proprotein convertase subtilisin-like/kexin type (PCSK9) - a 
regulator of low density lipoprotein cholesterol (LDLc) and peroxisome proliferator-activated receptor 
gamma (PPARG) – a regulator of high density lipoprotein (HDLc) was evaluated. The data showed that 
4-OH-lle down-regulated protein and mRNA expression of PCSK9 and up-regulated protein expression 
of PPARG. The reduction in PCSK9 levels correlated with the changes observed in low density 
lipoprotein receptor (LDLr) and LDLc, whereas the increase in PPARG correlated with the elevated 
mRNA expression of apolipoprotein A1 (Apo A1) and HDLc. Together these results provide substantial 
evidence for the regulatory effect of 4-OH-lle, in comparison to metformin, and FSE on PCSK9, PPARG 
and related lipid factors. 
 
Finally, the effect of 4-OH-lle on redox status and AO response was assessed by measuring nuclear factor 
E2-related factor 2 (Nrf2). In both models, there was an increase in the protein expression of 
phosphorylated Nrf2 accompanied by an increase in mRNA levels of superoxide dismutase 2 (SOD2) and 
glutathione peroxidase (GPx), and GSH levels. Mitochondria play a central role in contributing to 
elevated ROS levels. While nuclear responses like Nrf2 regulate ROS, mitochondria possess their own 
maintenance proteins. These include mitochondrial Lon protease 1 (LonP1), Sirtuin 3 (SIRT3) and 
peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) which play an integral 
role in combatting OS and mitochondrial dysfunction. The results showed that 4-OH-lle displayed a 
potent effect in inducing the AO response and increasing mitochondrial regulatory proteins. 
 
In conclusion, 4-OH-lle improved the compromised insulin signalling and the altered lipid profile as well 
as induced the AO response and mitochondrial maintenance proteins, in the presence of elevated glucose. 
Furthermore, the effect of 4-OH-lle was greater than the first-line drug; metformin and FSE, albeit in 
cultured human liver cells and a mouse model. Also, the crude seed extract displayed promising effects on 
all investigated parameters. Considering the active role of chronic hyperglycaemia in the onset and 
progression of CVD and diabetic complications, 4-OH-lle poses as a highly favourable alternate therapy 
in the treatment of T2D. Moreover, this has great importance in socio-economically challenged 
communities where T2D is a common disorder, access to healthcare facilities is limited, and plants serve 
as sources of easily accessible treatments.
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 1 
CHAPTER ONE 2 
INTRODUCTION 3 
 4 
Type 2 diabetes mellitus (T2D) is a chronic, progressive disorder attributed to exacerbated levels of 5 
blood glucose. Chronic hyperglycaemia observed in affected individuals’ increases the risk of defective 6 
insulin signalling, resulting in insulin resistance. T2D poses a global healthcare problem and has been 7 
listed amongst the four priority non-communicable diseases (NCDs) (WHO 2016). Globally in 2014, 8 
approximately 422 million individuals were diagnosed with diabetes mellitus (DM), in comparison to 108 9 
million individuals in 1980 (WHO 2016). Evidence shows that the incidence of DM has almost doubled 10 
since 1980, escalating from 4.7 to 8.5% in the mature population (WHO 2016). In 2015 the international 11 
diabetes federation (IDF) reported 2.28 million cases (7% of adults’ aged 21 to 79) of DM in South 12 
Africa, however, a significant number of these individuals remain undiagnosed (The International 13 
Diabetes Federation 2015). DM and its complications result in a considerable economic loss to affected 14 
individuals and their relatives, healthcare systems and national economies. The socio-economic impact of 15 
T2D has pushed the biochemical and molecular investigations of this disorder to the forefront of medical 16 
research. 17 
 18 
The main contributors to the development of T2D are excessive calorie consumption and sedentary 19 
lifestyles. In addition, individuals who are genetically predisposed to this disorder are considered high 20 
risk (WHO 2016). Rapid urbanization has exposed South Africans to high caloric diets and processed 21 
foods which contribute to increased rates of T2D. Intense advertising food campaigns, non-conducive 22 
physical activity environments and lack of interest by the government further exacerbates the problem. 23 
The healthcare system provides comprehensive facilities for DM prevention and care but these facilities 24 
are not commonly implemented (WHO 2016). This could be the consequence of a lack of funds or 25 
maladministration, resulting in poor treatment. Furthermore, the public sector is known for shortages of 26 
drugs, and improved treatments with minimal side effects has yet to be discovered. In addition to drug 27 
shortages, high treatment costs in both public and private sectors are also contributing factors (WHO 28 
2016). A key impediment to successful T2D therapy is the lack of inexpensive insulin, ultimately 29 
resulting in diabetic complications and premature deaths (WHO 2016). It has been reported that oral 30 
hypoglycaemic agents, as well as insulin, are only obtainable in a minority of low-income countries. 31 
Moreover, medicines that are critical to controlling DM as well as its complications, are often 32 
inaccessible in both low and middle-income nations (WHO 2016).  33 
 34 
2 
 
The liver is the metabolic hub of the body and central to glucose metabolism. Hepatic insulin signalling is 35 
fundamental for metabolic processes such as gluconeogenesis, glycogen storage and recruitment of 36 
glucose transporters (GLUT) (Leturque et al. 2009). Insulin signalling is regulated by insulin receptor 37 
(IR) which is responsible for the phosphorylation and stimulation of insulin receptor substrate (IRS). This 38 
activation is crucial for the integration of extracellular signals into intracellular responses (Copps et al. 39 
2016). These intracellular responses include the stimulation of protein kinase B (Akt) which potentiates 40 
the phosphorylation of glycogen synthase kinase 3α/β (GSK3α/β), and recruitment of GLUT2. During 41 
T2D, compromised IR signalling and accompanied downstream events lead to insulin resistance, resulting 42 
in the disruption of the body’s physiological response to hyperglycaemia. Consequently, attenuating 43 
hyperglycaemia and targeting defective IR signalling is central in maintaining glucose homeostasis.  44 
 45 
Following defective insulin signalling, hyperglycaemia induces the over-production of free fatty acids 46 
(FFA), resulting in an abnormal lipid profile; termed dyslipidaemia. Diabetic dyslipidaemia is 47 
characterised by reduced plasma levels of high density lipoprotein (HDL) and elevated low density 48 
lipoprotein (LDL), and triglycerides (TG) (Mullugeta et al. 2012). Restoration of plasma lipoproteins 49 
involve targeting abnormal LDL cholesterol (c) and HDL cholesterol (c) levels. New advancements in 50 
lipid-lowering agents has focused on regulators of proprotein convertase subtilisin/kexin type 9 (PCSK9) 51 
and agonists of peroxisome proliferator-activated receptor gamma (PPARG). PCSK9 functions as an LDL 52 
receptor (LDLr) inhibitor, targeting the receptor for lysosomal degradation (Burke et al. 2017). Therefore, 53 
a reduction in PCSK9, increases the LDLr pool ultimately reducing LDLc. PPARG agonists positively 54 
regulate PPARG expression, which in turn increases HDLc levels (Gervois et al. 2000). In T2D, diabetic 55 
dyslipidaemia poses a risk for the progression of atherosclerosis and subsequent cardiovascular disease 56 
(CVD). As a result, targeting both PCSK9 and PPARG could serve as prospective therapeutic 57 
interventions in T2D therapy. 58 
 59 
The cytotoxic effects of hyperglycaemia are further exacerbated by excessive reactive oxygen species 60 
(ROS) production, causing a redox imbalance termed oxidative stress (OS). T2D individuals are 61 
negatively affected by OS, which is important in the onset and progression of CVD and diabetic 62 
complications (Baynes 1991). Uncontrolled ROS production impairs the antioxidant (AO) response and 63 
detoxification system, elevates protein glycosylation and promotes mitochondrial dysfunction (Baynes 64 
1991). Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator in controlling the expression 65 
of AO defence proteins (Allard et al. 2016). Activated Nrf2 directly impacts the expression of 66 
cytoprotective genes: mitochondrial superoxide dismutase 2 (SOD2) and glutathione peroxidase (GPx), 67 
and non-enzymatic AO: reduced glutathione (GSH) (Giralt and Villarroya 2012, Dinkova-Kostova and 68 
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Abramov 2015). In addition to hyperglycaemic-induced ROS, mitochondria are also accountable for 69 
elevating ROS production via oxidative phosphorylation. Mitochondria possess Lon protease 1 (LonP1) 70 
which proteolytically clears glycosylated proteins, that ultimately forming advanced glycation end-71 
products (AGEs) (Pomatto et al. 2017). Another mitochondrial regulatory pathway involves NAD-72 
dependent deacetylase Sirtuin 3 (SIRT3) that target proteins required for energy metabolism and the rate 73 
of ROS production (Buler et al. 2012, Giralt and Villarroya 2012). This deacetylase activates peroxisome 74 
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) which sequentially induces the ROS-75 
detoxifying gene- SOD2 and drives mitochondrial biogenesis (Kong et al. 2010). Accordingly, controlling 76 
defective insulin signalling and hyperglycaemia is central to regulating dyslipidaemia, and OS which is 77 
essential in managing CVD and diabetic complications. 78 
 79 
The T2D regimen comprises of both self-care and anti-diabetic drugs. Self-care includes physical activity, 80 
no smoking, weight loss, diabetic diet and nutritional counselling. Following the failure of self-care 81 
treatment, the use of anti-diabetic drugs is the next line of treatment. Anti-diabetic drugs include multiple 82 
classes and their selection is dependent on the severity of DM and accompanying factors. T2D treatment 83 
include agents that raise insulin secretion in the pancreas, promote the sensitivity of specific organs to 84 
insulin and reduce glucose absorption rate in the gastrointestinal tract (GIT) (Haupt et al. 1991, Hermann 85 
et al. 1991, Owen et al. 2000). These agents are grouped into the following classes: alpha-glucosidase 86 
inhibitors, glycosurics, peptide analogs, sensitizers and secretagogues. The widely used first-line drug for 87 
treatment metformin (MF) belongs to the sensitizer group of drugs. This oral hypoglycaemic agent 88 
reduces hepatic glucose output and improves tissue sensitivity to insulin (Anisimov 2013). Although 89 
highly effective, MF is associated with some undesirable side effects such as dizziness, diarrhoea, and 90 
nausea and/or vomiting (Hermann 1979, Siavash et al. 2017). Consequently, poor self-care and the 91 
shortfalls of first-line therapy urges the requisite for complementary or alternate medicine for the 92 
treatment of T2D.  93 
 94 
The National Centre for Complementary and Alternative Medicine propose natural products for the 95 
possible treatment of T2D. Several studies support the use of various plants for their glucose lowering 96 
effects such as: bitter melon, fenugreek, gymnema, ginseng, prickly pear cactus and tronadora (Shapiro 97 
and Gong 2002, Tundis et al. 2010, Rios et al. 2015). Fenugreek (Trigonella foenum-graecum) is a yearly 98 
legume belonging to the Fabaceae family (Rios et al. 2015). It is known in the culinary world as a spice, 99 
enhancing the taste of food, and the medicinal world for its anti-diabetic, anti-carcinogenic, 100 
hypocholesterolaemic, AO and immunological properties (Rios et al. 2015). These reported effects are 101 
attributed to a bioactive compound - 4-hydroxyisoleucine (4-OH-lle), a peculiar amino acid located within 102 
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the plant’s seed. Numerous reviews have reported the medicinal value of fenugreek and its active 103 
compound but there is insufficient evidence in supporting its biochemical and molecular effects in T2D 104 
(Basch et al. 2003, Fuller and Stephens 2015, Rios et al. 2015). With regards to T2D, chronic 105 
hyperglycaemia negatively affects insulin signalling, lipid metabolism, and OS. Consequently, the 106 
regulation of these integrated pathways will allow for the restoration of glucose, lipids and ROS levels. 107 
Studies provide evidence from cell culture and animal models which demonstrated the ability of 4-OH-lle 108 
and fenugreek seeds in stimulating the insulin signalling pathway and enhancing insulin sensitivity 109 
(Fowden et al. 1973, Sauvaire et al. 1998, Broca et al. 2000, Maurya et al. 2014, Naicker et al. 2016). 110 
Furthermore, studies also reported the glucose lowering effect of both 4-OH-lle and fenugreek seeds 111 
(Broca et al. 1999, Singh et al. 2010, Haeri et al. 2012). 4-OH-lle and fenugreek seeds also regulate 112 
plasma TGs, total cholesterol, FFAs, HDLc and LDLc, accompanied by the improvement of liver 113 
function (Narender et al. 2006, Haeri et al. 2009, Singh et al. 2010, Avalos-Soriano et al. 2016). Diabetic 114 
animal studies have reported fenugreek and 4-OH-lle to reduce abnormal ROS levels via the regulation of 115 
thiobarbituric acid reactive substances (TBARS), catalase, SOD2 and related liver enzymes comparable to 116 
controls as well as disrupt free radical metabolism (Ravikumar and Anuradha 1999, Mohamad et al. 2004, 117 
Dixit et al. 2005, Belguith-Hadriche et al. 2010, Dutta et al. 2014).  118 
 119 
These studies provide compelling evidence on the anti-hyperglycaemic, anti-lipidemic and anti-oxidative 120 
effects of both fenugreek and its active compound. However, there is a lack of evidence focusing on the 121 
effect of 4-OH-lle in comparison to MF, and fenugreek seed on the specific biochemical and molecular 122 
responses within these integrating pathways. Understanding the interaction of this plant extract and its 123 
active compound will further enable its use as possible anti-diabetic agents. As a result, we hypothesize 124 
that 4-OH-lle and FSE regulate genes and proteins responsible for attenuating hyperglycaemia, 125 
dyslipidaemia and OS in hyperglycaemic HepG2 cells and C57BL/6 male mice.  126 
 127 
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CHAPTER TWO 266 
LITERATURE REVIEW 267 
 268 
2.1 Type 2 Diabetes Mellitus 269 
Diabetes, a disease initially described as sweet urine disease, has been affecting individuals for decades. 270 
In the early 1910’s, the American Diabetes Association reported that medical professionals initiated the 271 
first steps towards determining a cause and treatment regimen for DM (Kohen 2004). Insulin injections 272 
were the first effective treatment for this disorder, however, some cases were unresponsive to insulin 273 
injections (Kohen 2004). In 1963, Diabetic Medicine published that “sweet urine disease” could be 274 
defined as “insulin-sensitive” and “insulin-insensitive” (Kohen 2004, Zarshenas et al. 2014). The terms 275 
went on to be further categorised as type 1 diabetes mellitus (T1D) and T2D. T1D is regarded as an 276 
autoimmune disorder targeting pancreatic -cells, rendering the individual incapable of producing insulin 277 
(Ashcroft and Rorsman 2012). T2D comprises of an array of hyperglycaemic-induced dysfunctions; 278 
accompanied with insufficient insulin secretion, resistance to insulin action, and disproportionate and/or 279 
inappropriate secretion of glucagon (Kohen 2004). With regards to T1D, there is no cure, however 280 
treatment involves the infusion of insulin with a syringe, insulin pen or pump (Kohen 2004). As with 281 
T1D, there is no cure for T2D however, this condition can be managed in numerous ways such as: 282 
lifestyle modifications (control of carbohydrate (CHO) intake, physical activity, and weight loss), 283 
pharmacological agents and insulin. Therefore, it has become apparent that individuals diagnosed with 284 
T2D are efficiently able to reverse this disorder. 285 
 286 
2.1.1 Epidemiology  287 
In 2014, it was reported by the world health organization (WHO) that approximately 9% of the world’s 288 
inhabitants were burdened with DM, and more than 90% of these cases were T2D (WHO 2016). Among 289 
the list of NCDs, DM soars among the four main diseases, which include CVD, cancers and chronic lung 290 
diseases (WHO 2016). T2D is responsible for approximately 5 million deaths per year (WHO 2016). By 291 
the year 2030, it is expected that T2D will escalate to the 7th cause of death worldwide. T2D is associated 292 
with obesity, and the major burden arises in developing and middle-income nations due to urbanisation 293 
(WHO 2016). T2D is often undiagnosed and investigations to measure the number of newly occurring 294 
cases are complex, resulting in limited data on true incidence. Furthermore, in low- and middle-income 295 
countries there are limited statistics on the income gradient of DM (WHO 2016). However, existing 296 
statistics propose the prevalence of DM to be highest among the wealthy population, but this trend is 297 
reversing in a few middle-income countries (WHO 2016). For instance in sub-Saharan Africa, the number 298 
of individuals with DM is predicted to escalate from 19.8 million (2013) to 41.5 million (2035) (WHO 299 
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2016). In 2015, the IDF reported 2.28 million cases of DM in South Africa, conversely, reports have 300 
revealed that there is inadequate statistics accessible on the prevalence of T2D in South Africa (Olokoba 301 
et al. 2012, WHO 2016). However, studies investigating data trends within Africa provide evidence of a 302 
dramatic rise in prevalence in rural and urban settings (Olokoba et al. 2012). In Africa, the majority of the 303 
DM burden is T2D, with less than 10% of cases being T1D (Olokoba et al. 2012). The prevalence of T2D 304 
in adults is predicted to increase in the next two decades.  305 
 306 
2.1.2 Associated Risk Factors  307 
The increasing prevalence of T2D has a massive impact on the healthcare system worldwide. Recent 308 
statistics from the IDF propose that DM is directly responsible for approximately 5 million deaths 309 
annually, exceeding the combined burden of HIV/AIDS, tuberculosis and malaria (Bailey et al. 2016). 310 
DM, if poorly controlled, may cause blindness, kidney failure, lower limb amputation and numerous 311 
long-term consequences that negatively impact on the quality of life (Baquer et al. 2009). However, there 312 
is huge potential in attenuating and reversing the DM pandemic via the modification of risk factors 313 
through lifestyle changes. There are several risk factors which are associated with T2D (Fig 2.1). These 314 
include:  315 
 Age, a driving force in the incidence of T2D. As an individual ages, both impaired fasting 316 
glucose and glucose intolerance are progressively prevalent (Pippitt et al. 2016). Evidence 317 
estimates a normal glucose metabolism of approximately 30% over the age of 80 years old 318 
(Bailey et al. 2016). 319 
 Obesity, the main potentially modifiable risk factor for T2D. Visceral adiposity confers the 320 
highest risk accompanied with T2D (Wing 2010). Research has proven that obesity is accountable 321 
for 80-85% of the risk of developing T2D (Wing 2010). 322 
 Physical activity, positively impacts glucose metabolism and attenuates the risk of obesity. 323 
However, the lack of high intensity physical activity is not as alarming as sedentary behaviour 324 
amongst vast populations (Wing 2010).  325 
 Diet, numerous dietary factors are implicated in the onset of DM. Despite total caloric intake, 326 
certain dietary factors such as processed meat, unprocessed red meat, and sugar-sweetened 327 
beverages are associated with the risk of T2D (Wing 2010, Pippitt et al. 2016). Following the 328 
strong relationship between T2D and obesity, evidence for prevention of T2D arises from studies 329 
which couple dietary intervention with elevated physical activity (Wing 2010).  330 
 Socio-economic factors, two out of three diabetic individuals reside in urban areas, however, 331 
individuals in the lower socio-economic classes are disproportionally affected (Foster et al. 2015). 332 
This occurrence is poorly understood, however unhealthier lifestyles serve as a mediating factor 333 
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(Wing 2010). Globally, lower-middle income nations contribute to the prevalence of T2D, as 334 
these are the countries where urbanisation and economic progression has severely altered 335 
lifestyles (McIntyre et al. 2006). 336 
 Stress, cortisol and adrenalin are associated with stress reactions. These hormones are recognized 337 
for their surging effect on glucose levels, in response to insulin (Pernicova and Korbonits 2014).  338 
 339 
Figure 2.1: Graphical overview of type 2 diabetes mellitus associated risk factors (Prepared by 340 
author. Sources of images: http://szzljy.com/assets/download.php?file=/images/age/age6.jpg; 341 
http://www.slashdiabetes.com/obesity/; http://blogs.plos.org/globalhealth/2017/08/the-global-action-342 
plan-for-physical-activity/; http://www.doctoroz.com/article/21-day-weight-loss-breakthrough-diet-343 
faq; http://www.doctoroz.com/article/21-day-weight-loss-breakthrough-diet-faq; http://clipart-344 
library.com/animated-stress-cliparts.html) 345 
 346 
2.1.3 Screening and Diagnosis 347 
T2D is a metabolic disorder characterized by raised glucose levels accompanied with disrupted CHO, 348 
lipid and protein metabolism due to deficiencies in the secretion and/or action of insulin (Fisher and Kahn 349 
2003). Uncontrolled DM can result in blindness, limb amputations, kidney failure, vascular disease and 350 
heart disease (Alberti and Zimmet 1998). Hence screening patients prior to the development of signs and 351 
symptoms results in earlier diagnosis and treatment. It is imperative that diagnostic testing is performed in 352 
patients with a clinical past symptomatic of DM (Pippitt et al. 2016). Symptoms prompting consideration 353 
of DM include blurry vision, fatigue, numbness, polyuria, polydipsia, poor wound healing, tingling 354 
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sensations and weight loss (Pippitt et al. 2016). Screening for T2D is important for the following reasons 355 
(Pippitt et al. 2016):  356 
 Global increase in prevalence of T2D 357 
 Considerable proportion of people with T2D are undiagnosed  358 
 Significant fraction of new cases of T2D present with evidence of microvascular complications 359 
 A lengthy, latent and asymptomatic period in which T2D is detectable 360 
 Importance of the direct effects and long-term complications of T2D 361 
 Evidence in support of controlling blood-glucose, blood-pressure and blood-lipid levels in T2D 362 
 Evidence that treatment of dyslipidaemia and hypertension can avoid CVD in individuals with 363 
T2D 364 
The recommendations for the screening of T2D are listed below in table 1. 365 
 366 
Table 1 Recommendations for the screening of type 2 diabetes mellitus 367 
Screen asymptomatic individuals if the following risk factors are present: 
Age ≥ 45 years 
CVD or family history of T2D 
Chronic glucocorticoid exposure 
HDLc level < 0.91mmol/L and/or a TG level > 2.8mmol/L 
History of gestational DM or delivery of a baby > 4.1kg 
Hypertension (blood pressure > 140/90 mmHg or prescribed medication for hypertension) 
Glucose intolerance, impaired fasting glucose and/or metabolic syndrome 
Nonalcoholic fatty liver disease 
Overweight or obese 
Polycystic ovary syndrome 
Sedentary lifestyle 
Sleep disorders in the presence of glucose intolerance 
Persons with two or more risk factors should be screened annually 
 368 
2.1.3.1 Diagnostic Tests for Type 2 Diabetes Mellitus 369 
T2D is diagnosed based on the following; plasma glucose (PG) criteria, fasting plasma glucose (FPG), 2h 370 
PG value following a 75g oral glucose tolerance test (OGTT) and/or the A1C criteria (Table 2) 371 
(Association 2017). 372 
 373 
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Table 2 Criteria for the diagnosis of type 2 diabetes mellitus 374 
1. FPG ≥7.0 mmol/L (Fasting includes no caloric intake for at least 8h) 
2. 2h PG ≥11.1 mmol/L during an OGTT (as per  the WHO) 
3. A1C ≥6.5% (48 mmol/L) 
4. Patient with classic symptoms of hyperglycaemia or hyperglycaemic crisis, with a PG ≥11.1 
mmol/L 
 375 
2.1.4 Management  376 
The goals in managing T2D include the elimination of symptoms and reduced rate of development of 377 
complications. Both lifestyle and diet modifications are the most effective way to manage T2D (Olokoba 378 
et al. 2012). The incidence of T2D declined, in association with a body mass index of >25kg/m2, a high 379 
fibre and low saturated fat diet, consistent exercise, abstinence from smoking and moderate alcohol 380 
consumption (Olokoba et al. 2012). This suggests that T2D can be prevented by lifestyle modification. In 381 
some instances lifestyle modifications may be insufficient in controlling blood glucose levels – since T2D 382 
is a progressive disease – other interventions are necessary. These include the administration of 383 
pharmacological agents such as MF.  384 
 385 
2.1.4.1 Pharmacological Agent: Metformin 386 
Globally, the first line drug of choice for T2D treatment is the oral biguanide antiglycaemic agent, MF 387 
(1,1-dimethylbiguanide hydrochloride) (Group 2002). The primary mechanism of action is increasing 388 
peripheral insulin sensitivity and inhibition of hepatic glucose production (Group 2002) . 5' adenosine 389 
monophosphate-activated protein kinase (AMPK) is a crucial cellular regulator of both glucose and lipid 390 
metabolism, and is directly regulated by MF (Viollet et al. 2012). It is a multi-subunit enzyme regulating 391 
biosynthetic lipid pathways, owing to its role in the phosphorylation of significant enzymes such as 392 
acetyl-CoA carboxylase (ACC) (Fig 2.2) (Zhou et al. 2001). In the liver, MF activates AMPK resulting in 393 
reduced ACC activity, fatty acid (FA) oxidation, and suppressed expression of lipogenic enzymes (Fig 394 
2.2) (Zhou et al. 2001). In addition, AMPK activation suppresses expression of sterol regulating binding 395 
element 1c (SREBP1c), a key lipogenic transcription factor (Fig 2.2) (Streicher et al. 1996). The 396 
suppression of SREBP1c down-regulates gene expression of essential lipogenic enzymes, causing 397 
reduced fatty liver, and elevated hepatic sensitivity of insulin. With regards to glucose metabolism MF is 398 
responsible for attenuating gluconeogenesis. Gluconeogenesis is an energy dependent process, which 399 
depends on mitochondrial function. Metformin accumulates within the mitochondria inhibiting 400 
mitochondrial complex 1, and suppressing the production of adenosine triphosphate (ATP). As a result, 401 
the attenuated ATP levels reduce gluconeogenesis (Fig 2.2)  (Rena et al. 2017). Apart from its effect on 402 
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lipid and glucose metabolism, MF treatment is thought to have additional positive effects, including 403 
stabilization of weight gain and weight loss (Brufani et al. 2013). This occurs by suppression of hepatic 404 
glucose production, increase in insulin sensitivity, improving glucose uptake via phosphorylating GLUT-405 
enhancer factor, increasing FA oxidation, and reducing glucose absorption from the GIT (Group 2002, 406 
Brufani et al. 2013). Although highly effective and safe, MF therapy is associated with side effects, such 407 
as acute infections of the nose and throat and irritations of the GIT (Hermann 1979, Siavash et al. 2017). 408 
The sustained effectiveness of this compound is controversial, resulting in a constant search for new T2D 409 
therapies. 410 
 411 
Figure 2.2: Mechanism of action of metformin on hepatic and muscle glucose metabolism (Brufani 412 
et al. 2013). AMPK; Adenosine monophosphate-activated protein kinase, ACC; acetyl-coenzyme A 413 
carboxylase, SREBP-1; sterol regulatory element-binding protein-1, VLDL; very-low density 414 
lipoprotein. 415 
 416 
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2.1.5 Pathophysiology 417 
The pathophysiology of T2D comprises: peripheral insulin resistance, compromised regulation of hepatic 418 
glucose production, and diminished β-cell function resulting in β-cell failure (Fig 2.3) (Mahler and Adler 419 
1999). This results in reduced transport of glucose to the liver, adipose, and muscle cells (Olokoba et al. 420 
2012). Insulin resistance arises when liver, adipose and muscle cells become non-responsive to insulin. 421 
Under these conditions, TGs in adipose cells are degraded to produce FFAs for energy (Mahler and Adler 422 
1999). Muscles are disadvantaged of an energy source and liver cells fail to produce glycogen (Mahler 423 
and Adler 1999). The inability of cells to utilize glucose causes an overall rise in circulating glucose. 424 
Glycogen stores become markedly reduced, resulting in decreased availability of glucose accessible for 425 
essential cell functioning (Shulman 2000).  426 
 427 
Following CHO intake, there is an increase in plasma glucose and insulin secretion (Fig 2.3A). In muscle 428 
cells, insulin elevates glucose transport allowing for both glucose entry and glycogen storage (Fig 2.3A). 429 
In the liver, glycogen synthesis and lipogenesis are promoted by insulin, whilst gluconeogenesis is 430 
inhibited (Shulman 2000). In adipose cells, insulin reduces lipolysis and stimulates lipogenesis (Fig 431 
2.3A). This results in elevated hepatic gluconeogenesis and glycogenolysis, lipolysis and reduced hepatic 432 
lipid production (Fig 2.3B) (Khedoe et al. 2015). During T2D, ectopic lipid accumulation dysregulates 433 
lipid production (Fig 2.3C). Insulin-mediated glucose uptake in skeletal muscle is also impaired as a 434 
result of intramyocellular lipid accumulation, diverting glucose to the liver (Fig 2.3C). The capability of 435 
insulin to control gluconeogenesis and activate glycogen synthesis is impaired by hepatic lipid 436 
accumulation (Fig 2.3D) (Shulman 2000). In contrast, unaffected lipogenesis together with the elevated 437 
glucose leads to increased lipogenesis (Fig 2.3D). In adipose cells impaired insulin action permits 438 
increased lipolysis, promoting re-esterification of lipids in tissues (such as liver), further impairing insulin 439 
resistance (Fig 2.3D) (Khedoe et al. 2015). As a result, hyperglycaemia is coupled with a decline in 440 
pancreatic β-cell insulin secretion. As mentioned above increased FFA levels, inflammatory cytokines 441 
from adipose and oxidative factors are involved in the pathogenesis of T2D, and related CVD 442 
complications. 443 
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 444 
Figure 2.3: Pathophysiology of normal and abnormal glucose metabolism in type 2 diabetes 445 
mellitus (Shulman 2000). Normal glucose metabolism during a (A) fed state and (B) fasted state. 446 
“Abnormal” glucose metabolism during a (C) fed state and (D) fasted state 447 
 448 
2.2 Glucose Sensing and Insulin Receptor Signalling 449 
Pancreatic β-cells release the anabolic hormone, insulin in response to raised levels of nutrients in the 450 
blood. Insulin initiates the uptake of amino acids, FAs and protein into muscle, adipose and liver; 451 
stimulating the storage of these nutrients as protein, lipids and glycogen, respectively (Fisher and Kahn 452 
2003). However failure in the uptake and storage of these nutrients, due to the inability of insulin binding 453 
to its receptor and subsequent insulin resistance, results in T2D. The binding of insulin to insulin 454 
receptor-β (IRβ), initiates a cascade of tyrosine kinases which result in the uptake and storage of nutrients. 455 
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During T2D, this conventional insulin-receptor binding is defective, resulting in an imbalance in glucose 456 
homeostasis.  457 
 458 
2.2.1 Insulin Signalling 459 
The IR comprises two extracellular α subunits and two transmembrane β subunits linked via disulphide 460 
bonds. Binding of insulin to the α subunits, induces a conformational change followed by 461 
autophosphorylation of several tyrosine residues within the β subunit (Arner et al. 1987, Pirola et al. 462 
2004). These residues are recognized by phospho-tyrosine-binding domains on adaptor proteins such as 463 
members of the IRS family (Saltiel and Kahn 2001, Lizcano and Alessi 2002). Receptor mediated-464 
activation phosphorylates crucial tyrosine residues on IRS proteins, some of which are recognized 465 
through the Src homology 2 domain of phosphoinositide-3-kinase (PI3K) (Shulman 2000). The catalytic 466 
subunit of PI3K - p110, phosphorylates phosphatidylinositol (4, 5) bisphosphate (PtdIns (4, 5) P2) 467 
causing the formation of Ptd (3, 4, 5) P3, which is a significant downstream stimulant of Akt (Nolan et al. 468 
1994). 469 
 470 
Activation of Akt is governed by a dual regulatory mechanism; Akt is first recruited to the plasma 471 
membrane, and subsequent phosphorylation via phosphoinositide-dependent kinase-1 and mTOR 472 
Complex 2 (Lizcano and Alessi 2002, Gao et al. 2014). Once active, Akt enters the cytoplasm where it 473 
phosphorylates and inactivates GSK3α/β (Fig 2.4). This serine/threonine protein kinase facilitates 474 
addition of phosphate molecules onto serine and threonine amino acid residues (McManus et al. 2005). 475 
The main substrate of GSK3α/β is glycogen synthase (GS), an enzyme that catalyses the last step in 476 
glycogen synthesis (Fig 2.4). Phosphorylation of GS via GSK3α/β impedes glycogen synthesis, 477 
consequently the inactivation of GSK3α/β via Akt promotes glucose storage as glycogen (McManus et al. 478 
2005). Inactivated GSK3α/β is a major regulatory step in the stimulation of hepatic GS via insulin. 479 
Furthermore, glucose-6-phosphate is a precursor for the formation of hepatic glycogen. Glucokinase 480 
(Gck) is a hepatic enzyme which facilitates the phosphorylation of glucose to glucose-6-phosphate, 481 
providing a substrate for the conversion to glycogen. In muscle and adipocytes, insulin promotes glucose 482 
uptake via translocation of GLUT4, and via GLUT2 in the liver (Fig 2.4). GLUT4 translocation involves 483 
the PI3K/Akt pathway (Carlson et al. 2003), where as GLUT2 translocation involves activation of 484 
SREBP1c via insulin (Fig 2.4) (Horton et al. 2002). 485 
 486 
The transcription factor SREBP1c is responsible for regulating the transcription of genes involved in 487 
cholesterol and lipid synthesis (Sharawy et al. 2016). Raised glucose levels promote binding of SREBP1c 488 
to GLUT2 promoters, initiating GLUT2 transcription (Sharawy et al. 2016). GLUT2 recruitment 489 
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facilitates the uptake of extracellular glucose, ultimately, reducing circulating blood glucose and 490 
maintaining glucose homeostasis. Conversely, during T2D the above physiological processes are 491 
attenuated. Thus insulin resistance, compromised regulation of hepatic glucose production, and 492 
deteriorating β-cell function are attributable to a reduction in the normal physiology (Fig 2.4).  493 
 494 
Figure 2.4: Normal physiological process of insulin on genes and proteins involved in the proximal 495 
and distal signalling cascade (Prepared by author) 496 
 497 
2.3 Lipid Metabolism 498 
Insulin signalling is central in regulating several steps of lipid metabolism. Following disrupted IR 499 
signalling and glucose sensing, T2D individuals present with abnormal lipid profiles (Mullugeta et al. 500 
2012). Abnormal lipid profiles classified as diabetic dyslipidaemia  are characterized by elevated TGs and 501 
LDL particles, and depleted HDLc. Uncontrolled glucose levels potentiates FA flux, which gives rise to 502 
diabetic dyslipidaemia promoting TG production in hepatocytes. In the presence of heightened glucose 503 
levels, hepatocytes increase in packaging of TGs, which are transported to the cells via very low density 504 
lipoproteins (VLDL) (Biesenbach 1989). TGs are stripped from VLDL particles, which facilitates the 505 
delivery and subsequent digestion of TGs in the cells (Ginsberg et al. 2005). VLDL particles become 506 
denser and undergo remodelling to form LDL particles, which function to transport cholesterol used 507 
within the membranes and/or for production of steroid hormones (Ginsberg et al. 2005). Cellular 508 
cholesterol uptake is mediated via receptor mediated endocytosis. The LDL particles containing 509 
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cholesterol bind to specific LDLr, where hydrolysis within endosomes release cholesterol for use in the 510 
cell; which is followed by the recycling of the receptor to the cell surface (Biesenbach 1989, Taskinen 511 
2002).  512 
 513 
In T2D, over-production of LDLc overwhelms the LDLr pool, resulting in insufficient removal of LDLc. 514 
As a result untreated diabetic dyslipidaemia increases the risk for the onset of CVD and subsequent 515 
microvascular and macrovascular complications (Lorber 2014). Therefore, it is imperative to target the 516 
modifiable risk factors, which lead to development of long-term complications. Statins are the most 517 
popular class of lipid-lowering drugs. These drugs function by inhibiting the enzyme HMG CoA 518 
reductase which decreases the production of cholestrol in the liver. Unfortunately, the use of statins is 519 
accompanied by a range of side effects, from muscle damage and pain to liver damage (Banach et al. 520 
2015). New advancements, differing from the action of statins have emphasized the use of regulators of 521 
PCSK9 and agonists of PPARG in the treatment of dyslipidaemia (Gervois et al. 2000, Burke et al. 2017). 522 
Studies have reported PCSK9 as a potent circulating regulator of LDLc through its ability to induce 523 
degradation of the LDLr in lysosomes of hepatocytes (Grefhorst et al. 2008, Bhat et al. 2015, Burke et al. 524 
2017, Laugier-Robiolle et al. 2017). The transcription factor PPARG is responsible for mediating 525 
physiological effects on both glucose homeostasis and lipid metabolism (Memon et al. 2000, Kendall et 526 
al. 2006). The effects of PPARG in T2D has been well-documented, which include a direct impact on 527 
HDLc levels (Inoue et al. 2005, Kendall et al. 2006, Bermudez et al. 2010, Ahmadian et al. 2013). 528 
Following the disparity in lipid homeostasis present in T2D, targeting PCSK9 and PPARG will contribute 529 
to the restoration of lipid homeostasis (Fig 2.5).  530 
 531 
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Figure 2.5: Regulation of plasma lipoproteins during elevated glucose levels by proprotein 532 
convertase subtilisin-like/kexin type (PCSK9) and peroxisome proliferator-activated receptor 533 
gamma (PPARG) (Prepared by author).  534 
 535 
2.3.1 PCSK9, an Inhibitory Regulator of LDLr 536 
Lipoprotein transfer of cholesterol within plasma plays a functional role in the cell membrane, energy 537 
production and hormone synthesis (Virella and Lopes-Virella 2012). Cells use cholesterol via the 538 
internalization of lipoprotein ligands comprising chylomicrons, LDL and VLDL particles mediated by 539 
LDLr, followed by an endocytic process (Fig 2.6) (Olofsson et al. 2000, Virella and Lopes-Virella 2012). 540 
LDLr-mediated endocytosis aids in understanding lipoprotein clearance and LDLr deficiency, as risk 541 
factors for developing CVD. Raised LDL is a predominant risk factor for coronary artery disease and 542 
other atherosclerotic diseases, which governs the largest cause of all morbidities and mortalities in T2D 543 
individuals.  544 
  545 
LDLr is a cell membrane glycoprotein which functions by binding and internalizing circulating 546 
cholesterol containing lipoprotein particles (Virella and Lopes-Virella 2012). This receptor is ubiquitously 547 
expressed and central to the maintenance of cholesterol homeostasis in mammals. On the cell surface, 548 
clathrin-coated pits contain LDLr which bind to LDLc via adaptin (Virella and Lopes-Virella 2012). 549 
Following binding, the pits are pinched off to form clathrin-coated vesicles within the cell (Fig 2.6) 550 
(Virella and Lopes-Virella 2012). This allows LDLc to undergo endocytosis and avoids LDL diffusing 551 
around the membrane surface. This occurs in nucleated cells but predominantly within the liver, which is 552 
responsible for 70% of LDL removal from circulation. Once the coated vesicle is internalized, it sheds the 553 
clathrin-coat and fuses with an acidic endosome (Virella and Lopes-Virella 2012). Following this cycle, 554 
LDLr is either destroyed or recycled via endocytic cycle to the cell surface, to receive another LDL 555 
particle (Fig 2.6). The synthesis of LDLr is regulated by levels of free intracellular cholesterol, as well as, 556 
other molecules such as PCSK9. 557 
 558 
PCSK9 regulates the degradation of the LDLr in response to cholesterol levels within the cell; by binding 559 
to an extracellular part of the LDLr (Fig 2.7) (Burke et al. 2017). PCSK9 inhibits LDLr from creating a 560 
closed conformation, causing the receptor to be susceptible to enzymatic degradation (Fig 2.7) (Horton et 561 
al. 2007). LDLr’s without PCSK9 bound to them are therefore more likely to be recycled to the cell 562 
surface. Increased function of PCSK9 causes hypercholesterolemia, while reduced function is 563 
accompanied by low LDL. Therefore, inhibiting PCSK9 allows more LDLr’s to be recycled to the cell 564 
surface, causing an elevation in the clearance of LDLc from circulation. Several approaches to the 565 
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pharmacological inhibition of PCSK9 has been investigated. Antisense oligonucleotides and small 566 
interfering RNAs are responsible for the formation of PCSK9 (Burke et al. 2017). Furthermore, small 567 
adnectin polypeptides and monoclonal antibodies bind to mature PCSK9 preventing interaction with 568 
LDLr (Burke et al. 2017). Consequently, attenuating the levels of PCSK9 can be achieved prior 569 
to/following formation of these molecules, resulting in therapeutic opportunities for targeting PCSK9.  570 
 571 
Figure 2.6: Low density lipoprotein receptor mediated pathway 572 
(http://i0.wp.com/www.namrata.co/wp-content/uploads/2012/11/cholesterol-573 
metabolism.jpg?resize=628%2C484) 574 
 575 
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 576 
Figure 2.7: Cellular trafficking of PCSK9 (Poirier and Mayer 2013) 577 
 578 
2.3.2 PPARG; A Positive Regulator of Lipid Metabolism 579 
Lipoproteins are multifaceted particles responsible for the transport of lipids (Lund-Katz and Phillips 580 
2010). The anti-atherogenic lipoprotein, HDL, facilitates the efflux of cellular cholesterol. HDL partakes 581 
in the reverse cholesterol transport process, whereby surplus cholesterol within peripheral cells are 582 
transported to the liver for excretion (Zhou et al. 2015). Apolipoprotein-facilitated interactions of HDL 583 
particles with lipid transporters and receptors on the cell surface are crucial for this process (Lund-Katz 584 
and Phillips 2010). The interchangeable apolipoproteins within HDL are A, C and E families, which are 585 
structurally similar (Lund-Katz and Phillips 2010, Zhou et al. 2015). Lipoprotein particles in circulation 586 
act as binding agents for cell surface receptors, and facilitate lipoprotein remodelling (Zhou et al. 2015). 587 
With regards to HDL, the apolipoproteins contribute to particle remodelling via the transfer of proteins 588 
and enzymes. These reactions are essential for HDL metabolism and reverse cholesterol transport (Lund-589 
Katz and Phillips 2010, Zhou et al. 2015). 590 
 591 
HDL particles protect against CVD, OS and systemic inflammation via its anti-thrombotic, anti-592 
inflammatory, and AO activities, as well as, reverse cholesterol transport (Lund-Katz and Phillips 2010). 593 
Apolipoprotein A1 (Apo A1) is manufactured and released into circulation via the liver. The partial 594 
lipidation of ApoA1 by phospholipids and cholesterol form nascent HDL particles (Lund-Katz and 595 
Phillips 2010) (Fig 2.8). In vascular tissue, these particles initiate the release and transfer of free 596 
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cholesterol to the surface of HDL; free cholesterol is then re-esterified and stored within the HDL core 597 
(Lund-Katz and Phillips 2010, Zhou et al. 2015). This process converts lipid-deprived HDL3 to 598 
cholesterol ester-rich HDL2, which separate and release into circulation (Lund-Katz and Phillips 2010, 599 
Zhou et al. 2015). In circulation, part of the HDL cholesterol-ester is transferred to intermediate 600 
density lipoprotein (IDL) and LDL in exchange for TGs (Zhou et al. 2015). HDL2 then binds to HDL 601 
docking receptors allowing for the removal of HDL cholesterol-ester and hydrolysis of its TG, and 602 
phospholipid contents cellular uptake (Fig 2.8) (Zhou et al. 2015). Subsequently, the lipid-poor HDL 603 
separates and proceeds to circulation to repeat the cycle. 604 
 605 
Figure 2. 8: Production and metabolism of high density lipoprotein via reverse cholesterol 606 
transport (https://www.nature.com/articles/nrneph.2015.180/figures/1) 607 
 608 
As previously mentioned, HDL confers important protective functions in addition to its role in mediating 609 
reverse cholesterol transport (Fig 2.9) (Lund-Katz and Phillips 2010). HDL is a protecting agent against 610 
OS via the actions of its constituent AO enzymes, GPx and paraoxonase (Fig 2.9). Systemic inflammation 611 
is mitigated by HDL via the removal of oxidized phospholipids and FAs from LDL, VLDL, and IDL (Fig 612 
2.9) (Howard et al. 2000). This process limits the formation of oxidized phospholipids and their disposal 613 
in the liver. Anti-atherogenic HDL also stimulates proliferation and inhibits injury and apoptosis of 614 
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endothelial cells via attenuated caspase-3 activity and ROS generation (Giacco and Brownlee 2010). 615 
Furthermore, HDL enables restoration, relocation, and growth of endothelial cells and elevates the 616 
quantity of circulating endothelial progenitor cells - which are vital for vascular repair and inhibition of 617 
plaque formation (Lorber 2014). Subsequently, HDL particles in circulation are responsible for regulating 618 
multiple factors, hence targeting this lipoprotein is imperative in maintaining cholesterol homeostasis. 619 
 620 
A possible inducer of the anti-atherogenic lipoprotein is PPARG, which belongs to a subfamily of ligand-621 
inducible transcription factors (Issemann and Green 1990). This transcription factor is central in 622 
controlling the expression of gene networks involved in lipid metabolism, glucose homeostasis, 623 
inflammation, and cell proliferation (Forman et al. 1997, Dussault and Forman 2000, Evans et al. 2004). 624 
Ligand binding is followed by the formation of heterodimers with retinoid X receptor (RXR). PPARG-625 
RXR heterodimers bind to peroxisome proliferator response element, on the promoter region of specific 626 
target genes (Gervois et al. 2000). Transcription is triggered upon recruitment of different transcriptional 627 
cofactors (Gervois et al. 2000). PPARG is responsible for inducing apolipoproteins which play an integral 628 
role in transporting excess cholesterol to its acceptor – HDL, initiating reverse cholesterol transport 629 
(Gervois et al. 2000). The application of PPARG agonists has been investigated in multiple disease 630 
conditions, the only approved use for PPARG ligands is the use of thiazolidinedione’s in T2D (Fruchart et 631 
al. 2001, Fitzgerald et al. 2002, Lalloyer and Staels 2010). These complete PPARG agonists first arose as 632 
a new class of therapy alleviating insulin resistance in individuals with T2D (Fruchart et al. 2001, 633 
Fitzgerald et al. 2002, Lalloyer and Staels 2010). However, drugs from the thiazolidinedione group were 634 
withdrawn from the market due to severe adverse effects. These effects were caused by full PPARG 635 
activation and opposing agonistic effects of endogenous PPARG ligands such as FAs and prostanoids 636 
(Dussault and Forman 2000, Balakumar and Kathuria 2012). The PPARG agonist pioglitazone is 637 
currently used to treat both diabetes and fatty liver disease (Amano et al. 2018; Chandra et al. 2017). 638 
Consequently, research efforts have recently explored the prospective role of selective PPARG agonists - 639 
compounds that increase glucose homeostasis but reduce partial PPARG agonism side effects (Schupp et 640 
al. 2005, Balakumar and Kathuria 2012). Consequently, targeting PPARG poses potential benefit in 641 
potentiating the levels of HDL and its downstream effects in T2D. 642 
 643 
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 644 
Figure 2.9: Protective functions of high density lipoproteins 645 
(https://www.nature.com/articles/nrneph.2015.180/figures/2) 646 
 647 
2.4 Oxidative Stress and Mitochondrial Health 648 
Excessive nourishment and sedentary lifestyle potentiates glucose and FA overload, resulting in the over-649 
production of ROS (Baynes 1991). Disproportionate ROS causes OS, which is representative of the 650 
imbalance between ROS and the ability to detoxify their harmful effects (Baynes 1991). In T2D, 651 
hyperglycaemia induces ROS production via attenuation of the AO response and detoxification system, 652 
stimulation of protein kinase C (PKC) pathway, the formation of AGEs and reduced mitochondrial 653 
function. OS has been identified as a pathogenic mechanism in diabetic-related CVD and long-term 654 
complications. As a result, targeting factors responsible for mitigating OS levels and neutralizing the 655 
adverse effects of hyperglycaemia, are central to T2D treatment. 656 
 657 
Studies have established the role of nuclear factor erythroid 2-related factor 2 (Nrf2) in alleviating the 658 
complications of DM. Nrf2 is a transcription factor that functions as the major regulator of the 659 
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endogenous AO and detoxification system. Nrf2 executes its function once released from Kelch-like 660 
ECH-associated protein 1 (Keap1) repression, resulting in the stimulation of the antioxidant response 661 
element (ARE). This response element is central to the activation of genes coding for a number of AOs. 662 
Furthermore, protein kinase pathways such, as the diacylglycerol (DAG)-PKC pathway, has been 663 
associated in transducing OS signals to genes mediated through the ARE. This pathway is known to be 664 
activated by chronic DAG levels, resulting in elevated levels of PKC, promoting Nrf2 activation; whereas 665 
the formation of cytotoxic AGEs are counteracted by Nrf2 and mitochondrial Lon protease.  666 
 667 
An important source of ROS is the mitochondria, via oxidative phosphorylation. Interestingly, Nrf2 668 
counterbalances mitochondrial produced ROS via the transcription of cytoprotective genes; SOD2, GPx 669 
and GSH. Furthermore, the mitochondria possess regulatory proteins, enabling these organelles to combat 670 
the over-production of ROS. These regulatory proteins include both SIRT3 and PGC-1α. SIRT3 is central 671 
to regulating mitochondrial function since it is accountable for deacetylation of mitochondrial proteins, 672 
and regulating mitochondrial biogenesis via the induction of PGC-1α. Mitochondria are essential for 673 
bioenergetic and metabolic processes, including glucose and lipid metabolism (Kim et al. 2008). 674 
However, when mitochondria are unable to perform their primary function, this results in mitochondrial 675 
dysfunction (Dinkova-Kostova and Abramov 2015). Collectively, impaired AO defences and 676 
mitochondrial dysfunction form a vicious cycle causing OS. Thus, therapeutic intervention using AO 677 
supplements may be beneficial in interrupting this cycle. 678 
 679 
2.4.1 Nuclear factor erythroid 2-related factor 2 and the Antioxidant Response 680 
OS is central to the pathogenesis of T2D, and the onset of CVD and diabetic complications. As a result 681 
improving the endogenous cellular AO response and detoxification system will enable cells to prevent 682 
ROS induced damage (Allen and Tresini 2000, Ramachandran et al. 2011). Nrf2 regulates the 683 
endogenous AO and detoxification system, providing cells the ability to adapt to OS, by mediating the 684 
induction of cytoprotective genes (Fig 2.10) (Zhang 2006). Under non-stressed conditions, Nrf2 is 685 
inhibited by a negative regulator Keap1 which is located in the cytoplasm (Zhang 2006, Taguchi et al. 686 
2011). Keap1 is a repressor protein that binds to Nrf2 and stimulates its degradation via the ubiquitin 687 
proteasome pathway (Kansanen et al. 2013). Exposure to OS allows Nrf2 to escape Keap1 repression, 688 
translocating to the nucleus, which results in the phosphorylation and activation of Nrf2 (Fig 2.10). In the 689 
nucleus pNrf2 binds to and initiates ARE-dependent gene expression to preserve cellular redox balance 690 
(Zhang 2006). The ARE comprises a sequence involved in controlling the coordinated transcriptional 691 
activation of genes coding for various AO enzymes (Fig 2.10). The AO function of Nrf2 is central to the 692 
preservation of glucose metabolism in insulin-sensitive tissues, via insulin secretion and glucose 693 
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utilization (Uruno et al. 2015). The cytoprotective genes induced by Nrf2 include the endogenous AOs; 694 
SOD2 and GPx, which are involved in synthesizing the non-enzymatic AO; GSH. Reduced GSH serves 695 
as a major cellular AO determinant between cellular protection and toxic damage (Pompella et al. 2003, 696 
Victor et al. 2011). When this endogenous AO fails to provide adequate compensatory response to restore 697 
the redox balance, GSH levels are reduced and OS ensures (Allen and Tresini 2000). Following elevated 698 
ROS, superoxide radicals are converted to hydrogen peroxide by SOD2 which is reduced by GPx to water 699 
(Vats et al. 2015). The reduction of hydrogen peroxide to water is complemented by the conversion of 700 
reduced GSH into oxidized GSH. Studies have reported decreased Nrf2 in diabetic mice and patients with 701 
T2D, which contribute to elevated OS, endothelial dysfunction, insulin resistance and elevated cardiac 702 
insult (Li et al. 2011, Tan et al. 2011, Cheng et al. 2012). Furthermore, studies have showed that Nrf2 703 
induction improves insulin resistance in diabetic mice models (Uruno et al. 2013, David et al. 2017). 704 
Studies also confirm the relationship between activated Nrf2 and its downstream effects on both SOD2 705 
and GPx, which are reduced in T2D (Dong et al. 2008, Ramachandran et al. 2011, Giralt and Villarroya 706 
2012). Nrf2 induction alters AO, energy intake, and gluconeogenesis related gene expression in metabolic 707 
tissues (Uruno et al. 2013). Subsequently, Nrf2 plays an invaluable role in modulating the metabolic 708 
aberrations present in T2D, by initiating the AO response and detoxification system. 709 
 710 
2.4.2 Diacylglycerol-Protein kinase C Pathway 711 
Hyperglycaemic-induced intracellular and extracellular changes alter signal transduction pathways which 712 
negatively impact gene expression and protein function. PKC is a serine/threonine-related protein kinase, 713 
fundamental in several cellular functions, and signal transduction pathways (Geraldes and King 2010). 714 
There are various isoforms of PKC that function in a multiplicity of biological systems, which are 715 
stimulated by DAG (Geraldes and King 2010). DAG is a glyceride consisting of two FA chains 716 
covalently bonded to a glycerol molecule (Geraldes and King 2010). The levels of DAG are chronically 717 
heightened in a hyperglycaemia, owing to an elevation in the glycolytic intermediate - dihydroxyacetone 718 
phosphate (Geraldes and King 2010). Dihydroxyacetone phosphate is reduced to glycerol-3-phosphate, 719 
which consequently raises the de novo synthesis of DAG. In DM, DAG levels are raised in vascular 720 
(heart, retina and kidney) and non-vascular tissues (liver and skeletal muscles). Studies by Kang et al, 721 
2000 and Kang et al, 2001 provided substantial evidence on the involvement of PKC in phosphorylating 722 
Nrf2, and initiating its nuclear translocation in response to OS (Kang et al. 2000, Kang et al. 2001). 723 
Accordingly, PKC phosphorylates Nrf2 at Serine-40, promoting its dissociation from Keap1 (Huang et al. 724 
2002). This action of PKC is a crucial signalling event resulting in the ARE-mediated cellular AO 725 
response. 726 
 727 
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2.4.3 Advanced Glycation End-Products Pathway 728 
Diverse biochemical pathways have been suggested in linking the antagonistic effects of hyperglycaemia 729 
to vascular impediments. In addition to the DAG-PKC pathway, is an increase in the AGEs pathway.  730 
Glycation is the process whereby uncontrolled glucose forms covalent adducts with plasma proteins 731 
(Chevion et al. 2000). Glycation is a non-enzymatic process, central to the onset of diabetic 732 
complications, such as, nephropathy, neuropathy and retinopathy (Singh et al. 2014). Glucose-derived 733 
dicarbonyl precursors are responsible for accumulation of intracellular AGEs (Singh et al. 2014). 734 
Intracellular AGEs are important stimuli for triggering intracellular signalling pathways (Brownlee 2001). 735 
Glycation hinders normal functioning of proteins, which disrupts conformation, enzymatic activity, 736 
degradation ability, as well as receptor recognition (Brownlee 1995, Hammes et al. 1999). Glycation 737 
modifies cellular functions via denaturation and functional failing of target proteins, initiation of receptor-738 
mediated signalling and production of oxidative and carbonyl stress (Yonekura et al. 2005, Hsieh et al. 739 
2007). As a result, reducing the formation of AGEs is imperative in attenuating its effects on protein 740 
structure and function, and subsequent vascular complications. In addition to, the role of Nrf2 in 741 
mitigating hyperglycaemic-induced OS, Nrf2 plays a functional role in reducing the levels of AGEs. 742 
Recent evidence for this interaction was provided by Sampath et al, 2016 (Sampath et al. 2017). 743 
Following the multifaceted effects of Nrf2, the mitochondrial matrix possess an important protease, Lon 744 
protease 1 (LonP1) which is responsible for degrading oxidatively damaged proteins (Gumeni and 745 
Trougakos 2016, Pomatto et al. 2017). This protease degrades oxidized and damaged proteins, in 746 
association with chaperones which preserve the protein in an unfolded state until the initiation of the 747 
proteolytic reaction (Pomatto et al. 2017). Increased LonP1 will enable cells to efficiently reduce 748 
damaged proteins and attempt to restore cellular homeostasis. Studies compared diabetic and lean mice 749 
livers, and observed LonP1 protein levels to be significantly lower in diabetic mice (Lee et al. 2011). This 750 
suggests that LonP1 down-regulation is critical in mitochondrial dysfunction, and may be involved in the 751 
progression of insulin resistance and T2D (Lee et al. 2011). 752 
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 753 
Figure 2.10:  Schematic representation presenting the mechanism of cytoprotection via Nrf2 754 
activators (Rashmi et al. 2017) 755 
 756 
2.4.4 Mitochondrial Regulatory Pathways  757 
In mitochondria, ROS are generated at low levels as by-products of the electron transport chain (ETC) 758 
(Brownlee 2001). Mitochondria are double-membrane organelles with multiple critical cellular functions 759 
which include oxidative phosphorylation. Oxidative phosphorylation is the final stage of cellular 760 
respiration, consisting of two meticulously connected components; the ETC and chemiosmosis (Giacco 761 
and Brownlee 2010). The ETC comprises of proteins and organic molecules located in the inner 762 
mitochondrial membrane. In a sequence of redox reactions, electrons are transferred from one member of 763 
the ETC to the next (Liu et al. 2002). Energy is released during these reactions, which is captured as a 764 
proton gradient. This facilitates the production of ATP in a process called chemiosmosis (Montgomery 765 
and Turner 2015). During these processes, ROS production is necessary for the normal functioning of the 766 
cell, however excessive ROS production can be detrimental, making AO defences essential. In addition to 767 
the role of Nrf2 in the AO system, Nrf2 also influences mitochondrial function by protecting against 768 
mitochondrial toxins. The main small molecule AO - GSH is also a product of numerous downstream 769 
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target genes of Nrf2, which counterbalances the production of mitochondrial ROS (Holmström et al. 770 
2016). Mitochondrial integrity is critical for overall functioning. Mitochondrial integrity is regulated via 771 
mitophagy, a process which removes damaged mitochondria. Autophagic adaptor protein sequestosome-1 772 
(SQSTM1/p62) is a key protein responsible for mitophagy (Holmström et al. 2016). This protein 773 
competes with Nrf2 for its binding site on Keap1, as a result, raised p62 levels triggers the Nrf2 pathway, 774 
creating a positive feedback loop (Holmström et al. 2016). 775 
 776 
In order to maintain proper mitochondrial function, lysine acetylation has become an important post-777 
translational alteration of mitochondrial proteins (Nogueiras et al. 2012). In response to environmental 778 
stimuli, vital metabolic enzymes are acetylated within mitochondria. The SIRT family consists of seven 779 
members, three (SIRT 3, 4, 5) of which are located in the mitochondria (Nogueiras et al. 2012). SIRT3 is 780 
important in regulating mitochondrial function, as it is accountable for deacetylation of mitochondrial 781 
proteins. SIRT3 is responsible for targeting proteins involved in energy metabolism processes, which 782 
include the respiratory chain, tricarboxylic acid cycle and FA β-oxidation (Buler et al. 2012). Through 783 
these processes, SIRT3 regulates the flow of mitochondrial oxidative pathways and subsequently, the rate 784 
of ROS production (Giralt and Villarroya 2012). SIRT3-mediated deacetylation stimulates enzymes 785 
accountable for quenching ROS, thereby employing a profound protective action against OS-dependent 786 
pathologies, such as T2D (Nogueiras et al. 2012). In T2D, elevated OS contributes to the occurrence of 787 
mitochondrial dysfunction. As a result, elevated SIRT3 levels increase cellular respiration ultimately 788 
reducing ROS production (Fig 2.11). In addition, SIRT3 is essential for the induction of PGC-1α, and 789 
PGC-1α-dependent induction of ROS-detoxifying enzyme, SOD2 (Fig 2.11) (Kong et al. 2010). PGC-1α 790 
is a transcriptional coactivator which reacts with a wide range of transcription factors, involved in various 791 
biological responses such as mitochondrial biogenesis, glucose and FA metabolism (Moreno-Santos et al. 792 
2016). This transcriptional coactivator is documented to be a master-regulator of mitochondrial 793 
biogenesis - interacting with a complement of transcription factors and nuclear hormone receptors 794 
associated with mitochondrial function (Fig 2.11) (Moreno-Santos et al. 2016). With regards to T2D, 795 
chronic hyperglycaemia is related to reduced expression of PGC-1α (Moreno-Santos et al. 2016). 796 
Therefore, stimulation of PGC-1α expression is a crucial regulatory event, leading to initiation of energy 797 
metabolic pathways, which elevate ATP production and exert homeostatic control (Moreno-Santos et al. 798 
2016). Evidence has shown the significance of acetylation/deacetylation of mitochondrial proteins via 799 
SIRT3, and its possible role in the onset of insulin resistance. Thus, the development of new SIRT3-800 
targeted drugs may aid in regaining regular cellular redox status in T2D patients. 801 
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 802 
Figure 2.11 Regulation of mitochondrial dysfunction, during type 2 diabetes mellitus via Nrf2, 803 
LonP1, SIRT3 and PGC-1α (Prepared by Author) 804 
 805 
2.5 Natural Compounds for Medicinal Treatment 806 
Globally in rural areas, traditional medicine is a common practice. Apart from its use by traditional 807 
healers, its demand and use has increased with limited knowledge of side effects and therapeutic efficacy 808 
(Ulbricht et al. 2007). It was estimated by the WHO that 80% of the world’s population is dependent on 809 
natural compounds for their primary healthcare (Khosla et al. 1995). Between 1983 and 1994 the United 810 
States Food and Drug Administration permitted approximately 78% of new drugs from unmodified 811 
natural products or semi-synthetic drugs acquired from natural sources (Suffredini et al. 2006). During a 812 
survey, the usage of natural compounds increased from 3% (1993) to 37% (1998) (Briskin 2000). This 813 
shift has been facilitated by the low cost of herbal drugs coupled with the developing world. The ‘green’ 814 
movement in the developed world campaigns the essential safety of natural products, and the 815 
individualistic philosophy of society that encourages self-medication - with countless people choosing to 816 
treat themselves with herbal remedies (Neelakantan et al. 2014). 817 
 818 
Plants have been termed natural producers of medicinal compounds, which led to the discovery of new, 819 
inexpensive drugs, with high therapeutic potential. The exploitation of such medicinal compounds is 820 
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prehistoric. In the Middle Ages in Europe, internal bleeding and upper respiratory tract infections were 821 
treated by yarrow tea (Zarshenas et al. 2014). Salix leaves were prescribed by Hippocrates to reduce 822 
fever, (Zarshenas et al. 2014) and garlic and onions were thought to lower blood glucose, serum 823 
cholesterol and blood pressure, due to its proposed antibiotic properties (Bayan et al. 2014). Inflammation 824 
and pain were treated with salicin (white willow tree extract), which is now synthetically produced, and 825 
used as a staple over-the-counter drug (Huie 2002). Gymnema sylvestre is a woody plant that has been 826 
reported to be beneficial in diabetes therapy, via its ability to supress the desire for sugary foods (Leach 827 
2007). Other potential sources of anti-diabetic properties include Momordica charantia (bitter melon) and 828 
Opuntia ficus-indica (prickly pear cactus), which has been documented to display glucose lowering 829 
effects (Leung et al. 2009, Joseph and Jini 2013). Another commonly used plant is Trigonella foenum-830 
graecum (fenugreek). Its leaves and seeds are not only used as a nutritional source, but are also 831 
commonly prescribed in traditional medicine (Basch et al. 2003, Ulbricht et al. 2007).  832 
 833 
Trigonella foenum-graecum frequently known as fenugreek is a promising medicinal plant from the 834 
Fabaceae family (Basch et al. 2003). Fenugreek is indigenous to Southern Europe and Western Asia but 835 
cultivated worldwide. Fenugreek seeds contain a rare amino acid, 4-OH-lle – its biologically active 836 
compound (Ulbricht et al. 2007). Medical uses of fenugreek in Indian and Chinese medicine, include 837 
inducing labour, assisting digestion, and as a general tonic to increase metabolism and health (Basch et al. 838 
2003, Ulbricht et al. 2007). In ancient times, Egyptians used fenugreek together with honey for the 839 
treatment of anaemia, constipation, DM, dyspepsia, rheumatism and rickets (Ulbricht et al. 2007). 840 
Preliminary studies have proposed potential hypoglycaemic and anti-hyperlipidaemic properties of 841 
fenugreek seed powder. However, at present, evidence is insufficient to endorse fenugreek for or against 842 
the treatment of hyperglycaemia or hyperlipidaemia. 843 
 844 
2.5.1 Trigonella foenum-graecum (Fenugreek)  845 
Fenugreek is an annual self-pollinating leguminous bean. The seeds are sown in well-prepared soil which 846 
sprouts in approximately three days. Seedlings grow semi-erect, erect or branched based on its variety and 847 
attains a height of approximately 30 to 60cm (Fig 2.12A) (Ulbricht et al. 2007). It has compound trifoliate 848 
pinnate leaves, axillary yellow to white flowers, and 3 to 15cm long thin pointed hoop-like beaked pods 849 
(Fig 2.12B) (Ulbricht et al. 2007). Every pod comprises 10 to 20 oblong brown-greenish seeds with 850 
unique hoop-like groves (Ulbricht et al. 2007). Seed shape-size, number of seeds in a pod, pods and plant 851 
height varies from one fenugreek species to another (Fig 2.12C) (Ulbricht et al. 2007). 852 
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 853 
Figure 2.12 Trigonella foenum-graecum (A) leaves, (B) pods and (C) seeds used for medicinal 854 
purposes (http://www.punmiris.com/himg/o.12961.jpg) 855 
 856 
2.5.2 Fenugreek Seeds 857 
Fenugreek seeds are known to be powerfully aromatic and pungent. These seeds are common spices 858 
widely used for both their culinary and medicinal properties. The seeds are the most important and useful 859 
part of the plant. These seeds are hard, dark yellow in colour, small in size and have a four-faced stone 860 
like structure (Fig 2.13) (Yoshikawa et al. 1997). Naturally the seed is 3-6mm long, 2-5mm wide and 861 
2mm thick (Yoshikawa et al. 1997). The seeds are rich in phytonutrients, vitamins, minerals and soluble 862 
dietary fibre (Grant Reid and Derek Bewley 1979). Major fibre content in the plant comprises of non-863 
starch polysaccharides (NSPs), such as, saponins, hemicellulose, mucilage, tannin, and pectin (Grant Reid 864 
and Derek Bewley 1979). These NSPs aid in reducing LDLc via inhibition of bile salt re-absorption; 865 
confers protection to the colon mucus membrane by binding to toxins present in food; as well as 866 
augments bowel movements (Grant Reid and Derek Bewley 1979, Fuller and Stephens 2015). The 867 
medicinal properties of the plant are attributed to the phytochemical compounds within the seed, such as, 868 
choline, diosgenin, gitogenin, neotigogens, trigonelline and yamogenin (Sauvaire et al. 1998). Likewise, 869 
this seed is an exceptional source of minerals like copper, calcium, iron, manganese, magnesium, 870 
potassium, selenium and zinc (Yoshikawa et al. 1997). Potassium is significant in controlling heart rate 871 
and blood pressure, and iron is essential for red blood cell production. Moreover the seed is rich in 872 
essential vitamins which are optimum for healthy living, such as, folic acid, niacin, pyridoxine, thiamin, 873 
riboflavin, vitamin A and C (Yoshikawa et al. 1997). In addition to these properties it has been recognised 874 
that 4-OH-lle has facilitator action on insulin secretion (Sauvaire et al. 1998). 875 
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 876 
Figure 2.13 Dark yellow, four-faced stone like structure of fenugreek seeds 877 
(http://qafexporters.com/wp-content/uploads/2015/08/1280px-Methi_by_49264526.jpg) 878 
 879 
2.5.3 Biologically Active Compound: 4-hydroxyisoleucine 880 
The composition of fenugreek consists of a large number of chemical components, such as, amino acids, 881 
proteins, lipids and alkaloids, which include trigonelline, vitamins, minerals, galactomannan, fibre, 882 
flavonoids, saponins and coumarin (Al-Jasass and Al-Jasser 2012). Active compounds of the plant 883 
include soluble fibre, saponins, trigonelline, diosgenin and 4-OH-lle. Moreover hypoglycaemic activity 884 
has been primarily attributed to dietary fibre, saponin and 4-OH-lle (Sauvaire et al. 1998). The natural 885 
non-proteinogenic amino acid, 4-OH-lle possesses biological insulinotropic activity (Khosla et al. 1995). 886 
4-OH-lle is a branched-chain amino acid, extracted from fenugreek seeds, with an absolute stereo 887 
configuration of (2S, 3R, 4S) (Fig 2.14) (Fowden et al. 1973). 4-OH-lle has been reported to function by 888 
enhancing “glucose-induced release of insulin” (Broca et al. 1999). In comparison to other 889 
pharmacological drugs used for T2D therapy (e.g. sulfonylureas), the insulin response facilitated by 4-890 
OH-lle is dependent on glucose concentration (Fowden et al. 1973, Khosla et al. 1995). This response is 891 
ineffective at 3-5mmol/1 glucose, conversely 4-OH-lle potentiates insulin secretion induced by 892 
supranormal, 6.6 - 16.7mmol/1 glucose (Broca et al. 2000). This property of 4-OH-lle permits the 893 
occurrence of undesirable side-effects such as, hypoglycaemia in T2D therapy (Korthikunta et al. 2015). 894 
Glucose-induced insulin release is increased by 4-OH-lle, in the range of 100μmol/l to 1mmol/l 895 
(Korthikunta et al. 2015). In both rats and humans, this is mediated via a direct effect on isolated islets of 896 
Langerhans. In addition, in isolated perfused rat pancreas treated with 4-OH-lle, it was shown i) that 897 
insulin secretion was biphasic, ii) this effect ensued in the absence of changes in pancreatic activity, and 898 
iii) greater the glucose concentration, greater the response of insulin (Korthikunta et al. 2015). Moreover, 899 
35 
 
4-OH-lle did not interact with other agonists of insulin secretion, such as leucine, arginine, tolbutamide, 900 
and glyceraldehyde (Korthikunta et al. 2015). 901 
 902 
Figure 2.14 Chemical structure of 4-hydroxyisoleucine 903 
(http://www.sigmaaldrich.com/content/dam/sigmaaldrich/structure3/194/mfcd07357252.eps/_jcr_co904 
ntent/renditions/mfcd07357252-large.png) 905 
 906 
2.5.4 Pharmacological Action of Fenugreek Seeds and 4-hydroxyisoleucine 907 
As previously mentioned, fenugreek possesses anti-diabetic and anti-lipidaemic effects. However, the 908 
particular mechanism of action remains unclear, as more work is required. The anti-diabetic property of 909 
fenugreek is owed to the formation of a colloidal-type suspension in the stomach and intestine (Yadav and 910 
Baquer 2014). Whereas the anti-lipidaemic effects of fenugreek is due to inhibited intestinal cholesterol 911 
absorption, improved loss of bile through faecal excretion, and effects of amino acid patterns on serum 912 
cholesterol (Yadav and Baquer 2014, Zarshenas et al. 2014). Fenugreek also comprises coumarins and 913 
additional constituents which affect platelet aggregation. Furthermore, this plant’s components have also 914 
shown evidence of cardiotonic, diuretic, anti-inflammatory, anti-hypertensive, and anti-viral properties 915 
(Zarshenas et al. 2014). 916 
 917 
2.5.4.1 Evidence Based Studies on the Anti-diabetic Properties of Fenugreek 918 
The action of fenugreek on lowering blood glucose levels was said to be almost analogous to that of 919 
insulin, mimicking its effects (Baquer 2011). Baquer et al, 2011 and Ardekani et al, 2009 reported the 920 
unusual amino acid, to display in vitro insulinotrophic activity and, anti-diabetic properties in animal 921 
models (Haeri et al. 2009). According to Ardekani et al, 2009, the amino acid is a useful and well-922 
tolerated treatment for insulin resistance, as it serves as a hypoglycaemic and, a protective agent for 923 
hepatocytes. (Haeri et al. 2009). In addition, a meta-analysis on the effect of herbs on glucose homeostasis 924 
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in T2D patients, stated that HbA1c was significantly reduced in the group supplemented with fenugreek 925 
(Suksomboon et al. 2011). Furthermore, it was reported that ocular histopathological, and biochemical 926 
irregularities relevant to diabetic retinopathy, were controlled when using fenugreek, and sodium 927 
orthovandate independently, or in low dose combination (Prabhakar and Doble 2011). Another review 928 
article by Assad and Morse, 2013 included three separate studies that assessed the effect of fenugreek in 929 
patients with DM (Assad 2013). The first study assessed the effect of fenugreek use in patients with T1D, 930 
and showed a significant reduction of fasting blood glucose, TGs, total cholesterol, VLDL, and LDL 931 
levels (Assad 2013). The second study assessed the effect of fenugreek usage (25g fenugreek 932 
powder/day) in patients with T2D, and showed that fasting blood glucose levels were decreased, and 933 
glucose tolerance was improved (Assad 2013). The third study showed fenugreek to improve glycaemic 934 
control, insulin sensitivity, and hypertriglyceridemia in newly diagnosed T2D patients (Assad 2013). 935 
 936 
2.5.4.2 Evidence Based Studies on the Anti-lipidemic Properties of Fenugreek 937 
Anti-lipidemic properties were noted in the Hazra et al, 1996 trial on T1D; minor but statistically 938 
significant decreases were found in TG, and LDLc levels, but HDLc levels remained unchanged (Sharma 939 
et al. 1996). These results were based on a group of 15 non-obese, asymptomatic, hyperlipidaemic adults, 940 
who ingested 100g defatted fenugreek powder/day over 3 weeks (Sharma et al. 1996). In a later study, 60 941 
patient diets were supplemented with 25g powered fenugreek seed/day for 24 weeks; lipid profiles were 942 
normalized by a decrease of 14-16% in LDLc and TG levels, and a 10% rise in HDLc (Sharma et al. 943 
1996). Likewise, Sowmya and Rajyalakshmi, 1999 observed substantial decreases in TG and, LDLc 944 
levels in 20 adults with hypercholesterolemia, who received 12.5-18g powdered, germinated fenugreek 945 
seeds for a month -  but no changes were observed in HDLc, VLDL, or TG levels (Sowmya and 946 
Rajyalakshmi 1999). In another study, Sharma et al, 1990 also described a reduction in total cholesterol 947 
levels in 5 diabetic patients treated with fenugreek seed powder (25g orally/day) over 21 days 948 
(Neelakantan et al. 2014). Also, Bordia et al, 1997 investigated the effects of fenugreek seed powder 949 
(2.5g administered twice daily for 3 months) in a group of 40 individuals with coronary artery disease and 950 
T2D, and observed reductions in TG levels but no changes in HDLc levels (Bordia et al. 1997).  951 
 952 
2.5.4.3 Evidence Based Studies on the Anti-diabetic and Anti-lipidemic Properties of 4-953 
hydroxyisoleucine 954 
The molecular mechanism of action of 4-OH-lle has been displayed in in vitro studies. For example in rat 955 
muscle cells, glucose uptake and GLUT4 translocation to the plasma membrane was elevated following a 956 
16h exposure to 4-OH-lle (Jaiswal et al. 2012). Another study treated L6 myotubes with 4-OH-lle, 957 
resulted in reduced insulin resistance (Maurya et al. 2014). 4-OH-lle displayed its inhibitory effect on 958 
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both the production of ROS, as well as, reduced activation of the JNK1/2 pathway. The anti-inflammatory 959 
potential of 4-OH-lle on 3T3-L1 adipocytes was confirmed by an increase in glucose uptake accompanied 960 
with reduced TNF-α mRNA expression and secretion (Yu et al. 2013). As previously mentioned, the anti-961 
diabetic properties of 4-OH-lle are associated with its capability to stimulate insulin. This was observed in 962 
both diabetic dogs and rats which displayed an improvement in glucose and insulin tolerance, and reduced 963 
hyperglycaemia (Broca et al. 1999). The secretagogue potential of 4-OH-lle is of particular interest, with 964 
regards to insulin resistance. In STZ-treated rats the stimulating effect of 4-OH-lle resulted in an 965 
improved diabetic state (Broca et al. 2004). Also, in normal dogs and rats, 4-OH-lle improved insulin 966 
secretion, and glucose tolerance (Broca et al. 1999). During a diabetic state, reversal of defective insulin 967 
secretion is highly desirable, as well as, improving insulin sensitivity in both peripheral and hepatic 968 
tissues. The insulin-sensitising efficacy of 4-OH-lle was confirmed in two rat models. These models used 969 
the hyperinsulinaemic clamp method, which improved insulin sensitivity, and reduced hepatic glucose 970 
output in sucrose and lipid-fed rats (Broca et al. 2004). Alloxan-induced diabetic rats treated with 971 
fenugreek seed powder containing 28% 4-OH-lle, displayed improvements in blood glucose level, and 972 
body weight, when compared to the diabetic control (Khosla et al. 1995). A study by Narender et al, 2006 973 
observed reduced plasma TGs, total cholesterol (TC), and FFAs, complemented with a 39% rise in HDLc, 974 
in dyslipidaemic hamsters (Narender et al. 2006). Haeri et al, 2009 investigated the effect of 4-OH-lle 975 
(50mg/kg for 8 weeks) on fructose-fed and STZ-induced diabetic rats (Haeri et al. 2009). These rats 976 
displayed improved liver function markers, decreased blood glucose and restoration of blood lipid levels 977 
(Haeri et al. 2009). The glucose-dependent and insulin-sensitising potential of 4-OH-lle has been 978 
observed via its effects on pancreatic islets, liver, muscle and adipose tissue. These effects, culminated 979 
with the lack of acute toxicity, suggests that this compound, serves as a prospective natural therapeutic 980 
intervention in obesity and insulin resistance.  981 
 982 
2.5.4.4 Evidence Based Studies on the Antioxidant Properties of Fenugreek Seed and 4-983 
hydroxyisoleucine 984 
Studies have reported the AO effect of fenugreek in attenuating ROS levels. Mohamad et al, 2004 985 
observed SOD2 and related liver enzyme levels, comparable to the diabetic group of fenugreek seed 986 
treated rats (Mohamad et al. 2004). Ravikumar and Anuradha, 1999 showed supplementation of diabetic 987 
animal diets with fenugreek seed, interrupted free radical metabolism (Ravikumar and Anuradha 1999). 988 
In a second study, they also showed that treatment with fenugreek seed powder improved AO status, via 989 
reduction in peroxidation (Anuradha and Ravikumar 2001). Another study, investigated the AO activities 990 
of various extracts of fenugreek seeds in cholesterol-fed rats, and observed a reduction in TBARS, and 991 
increase in catalase and SOD2 gene expression (Belguith-Hadriche et al. 2010). Additionally Dixit et al, 992 
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2005 revealed significant AO potential of germinated fenugreek seeds, which is due to the presence of 993 
flavonoids and polyphenols (Dixit et al. 2005). Kandhare et al, 2015 observed standardized fenugreek 994 
seed extract to execute anti-fibrotic efficacy, via stimulation of Nrf2, which in turn controls anti-995 
inflammatory and fibrogenic molecules (Kandhare et al. 2015). The bioactive component of fenugreek 996 
seeds, 4-OH-lle, independently possesses AO activity as shown by Dutta et al, 2014. This study proved 997 
that 4-OH-lle scavenges hydroxyl, superoxide anion, hydrogen peroxide and DPPH radicals, decreased 998 
lipid peroxidation and protein carbonyl levels, and concomitantly increased GSH levels (Dutta et al. 999 
2014). An important study, by Mayakrishnan et al, 2015 found both trigonelline and diosgenin to display 1000 
protective effects via a substantial decrease in liver TGs, expression of liver ER stress marker proteins, 1001 
and rise in liver glycogen content (Mayakrishnan et al. 2015). Other findings, based on other organ 1002 
systems also validates the potent AO potential of fenugreek seeds (Kaviarasan et al. 2004, Gupta et al. 1003 
2010). 1004 
 1005 
2.5.5 Adverse Effects and Safety 1006 
Fenugreek has been considered non-toxic and well-tolerated, with minimal side effects has been related 1007 
with its usage (Wani and Kumar , Muraki et al. 2011). Fenugreek should not be taken during pregnancy 1008 
and lactation and/or individuals with liver or kidney impairment should be avoided, due to inadequate 1009 
data suggesting usage (Neelakantan et al. 2014). Other reported side effects include dizziness, flatulence, 1010 
hypoglycaemia, transient diarrhoea and maple syrup urine, and decrease in blood urea (Vijayakumar et al. 1011 
2005, Neelakantan et al. 2014). Moreover, fenugreek has been documented to cause allergic reactions 1012 
such as hoarseness, facial angioedema, nasal congestion, persistent coughing, shock and wheezing 1013 
(Neelakantan et al. 2014). Continual chronic use of fenugreek should be avoided to prevent adverse 1014 
reactions or toxicities, due to long-term data being unavailable (Vijayakumar et al. 2005, Neelakantan et 1015 
al. 2014). Most importantly hypoglycaemia is an expected effect, thus care should be taken following 1016 
fenugreek supplementation (Neelakantan et al. 2014).  1017 
 1018 
Despite these documented adverse effects and warnings, there has been reports on the tolerability and 1019 
outcome of fenugreek treatment. No clinical hepatic and/or renal toxicity and haematological 1020 
irregularities were observed in a group of diabetic individuals, who were administered 25g/day of 1021 
fenugreek for 24 weeks (Sharma et al. 1996). It was also shown in an animal study that fenugreek failed 1022 
to induce signs of toxicity or mortality (Muralidhara et al. 1999). However, the data generated to date is 1023 
minimal regarding the adverse effects and safety, and requires well-designed clinical trials to assess the 1024 
outcome of fenugreek on insulin resistance and secretion, and cholesterol metabolism (Basch et al. 2003).  1025 
 1026 
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2.5.6 Drug Interactions  1027 
The administration of fenugreek in combination with other drugs could pose potential negative 1028 
interactions, affecting their activity. Fenugreek powder is abundant in fibre and could hinder the 1029 
absorption of oral medication (Wani and Kumar). Furthermore, simultaneous use of the plant with other 1030 
hypoglycaemic agents, such as insulin and MF may result in hypoglycaemic episodes (Wani and Kumar , 1031 
Neelakantan et al. 2014). Also, fenugreek can impede the activity of corticosteroids, warfarin, insulin and 1032 
hormone therapy, due to the high content of mucilaginous fibre in the plant, and viscosity in the gut 1033 
(Neelakantan et al. 2014) (Muralidhara et al. 1999). Coumarins found in fenugreek have anti-platelet 1034 
effects (Neelakantan et al. 2014); thus simultaneous use of anti-platelet or anti-coagulant drugs (aspirin, 1035 
clopidrogel, non-steroidal anti-inflammatory drugs, such as ibuprofen, diclofenac, naproxen, heparin, 1036 
dalteparin and enoxaparin) may elevate the risk of bruising and bleeding (Neelakantan et al. 2014). 1037 
Therefore immense care should be taken upon administration of fenugreek in combination with other 1038 
drugs. 1039 
 1040 
2.6 Research Problem and Significance 1041 
T2D continues to negatively impact socio-economic development in multiple communities, despite efforts 1042 
to control the disorder (WHO 2016). The incidence of T2D in different communities is a well-known 1043 
phenomenon but under-diagnosed and poorly managed. Both self-care and anti-diabetic drugs have been 1044 
widely employed as the priority therapy in treating T2D. However, the lack in compliance to self-care 1045 
requirements, and unwanted side effects accompanying MF pose a potential problem (Rios et al. 2015). 1046 
When strictly adhered to, self-care regimens efficiently maintain basal glucose levels. However, due to 1047 
excessive calorie consumption, and sedentary lifestyle self-care regimens have become redundant. This 1048 
failure in compliance, leads to the use of anti-diabetic drugs, such as MF which achieve basal glucose 1049 
levels. Upon achieving this goal, unwanted side effects and complications make the use of this drug 1050 
undesirable. Therefore, posing the requirement for new anti-diabetic therapy as T2D is a threat to public 1051 
health especially in poor communities.  1052 
 1053 
Long-term exposure to chronic hyperglycaemia due to insulin resistance plays an active role in elevating 1054 
FFAs and ROS production. The elevated levels of FFAs contributes to an abnormal lipid profile, 1055 
predisposing individuals to dyslipidaemia. Furthermore, an over-production in ROS surpasses the 1056 
endogenous AO response and detoxification system, resulting in a highly toxic oxidative state. Both 1057 
dyslipidaemia and elevated OS are major risk factors for the onset and progression of CVD, and 1058 
microvascular and macrovascular complications. Therefore, uncontrolled glucose levels either due to lack 1059 
of self-care or unwanted side effects of MF, pose severe health risks for T2D individuals.  1060 
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Consequently, there is a need for developing high quality treatment alternatives for chronic 1061 
hyperglycaemia, to improve the long-term outcomes of T2D. Over decades plants have been used for 1062 
treatment of several disorders, and several bioactive compounds isolated from these plants produced 1063 
effective drugs (Rios et al. 2015). Moreover, natural therapy is currently a significant source for the 1064 
development of new treatments (Rios et al. 2015). Natural therapy possesses chemical diversity, which 1065 
aids an array of biological functions, posing plants as an important source for new treatment opportunities 1066 
(Rios et al. 2015). Fenugreek has been traditionally used to treat an array of illnesses and disease, many of 1067 
which has been documented (Basch et al. 2003). In addition, studies have validated the proposed 1068 
traditional usage and therapeutic outcomes of both 4-OH-lle and fenugreek seed (Neelakantan et al. 2014, 1069 
Fuller and Stephens 2015, Gong et al. 2016). However, there is minimal evidence with regards to 4-OH-1070 
lle and the seed; and specific genes, proteins, and related factors in managing and controlling glucose and 1071 
its long-term effects. This indicates the need for research on the molecular and biochemical aspects of 4-1072 
OH-lle and fenugreek seed in regulating hyperglycaemia and subsequent downstream effects. 1073 
 1074 
Consequently, we hypothesized that 4-OH-lle in comparison to MF, and FSE increased biochemical and 1075 
molecular responses following chronic exposure to hyperglycaemia in human hepatoma (HepG2) cells 1076 
and C57BL/6 male mice. In order to test our hypothesis we measured anti-diabetic effects of 4-OH-lle in 1077 
comparison to MF, and FSE relative to insulin signalling, lipid metabolism and OS, during normal and 1078 
hyperglycaemic conditions in HepG2 cells and C57BL/6 male mice.  1079 
 1080 
2.7 Research Aims, Objectives and Hypothesis 1081 
2.7.1 Research Aim 1082 
This study investigated the anti-hyperglycaemic, anti-lipidaemic and anti-oxidative effects of 4-OH-lle in 1083 
hyperglycaemic HepG2 cells and C57BL/6 male mice. 1084 
 1085 
2.7.2 Research Objectives   1086 
To determine the effect of 4-OH-lle in comparison to MF, and FSE in hyperglycaemic HepG2 cells and 1087 
C57BL/6 male mice:  1088 
1. On a broad class of proteins and genes regulating insulin signalling and glucose sensing. 1089 
2. On PCSK9, PPARG, and the lipid profile relative to lipid metabolism. 1090 
3. On oxidative markers, AO response and mitochondrial proteins relative to OS. 1091 
 1092 
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2.7.3 Research Hypotheses 1093 
During hyperglycaemia, 4-OH-lle regulates insulin signalling and glucose sensing, dyslipidaemia and OS, 1094 
in comparison to MF, and FSE. 1095 
 1096 
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Abstract 1597 
Type two diabetes mellitus (T2D) is a metabolic disorder characterized by chronic hyperglycaemia and 1598 
compromised insulin receptor (IR) signaling ultimately contributing to insulin resistance. Previous studies 1599 
showed beneficial glucose lowering effects of a novel amino acid, 4-hydroxyisolecuine (4-OH-lle) found 1600 
abundantly in fenugreek seeds, displaying potent anti-diabetic activity. Based on our previous in vitro 1601 
study, we investigated the effect of 4-OH-lle and metformin (MF), on hepatic IR signaling in 1602 
normoglycaemic (NG) and streptozotocin-induced diabetic (hyperglycaemic –HG) C57BL/6 male mice. 1603 
Mice (both normoglycaemic and hyperglycaemic) were treated via oral administration with 4-OH-lle and 1604 
MF for 15 days. The oral glucose tolerance test was performed to evaluate glucose sensing ability. 4-OH-1605 
lle enhanced glucose utilization, exceeding the effects of MF, under both conditions. We investigated 1606 
protein and gene expression of IRβ, glucose transporter2 (GLUT2), phosphorylated - IR substrate1 1607 
(pIRS1); protein kinase B (pAkt) and glycogen synthase kinase3α/β (pGSK3α/β). 4-OH-lle induced the 1608 
most significant effect on the insulin signaling cascade with increased protein and gene expression of IRβ, 1609 
pIRS1, pAkt, pGSK3α/β, and GLUT2, under both conditions. The glucose-lowering effect of 4-OH-lle 1610 
exceeds that of MF by stimulation of the hepatic insulin signaling pathway in mice. 1611 
 1612 
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Introduction 1631 
Hepatic insulin signalling is central to metabolic processes including glycogen synthesis, glycogen 1632 
storage, recruitment of glucose transporters and lipid synthesis [1]. Autophosphorylation of the insulin 1633 
receptor (IR) by insulin recruits and activates intracellular down-stream signalling molecules, leading to 1634 
glucose uptake and subsequent biological effects. Conversely, defective insulin signalling, defined as 1635 
insulin resistance results in post-prandial hyperglycaemia, dysregulated glucose utilization and lipid 1636 
metabolism [1]. During insulin resistance, there is conventional binding of insulin to the IR but signal 1637 
transduction is impaired [2]. The integral role of this signalling cascade in glucose homeostasis leads to a 1638 
disorder classified by chronic hyperglycaemia - type 2 diabetes mellitus (T2D).  1639 
 1640 
Presently, the treatment of T2D principally involves a sustained reduction in hyperglycaemia using agents 1641 
that increase insulin secretion in the pancreas, stimulate the sensitivity of the liver to insulin and decrease 1642 
glucose absorption rate in the gastrointestinal tract (GIT) [1, 2, 3]. The commonly used first-line drug for 1643 
treatment of T2D is metformin (MF) which belongs to the sensitizer group of drugs. This oral 1644 
hypoglycaemic agent decreases hepatic glucose output and improves tissue sensitivity to insulin [4]. 1645 
Although highly effective, some minor side effects have been recorded with chronic use; there is still an 1646 
increasing demand for new compounds or therapeutic alternatives, with less or no side effects for the 1647 
treatment of T2D. 1648 
 1649 
Alternative therapeutic interventions have become a focus for the treatment for T2D. Alternatives such as 1650 
herbal medicines have gained attention for anti-diabetic potential [15, 16]. Trigonella foenum-graecum, 1651 
commonly known as fenugreek, has been investigated as a therapeutic intervention in diabetes [16-18]. 1652 
Cell culture, animal model and meta-analysis studies by Khosla et al, 1995, Vijayakumar et al, 2005 and 1653 
Neelakantan et al, 2014 established the glucose lowering properties of fenugreek seeds [18, 19, 20]. The 1654 
anti-diabetic effect of fenugreek seeds is largely attributed to a high content of the branched-chain amino 1655 
acid derivative, 4-OH-lle, which comprises about 80% free amino acid content within the seed [21]. 1656 
Animal studies demonstrated 4-OH-lle to possess an insulinotrophic effect; functions as an insulin 1657 
secretagogue only at elevated blood glucose levels and stimulates the insulin signalling pathway [17, 21, 1658 
22], making 4-OH-lle a strong candidate as an antidiabetic compound. Most importantly, Vijayakumar 1659 
and his group observed the hypoglycaemic effect of FSE in vivo, and concluded the effect to be mediated 1660 
by the activation of an insulin signalling pathway in adipocytes and liver cells [19]. Our previous in vitro 1661 
study using HepG2 human liver cells as a model was the first to show that FSE and its biologically active 1662 
compound 4-OH-lle, in comparison to MF, significantly influenced the insulin signalling pathway and 1663 
subsequently increased hepatic glucose uptake [13]. The objective of the present in vivo study was 1664 
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therefore to investigate the effect of 4-OH-lle in comparison to MF, on glucose sensing, IRβ-IRS1 and 1665 
Akt signalling in normal and streptozotocin (STZ)-induced diabetic C57Bl/6 male mice. 1666 
 1667 
Materials and methods 1668 
Materials 1669 
4-OH-Ile (50118) and STZ (S0130) were purchased from Sigma Aldrich (St Louis, MO, USA). Whole 1670 
fenugreek seeds were purchased from Agricol Niche Brands, a South African seed company. A herbarium 1671 
voucher of flowering material was lodged at the Ward Herbarium (UDW-UKZN; N.Naicker 1). All other 1672 
consumables were purchased from Merck (Darmstadt, Germany), unless otherwise stated.   1673 
 1674 
Animals 1675 
Six-week-old male C57BL/6 mice (n=40) were procured from the Biomedical Resource Unit at the 1676 
Westville Campus of the University of KwaZulu-Natal (UKZN), Durban, South Africa. Mice with a mean 1677 
body weight (BW) of 20 ± 2.99g were randomly divided into 2 groups: non-diabetic (normoglycaemic) 1678 
and diabetic (hyperglycaemic-HG). Each group were further subdivided into 4 groups of 5 mice each as 1679 
follows: Control (C), MF, FSE and 4-OH-lle. Mice were housed in polycarbonated cages in a humidity 1680 
and temperature controlled room (40-60% humidity, 23 ± 1oC) with a 12 hour (hr) light dark cycle. The 1681 
mice were fed a commercially available pellet diet and normal drinking water ad libitum throughout the 1682 
15 day experimental period. The mice were maintained according to the rules and regulations of the 1683 
Experimental Animal Ethics Committee of the UKZN (Ethical approval number: AREC/057/016). 1684 
 1685 
Induction of diabetes 1686 
Diabetes mellitus is a disease characterized by a relative or absolute lack of insulin resulting in 1687 
hyperglycaemia. Type 2 diabetes mellitus is associated with insulin resistance, as well as a lack of 1688 
appropriate compensation by beta cells, causes insulin deficiency [63-66]. Type 2 diabetes mellitus is 1689 
established in both non-obese and obese animal models with varying degrees of insulin resistance and 1690 
beta cell failure. The mice model should possess characteristics which emulate the pathophysiology and 1691 
complications of T2D comparable to the human condition [63-66]. Streptozotocin is a chemical that is 1692 
principally toxic to the insulin-producing β cells of the pancreas in mammals [23, 61]. Streptozotocin 1693 
offers the additional benefit of being able to select specific traits of interest with regards to disease 1694 
specific conditions [24]. In relation to T2D, STZ allows for the replication of the metabolic characteristics 1695 
and disturbances observed in this disease [25]. Administration of multiple low doses or a low single dose 1696 
of STZ damages pancreatic β cells through alkylation of DNA - by causing partial destruction (and not 1697 
total knockout) of these cells, resulting in hyperglycaemia [23, 26]. Therefore displaying the 1698 
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pathophysiological characteristics of T2D which include inadequate β-cell mass and β-cell dysfunction. 1699 
As a result T2D was induced in all mice in the diabetic group (HG group) by an intraperitoneal (i.p.) 1700 
administration of STZ (50mg/kg BW) dissolved in 0.1M citrate buffer (pH 4.4) following an overnight 1701 
fast (12hr) [27, 28]. The optimal dosage of 50mg/kg was determined by a pilot study which included a 1702 
range of STZ concentrations (50mg/kg, 100mg/kg and 150mg/kg BW). The blood was collected from the 1703 
tail vein, using a glucometer (Accu-Chek) to monitor and measure the fasting blood glucose (FBG) over a 1704 
10 day period prior to administration of treatment. Once a blood glucose of >7mmol/L and <16mmol/L 1705 
was achieved and stable, the treatment period was inducted.    1706 
 1707 
Treatment preparation of stock solutions 1708 
Whole fenugreek seeds were crushed using a mortar and pestle, suspended in deionized water (1000 1709 
mg/mL), and placed on a stirrer at room temperature (RT) for 3Hr. The aqueous solution was transferred 1710 
to a sterile conical tube and centrifuged (3600xg for 10min) at RT. Supernatant (FSE) was removed, 1711 
freeze-dried, and stored at -20oC. Metformin tablets were also crushed with a mortar and pestle and 1712 
suspended in 0.1M phosphate-buffered saline (PBS) (50mg/mL). The solution was then filter sterilized 1713 
(0.45-mm filter). 4-hydroxyisoleucine was obtained in a liquid form, and treatments were prepared from a 1714 
stock solution (as per manufacture instructions). Subsequent treatments were prepared in 0.1M phosphate 1715 
buffer solution (PBS) solution for in vivo.  1716 
 1717 
Treatment preparations 1718 
Preparation of treatments were guided by the protocol Naicker et al, 2016 [13]. The concentration of 4-1719 
OH-lle (100mg/kg BW), MF (20mg/kg BW), FSE (100mg/kg BW) and were based on previous animal 1720 
studies which evaluated a range of concentrations and reported the outcomes of the range which we based 1721 
our optimal concentration [17, 29-32]. Mice were treated once daily for the 15 day treatment period via 1722 
oral gavage.  1723 
 1724 
Oral glucose tolerance test (OGTT) 1725 
Glucose tolerance ability was measured by the OGTT performed on day 15 (last experimental day) of the 1726 
experimental period. After an overnight fast (12hr), mice in NG and HG groups were orally dosed with a 1727 
D-glucose solution (2.0g/kg BW). The blood glucose concentrations were subsequently measured at 0 1728 
(prior to oral glucose dosing), 30, 60, 90, and 120 min after the oral dosing of glucose. In order to give a 1729 
clear quantitative indication of glucose intolerance in the different animal groups, area under the curve 1730 
(AUC) values were calculated using the formula below (Supplementary data, table 1, 2) [33]: 1731 
AUC = [(B2 + B1) / 2] × (A2 – A1) 1732 
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B1 and B2 = Initial and final blood glucose values (mg/dl) at a given time period respectively 1733 
A1 and A2 = Initial and final time periods (min) respectively 1734 
Where: (A2 – A1) = (30 – 0), (60 – 30), (90 – 60) and (120 – 90) 1735 
(B2 + B1) = Blood glucose values at the above mentioned time periods 1736 
 1737 
Animals post treatment 1738 
At the end of the treatment period, the mice were sacrificed using isoflurane. Fasting plasma samples 1739 
were obtained from the body of the mice; blood samples were collected using anticoagulant EDTA tubes. 1740 
The blood glucose levels were measured at an accredited laboratory (AMPATH).  Liver samples were 1741 
harvested, rinse twice in saline, dissected and stored in cytobuster and triazol at -80oC until analysis. 1742 
 1743 
Western blotting 1744 
Western blots were performed to quantify expression of phosphorylated (p-) and total proteins in the 1745 
insulin signaling pathway. These include phosphorylated and total; IRS1 (pIRS1/IRS1), Akt (pAkt/Akt), 1746 
GSK3α/β (pGSK 3α/β/pGSK 3α/β) and total insulin receptor β (IRβ) and GLUT2. Crude protein was 1747 
isolated using Cytobuster (Novagen) supplemented with protease and phosphate inhibitors (Roche: 1748 
04693124001 and 04906837001). Liver samples were homogenized and incubated in cell lysis buffer for 1749 
10 min and then centrifuged (4oC, 12,000g). Crude protein was quantified by the bicinchoninic acid 1750 
(BCA) assay and standardized to 1mg/mL. Samples were boiled in Laemmli buffer [dH2O, 0.5M Tris–1751 
HCl (pH 6.8), glycerol, 10% SDS, β-mercaptoethanol, and 1% bromophenol blue] for 5 min. Samples 1752 
were electrophoresed on a sodium dodecyl sulphate polyacrylamide gel (4% stacking and 10% resolving) 1753 
for 1hr at 150V and transferred on to nitrocellulose using the TransBlot Turbo Blotting System (BioRad) 1754 
using a preinstalled Standard SD program. All membranes were blocked for 2hr in 3% BSA in Tween20-1755 
Tris-buffered saline (TTBS - 0.15M NaCl, 2.68M KCl, 24. 86M Tris, 500µl Tween20, pH 7.4) at RT on a 1756 
shaker. Thereafter, the membranes were incubated with primary antibody [pIRS1 (CS2381), anti-IRβ 1757 
(CS3050), anti-GLUT2 (AB54460), pAkt (CS9271) and pGSK3α/β (CS9331); 1:5000] at 4oC overnight. 1758 
The membranes were then equilibrated to RT on a shaker for 1hr, followed by 5 washes (10min) with 1759 
TTBS. Membranes were then probed with horseradish peroxidase conjugated-secondary antibody [anti-1760 
rabbit 1:10000 (CS7074)] for 1hr, followed by 5 washes (10min) with TTBS. Chemiluminescent signal 1761 
was detected using ECL Clarity Western detection reagent (BioRad) and captured on the BioRad 1762 
ChemiDoc Viewing System. Data were expressed as relative band density (RBD) and expression of 1763 
proteins was analyzed with the BioRad ChemiDoc MP Imaging System with Image Lab software. 1764 
Membranes were quenched (5% H2O2 at 37oC for 30min) and proteins were normalized against anti-1765 
IRS1 (CS2382), anti-Akt (CS9331), anti-GSK3α/β (cs9315) and β-actin (A5316), 1:1000. 1766 
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Quantitative PCR 1767 
The RNA expression of genes of interest was determined by qPCR. These included IRβ, IRS1, Akt, 1768 
GSK3α/β, GS, GK, GLUT2 and SREBP1c. Total RNA was isolated using an in-house protocol [34]. 1769 
RNA was quantified using a spectrophotometer (Nanodrop2000) and standardized to 1,000ng/µl. 1770 
Standardized RNA was reverse transcribed to complementary DNA (cDNA) using the iScriptTM cDNA 1771 
Synthesis kit (Bio-Rad; 107-8890) as per the manufacturer’s instruction. A reaction volume of 10μl was 1772 
prepared consisting of 5X IQ™ SYBR® green supermix (Bio-Rad; 170-880), nuclease free water, 1μl 1773 
cDNA template (1,000ng/ml), and 1μl sense and anti-sense primer (25µM primer stock, Inqaba 1774 
Biotec™). The mRNA expression was normalized against a housekeeping gene (18S). Thermocycler 1775 
conditions were carried out using the CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad, 1776 
Hercules, CA) as follows:  initial denaturation (95°C, 10min), 40 cycles of denaturation [95°C, 15seconds 1777 
(s)], annealing and extension (72°C, 30s). mRNA expression was determined using the method described 1778 
by Livak and Schmittgen, 2001 to calculate relative fold change [35]. Primer sequences and annealing 1779 
temperatures are shown supplementary data, table 3. 1780 
 1781 
Measurement of glucose concentration 1782 
Measurement of glucose concentration was performed by an accredited pathology laboratory AMPATH 1783 
Laboratories, Durban, South Africa (Incorporated Pathology Laboratory practices of: Drs Du Buisson, 1784 
Kramer, Swart, Bouwer Inc). 1785 
 1786 
Liquid chromatography–mass spectrometry (LC-MS) 1787 
Liquid chromatography–mass spectrometry (LC-MS) is an analytic chemistry technique which combines 1788 
the physical separation capabilities of liquid chromatography (or HPLC) with the mass analysis 1789 
capabilities of mass spectrometry (MS). 1mg of crude FSE was weighed and dissolved in 10ml MeOH. 1790 
Each sample was vortexed and sonicated to allow for complete dissolution. Then the extract was 1791 
subjected to solid phase extraction (SPE), using a Supelco C18 100mg solid phase cartridge. The extract 1792 
was eluted with MeOH. A 1:100 dilution of the sample was prepared using MeOH and injected into the 1793 
LC-MS. The instrumentation used was the Shimadzu 202 UFLC-MS, mobile A: 0.1% FA in H20 and 1794 
mobile phase B: 0.1% FA in CAN. Separation was achieved using a YMC Triart C18 analytical column 1795 
(4.6mm x 150mm), using a gradient elution method from 5% B to 95 B over 25min. Data was collected at 1796 
265 nm and analyzed using the Shimadzu Lab Solutions software (Supplementary data Fig 1, 2, 3 and 1797 
table 4). 1798 
 1799 
 1800 
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Statistical analyses 1801 
Statistical analyses was performed using GraphPad Prism v5.0 software (GraphPad Software, Inc.). The 1802 
data was expressed as relative fold change to respective controls in the qPCR and western blotting 1803 
experiments. With regards to western blotting, the phosphorylated proteins were normalized against the 1804 
total protein. Followed by the total protein against actin. The data was expressed as the mean + SD for the 1805 
OGTT and glucose measurements. Following each experiment in vitro and in vivo, 4-OH-lle was 1806 
compared to MF and the untreated control. We then analyzed FSE in comparison to the untreated control. 1807 
Statistical comparisons for 4-OH-lle, MF and the untreated control were made using a one-way analysis 1808 
of variance (ANOVA), nonparametric test (Kruskal Wallis test) and a Dunn’s post-test; and a non-1809 
parametric Mann-Whitney test was used for FSE and the untreated control. The data were considered 1810 
statistically significant with a value of p < 0.05. 1811 
 1812 
Results 1813 
4-hydroxyisoleucine reduces excess blood glucose levels 1814 
Glucose utilization of male C57BL/6 mice were assessed by an OGTT and quantification of circulating 1815 
glucose levels. Treated mice under both NG (p=0.0154; Fig 1 a) and HG (p=0.0245; Fig 1 b) conditions 1816 
efficiently utilized glucose, compared to their respective control groups. Two hours after the glucose 1817 
administration, the blood glucose levels of the HG group were significantly higher than the NG group 1818 
(p<0.005).  More importantly, under a HG state, the excess blood glucose was reduced following 1819 
treatment with 4-OH-lle (p=0.0021; Fig.1 d). Under NG conditions (p=0.00231) the blood glucose levels 1820 
of MF and 4-OH-lle were significantly lower than the NC (p<0.005; Fig.1 c).  1821 
 1822 
Table 1 Area under the curve (AUC) values for the OGTT at day 15 of experimental period for 1823 
normoglycaemic group 1824 
Area under curve (AUC) Control FSE MET 4-OH-lle 
AUC 1 (30-0 min) 217.5 ± 50* 199.5 ± 21# 192 ± 47+ 183 ± 24+ 
AUC 2 (60-30 min) 222 ± 34* 202.5 ± 72# 190.5 ± 24+ 187.5 ± 48+ 
AUC 3 (90-30 min) 223.5 ± 61* 201 ± 45# 192.45 ± 13+ 185.25 ± 23+ 
AUC 4 (120-90 min) 221.25 ± 19* 207 ± 35# 190.65 ± 175+ 184.5 ± 25+ 
Total AUC 884.25 ± 124 810 ± 264 765.6 ± 119 740.25 ± 249 
Data are shown as mean ± SD of 5 animals; *, #, + Values with different superscript letters within a row are significantly different 1825 
from each group of animals (Tukey’s multiple range posthoc test, p < 0.05). FSE: fenugreek seed extract, MET: Metformin, 4-1826 
OH-lle: 4-hydroxyisoleucine 1827 
 1828 
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Table 2 Area under the curve (AUC) values for the OGTT at day 15 of experimental period for 1829 
hyperglycaemic group 1830 
Area under curve (AUC) Control FSE MET 4-OH-lle 
     
AUC 1 (30-0 min) 498 ± 29* 484.5 ± 17# 447 ± 33+ 423 ± 17+ 
AUC 2 (60-30 min) 508.5 ± 54* 465 ± 89# 438 ± 55+ 453 ± 18+ 
AUC 3 (90-30 min) 519 ± 45* 448.5 ± 16# 433.5 ± 12+ 445.5 ± 19+ 
AUC 4 (120-90 min) 519 ± 34* 448.5 ± 10# 435.75 ± 11+ 445.5 ± 15+ 
Total AUC 2044.5 ± 163* 1846.5 ± 257# 1754.25 ± 175+ 1767 ± 138 
 
Data are shown as mean ± SD of 5 animals; *,#,+ Values with different superscript letters within a row are significantly different 1831 
from each group of animals (Tukey’s multiple range posthoc test, p < 0.05). FSE: fenugreek seed extract, MET: Metformin, 4-1832 
OH-lle: 4-hydroxyisoleucine 1833 
 1834 
Fig.1 Average concentrations (mean+SD) of blood glucose levels in the serum of mice, and oral glucose 1835 
tolerance test at day 15 of experimental period; blood glucose levels were measured at 0, 30, 60, 90 and 1836 
120min time intervals following an overnight fast, following treatment with metformin (MF), fenugreek 1837 
seed extract (FSE) and 4-hydroxyisoleucine (4-OH-lle), compared to the relative control (C). Average 1838 
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blood glucose (A) normoglycaemic (p=0.00231) and (B) hyperglycaemic (p=0.0245). Oral glucose 1839 
tolerance test (C) normoglycaemic (p=0.0154) and hyperglycaemic (p=0.0021). 1840 
 1841 
4-hydroxyisoleucine positively regulates the total protein expression of IRS1, IRβ, Akt, GSK3α/β 1842 
and GLUT2 and phosphorylated protein expression of pIRS1, pAkt and pGSK3α/β 1843 
The effects of 4-OH-lle and MF on phosphorylated total expression (IRS1, IRβ, GSK3α/β and GLUT2) 1844 
and (pAkt and pGSK3α/β) of proteins regulating the insulin signaling cascade were assessed by western 1845 
blotting. Under NG conditions, 4-OH-lle significantly up-regulated the total protein expression of IRβ 1846 
2.2-fold (1.08±0.02RBD), (Fig.2 a). 4-OH-lle (2.1-fold; 0.98±0.01RBD) and MF (2.5-fold; 1847 
1.28±0.03RBD) upregulated the phosphorylated expression of IRS1 (p=0.00279) greater than the total 1848 
protein expression (Fig.2 a). However, 4-OH-lle increased the total protein expression of IRS1 1849 
(p=0.00279) by 1.6-fold (0.98±0.01RBD) (Fig.2 a). More importantly, under a HG condition, MF and 4-1850 
OH-lle also increased total protein expression of IRβ (p=0.0121) by 2.8 (0.96±0.01RBD) - and 1.6 1851 
(0.89±0.01RBD) -fold (Fig.2 b). The phosphorylated expression of IRS1 (p=0.00279) was increased 1852 
under a HG condition (Fig.2 b) by 4-OH-lle (1.6-fold; 0.89±0.01RBD) as well as the total protein 1853 
expression by 1.5-fold (0.96±0.03RBD). Our data shows that the novel amino acid 4-OH-lle has the 1854 
potential to work as efficiently as the first line of drug MF in stimulating the IR signal. Above all, in a HG 1855 
state 4-OH-lle stimulated a strong receptor signal as seen by the 2.4-fold change in IRβ total protein 1856 
expression. This shows that 4-OH-lle can effectively increase the total protein expression of IRβ and 1857 
translate this activation into the phosphorylation of pIRS1. Also, under a normal condition 4-OH-lle 1858 
significantly upregulated the total protein expression of GLUT2 (p=0.0011) by 2.8-fold (1.08±0.03RBD), 1859 
(Fig.2 a). Under a HG state 4-OH-lle elicited the most significant response by increasing GLUT2 1860 
(p=0.0022) total protein expression by 2.9 (1.28±0.03RBD) (Fig.2 b). Again, 4-OH-lle consistently 1861 
maintained an increase in GLUT2 total protein expression under both conditions. Following the increase 1862 
in total and phosphorylated protein expression of the IR’s – 4-OH-lle significantly increased the total and 1863 
phosphorylated protein expression of Akt and GSK3α/β under both conditions. 4-OH-lle upregulated 1864 
pAkt by 2-fold (1.08±0.03RBD) and Akt by 2.2-fold (1.10±0.02RBD) under a normal condition 1865 
(p=0.0121) (Fig.3 a). The expression of pAkt and Akt was increased by 2.3-fold (1.08±0.03RBD) and 1866 
1.9-fold (1.20±0.03RBD) under a HG condition (p=0.0351) (Fig.3 b). Phosphorylated protein expression 1867 
of GSK3α/β was also up-regulated by 4-OH-lle 1.8- and 1.5-fold, under a NG (p=0.0468) and HG 1868 
(p=0.0357) condition, respectively (Fig.3 a, b). Lastly the total protein expression of GSK3α/β was 1869 
increased by 1.9- and 2.1-fold under a NG and HG condition (Fig.3 a, b). 1870 
61 
 
1871 
Fig.2 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 1872 
(C) on phosphorylation of insulin receptor β (IRβ), insulin receptor substrate 1 (IRS1) and glucose 1873 
transporter 2 (GLUT2) on mice liver under normoglycaemic (A) and hyperglycaemic (B) conditions. *P< 1874 
0.05; **P< 0.005 relative to control. 1875 
 1876 
 1877 
 1878 
 1879 
 1880 
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4-hydroxyisoleucine increases the gene expression of IRS1, IRβ, GLUT2 and SREBP1c 1881 
The effects of MF and 4-OH-lle on IRS1, IRβ and GLUT2 gene expression was investigated using qPCR. 1882 
The gene expression of IRS1 (p=0.0049), IRβ (p=0.0100) and GLUT2 (p=0.0110) was increased by MF 1883 
and 4-OH-lle under a NG condition (Fig.5). 4-OH-lle (2.5- and 3.9 fold) displayed a greater increase in 1884 
gene expression of IRS1 compared to MF under both conditions (Fig.6 a). 4-OH-lle preceded the effects 1885 
of MF on IRβ (2.3- and 3.1-fold) and GLUT2 (1.6- and 2.8-fold) gene expression (Fig.5 b, c). MF (1.5-1886 
fold) and 4-OH-lle (1.6-fold) also elevated the gene expression of SREBP1c under a NG state (Fig.5 d). 1887 
Similar trends were displayed under a hyperglycaemic condition. Most importantly, 4-OH-lle displayed 1888 
the greatest increase in IRS1, IRβ, GLUT2 and SREBP1c gene expression compared to MF (Fig.5). 1889 
1890 
Fig.3 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 1891 
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(C) on phosphorylation of protein kinase b (Akt) and glycogen synthase kinase 3α/β on mice liver under 1892 
normoglycaemic (A) and hyperglycaemic (B) conditions. *P< 0.05; **P< 0.005 relative to control. 1893 
 1894 
4-hydroxyisoleucine increases the gene expression of AKT, GSK3α/β, GS and Gck 1895 
The effects of MF and 4-OH-lle on AKT, GSK3α/β, GS and Gck gene expression was investigated using 1896 
qPCR. The gene expression of AKT (p=0.0031) was increased by MF (1.4- and 1.6-fold) and 4-OH-lle 1897 
(3.6- and 3-fold) by both conditions, respectively (Fig.6 a). This increase in AKT gene expression 1898 
correlates with the increased gene expression of GSK3α/β (p=0.0072) by MF (1.1- and 1.4-fold) and 4-1899 
OH-lle (1.1- and 2.5-fold), under a NG and HG condition (Fig.6 b). GSK3α/β is important for the 1900 
activation of GS. The gene expression of GS (p=0.0081) was profoundly increased by 4-OH-lle (3.2-fold) 1901 
under a HG condition (Fig.6 c). Gck (p=0.0436) displayed a steady increased in gene expression by MF 1902 
(1.5- and 1.9-fold) and 4-OH-lle (1.6- and 1.7-fold) (Fig.6 d) under both condition, respectively.   1903 
 1904 
1905 
Fig.4 Fenugreek seed extract (FSE) treatment relative to the untreated control (C) on phosphorylation of 1906 
insulin receptor β (IRβ), insulin receptor substrate 1 (IRS1), glucose transporter 2 (GLUT2), protein 1907 
kinase b (Akt) and glycogen synthase kinase 3α/β on mice liver under normoglycaemic (A and C) and 1908 
hyperglycaemic conditions (B and D) . *P< 0.05; **P< 0.005 relative to control. 1909 
 1910 
 1911 
 1912 
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Effect of FSE on protein expression of IRS1, IRβ, Akt, GSK3α/β and GLUT2 and phosphorylated 1913 
protein expression of pIRS1, pAkt and pGSK3α/β and gene expression of IRS1, IRβ, GLUT2, 1914 
SREBP1c, AKT, GSK3α/β, GS and Gck 1915 
Following the preceding data on 4-OH-lle, we further investigated the effect of FSE on the on protein 1916 
expression of IRS1, IRβ, Akt, GSK3α/β and GLUT2 and phosphorylated protein expression of pIRS1, 1917 
pAkt and pGSK3α/β. Interestingly under NG conditions, FSE significantly up-regulated the total protein 1918 
expression of IRβ (p=0.0729) by 2.5-fold (1.28±0.03RBD) (Fig.4 a). FSE (2.2-fold; 1.08±0.02RBD) 1919 
upregulated the phosphorylated expression of IRS1 (p=0.00279) greater than the total protein expression 1920 
(Fig.4 a). FSE, under HG conditions, significantly increased the total protein expressions of IRβ 1921 
(p=0.0121) by 2.5-fold (1.98±0.03RBD) (Fig.4 b) and IRS1 by (2.1-fold; 1.06±0.03RBD). Under NG 1922 
conditions, FSE significantly upregulated the total protein expression of GLUT2 (p=0.0011) by 2.3 1923 
(1.12±0.03RBD). (Fig.4 a). However, under a HG state FSE increased GLUT2 (p=0.0022) total protein 1924 
expression by 2.5 (1.28±0.03RBD) (Fig.4 a). Following the increase in total and phosphorylated protein 1925 
expression of the IR’s – FSE significantly increased the total and phosphorylated protein expression of 1926 
Akt and GSK3α/β under both conditions. FSE upregulated pAkt by 1.9-fold (1.08±0.03RBD) and Akt by 1927 
2-fold (1.10±0.02RBD) under NG conditions (p=0.0121) (Fig.5). The expression of pAkt and Akt was 1928 
increased by 2.1-fold (1.08±0.03RBI) and 2-fold (1.20±0.03RBD) under HG conditions (p=0.0351) 1929 
(Fig.6). Phosphorylated protein expression of GSK3α/β was also up-regulated by FSE 2- and 2.5-fold, 1930 
under a NG (p=0.0468) and HG (p=0.0357) condition, respectively (Fig.5, 6). Lastly the total protein 1931 
expression of GSK3α/β was increased by 2.1- and 2-fold under a NG and HG condition. 1932 
 1933 
Further, we investigated the gene expression of IRS1, IRβ, GLUT2, SREBP1c, AKT, GSK3α/β, GS and 1934 
Gck by FSE. The gene expression of IRS1 (p=0.0049), IRβ (p=0.0100) and GLUT2 (p=0.0110) was 1935 
increased by FSE under a NG condition (Fig.7). FSE (2.1-fold) showed an increase in the gene expression 1936 
of IRS1 (Fig.7 a). Also FSE increased IRβ and GLUT2 (3.8- and 2.6-fold) gene expression, respectively 1937 
(Fig.7 b, c). FSE (2.2-fold) elevated the gene expression of SREBP1c under a NG state. The gene 1938 
expression of AKT (p=0.0031) was increased by FSE (2.2- and 3.2-fold), under a NG and HG condition, 1939 
respectively (Fig.8 a). This increase in AKT gene expression correlates with the increased gene expression 1940 
of GSK3α/β (p=0.0072) by FSE (2.2- and 3.5-fold) under both conditions (Fig.8 b). The gene expression 1941 
of GS (p=0.0081) was increased by FSE (2.6-fold) under a HG condition (Fig.8 c). Gck (p=0.0436) 1942 
displayed a steady increased in gene expression by FSE (2.6- and 3.5-fold) (Fig.8 d) under both condition, 1943 
respectively.   1944 
 1945 
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1946 
Fig.5 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control on 1947 
the gene expression of insulin receptor substrate 1 (A), insulin receptor β (B), glucose transporter 2 (C) 1948 
and sterol regulatory binding protein 1c on mice liver under normo- and hyperglycaemic conditions. *P< 1949 
0.05; **P< 0.005 relative to control. 1950 
 1951 
 1952 
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1953 
Fig.6 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control on 1954 
the gene expression of protein kinase B (A), glycogen synthase kinase 3α/β (B), glycogen synthase (C) 1955 
and glucokinase (D) on mice liver under normo- and hyperglycaemic conditions. *P< 0.05; **P< 0.005 1956 
relative to control. 1957 
 1958 
 1959 
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1960 
Fig.7 Fenugreek seed extract (FSE) treatment relative to the untreated control on the gene expression of 1961 
insulin receptor substrate 1 (A), insulin receptor β (B), glucose transporter 2 (C) and sterol regulatory 1962 
binding protein 1c on mice liver under normo- and hyperglycaemic conditions. *P< 0.05; **P< 0.005 1963 
relative to control. 1964 
 1965 
 1966 
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1967 
Fig.8 Fenugreek seed extract (FSE) treatments relative to the untreated control on the gene expression of 1968 
protein kinase B (A), glycogen synthase kinase 3α/β (B), glycogen synthase (C) and glucokinase (D) on 1969 
mice liver under normo- and hyperglycaemic conditions. *P< 0.05; **P< 0.005 relative to control. 1970 
 1971 
Discussion 1972 
4-hydroxyisoleucine has been proposed as an anti-diabetic alternative therapy, being linked to improved 1973 
insulin action, reduced post-prandial glucose levels and stimulation of the insulin signalling pathway [29, 1974 
36-38, 40]. We previously showed, using an in vitro (HepG2 liver cells) model, the reduction of 1975 
extracellular glucose levels by 4-OH-lle, MF and FSE via induction of the insulin signalling pathway 1976 
[13[. Furthermore, this study showed that 4-OH-lle stimulated the proximal and distal insulin signalling 1977 
pathways, and subsequently GLUT2 recruitment. This study was validated by investigating the effect of 1978 
4-OH-lle in comparison to MF on glucose sensing, insulin signalling, and consequently GLUT2 1979 
recruitment in C57BL/6 male mice. 4-OH-lle significantly improved glucose homeostasis, IRβ-IRS1 and 1980 
Akt signalling in normal and STZ-induced diabetic mice by effectively lowering blood glucose levels and 1981 
enhancing receptor signalling, respectively. Chronic hyperglycaemia is the hallmark of T2D, and primary 1982 
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treatment involves managing the high glucose levels. A recent study on skeletal muscle cells showed that 1983 
4-OH-lle inhibited inflammation-stimulated IRS1 serine phosphorylation and restored insulin-stimulated 1984 
IRS1 tyrosine phosphorylation in the presence of palmitate, leading to enhanced insulin sensitivity [41]. 1985 
A previous in vitro study by Broca et al, 1999 showed that 4-OH-lle (200 μM) potentiated glucose (16.7 1986 
mM)-induced insulin release from rat-isolated islets [42]. Haeri et al, 2009 examined the effect of 4-OH-1987 
lle on liver function and blood glucose and concluded that 4-OH-lle is a well-tolerated treatment for 1988 
insulin resistance, both directly as a hypoglycaemic and as a protective agent for the liver [43]. More 1989 
importantly Singh et al, 2010 confirmed the anti-hyperglycaemic property of 4-OH-lle where they showed 1990 
that 4-OH-lle suppressed progression of T2D by enhancement of insulin sensitivity and glucose uptake in 1991 
peripheral tissue [30]. In our in vivo study, we compared the effect of 4-OH-lle and MF on proximal and 1992 
distal signalling and recruitment of GLUT2 under both normal and hyperglycaemic conditions.  1993 
 1994 
Glucose uptake by the target tissues of insulin is enabled mostly by translocation of glucose transporters 1995 
from an intracellular site to the plasma membrane. It was reported that IR’s and GLUT2 form a receptor 1996 
transporter complex in liver cells [46-47]. This results in a mechanism of insulin facilitated hepatic 1997 
glucose regulation. Using C57BL/6 male mice livers (both normo- and hyperglycaemic) we investigated 1998 
the total protein expression of GLUT2. Under both conditions 4-OH-lle significantly increased the protein 1999 
expression of GLUT2 (Fig.2 a, b). Furthermore, these findings correlated well with the increased gene 2000 
expression of GLUT2 (Fig.5 b). The sterol regulatory binding protein 1c (SREBP1c) plays a key role in 2001 
the translocation of GLUT2 to the cell surface (Ono et al. 2003). We investigated the gene expression of 2002 
SREBP1c; 4-OH-lle increased the gene expression of SREBP1c under both conditions (Fig.5d). 2003 
  2004 
The action of insulin is initiated by its binding to the IR. This leads to autophosphorylation of the IR and 2005 
subsequent increase in tyrosine phosphorylation of several proteins including pIRS1 and pAkt. In this 2006 
study the effects of 4-OH-lle on tyrosine phosphorylation of the IRβ and the downstream signalling 2007 
molecules in the primary cellular targets of liver cells were investigated. The results revealed that under 2008 
both conditions 4-OH-lle activated the tyrosine phosphorylation of IRβ (Fig.2 a, b), subsequently 2009 
enhancing tyrosine phosphorylation of IRS1 (Fig.2 a, b) and Akt (Fig.2 a, b). These results correlate well 2010 
with the increased gene expressions of IRβ, IRS1 and Akt. Activated Akt phosphorylates substrates that 2011 
control insulin-mediated glucose transport, protein and glycogen synthesis [49]. An important response to 2012 
Akt activation is the phosphorylation and inactivation of GSK3α/β [54]. A major substrate of GSK3α/β is 2013 
GS, an enzyme that catalyses the final step in glycogen synthesis [50]. Phosphorylation of GS by 2014 
GSK3α/β inhibits glycogen synthesis; conversely, inactivation of GSK3α/β by pAkt promotes glucose 2015 
storage as glycogen [7]. Thereafter, the effect of 4-OH-lle on the total and phosphorylated protein 2016 
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expression of GSK3α/β and the gene expression of GSK3α/β, GS and Gck was investigated. The results 2017 
showed a consistent amplification by 4-OH-lle in comparison to MF in the protein expression of 2018 
GSK3α/β (Fig.3 a, b). This increased protein expression correlated with increases in GSK3α/β gene 2019 
expression (Fig.5, 6). Furthermore, 4-OH-lle significantly stimulated the gene expression of GS and Gck. 2020 
This strongly suggests that the liver could be target site for 4-OH-lle and activating the insulin signalling 2021 
pathway.  2022 
 2023 
Based on our previous in vitro data and literature, we further investigated FSE using the same parameters 2024 
as 4-OH-lle and MF.  FSE significantly increased the total and phosphorylated protein expressions of 2025 
IRS1 (pIRS1/IRS1), Akt (pAkt/Akt), GSK3α/β (pGSK 3α/β), total insulin receptor β (IRβ) and GLUT2. 2026 
Also, FSE elevated the gene expressions of IRβ, IRS1, Akt, GSK3α/β, GS, GK, GLUT2 and SREBP1c. It 2027 
is well established that 4-OH-lle is the most abundant unusual free amino acid in fenugreek seeds and 2028 
accounts for the seeds antidiabetic effects. Interestingly, this study shows that 4-OH-lle exerts a potent 2029 
effect on receptor signalling and glucose sensing as opposed to that of FSE alone. Studies have also 2030 
reported the presence of diosgenin – a biologically active steroid sapogenin as a possible mediator in the 2031 
seeds effect to maintain glucose homeostasis and insulin signalling [55]. Diabetic animal models provide 2032 
evidence for the role of diosgenin in glycaemic control by decreasing proteins involved in 2033 
gluconeogenesis and glucose export [56]. Furthermore, fenugreek seeds constitute a large amount of 2034 
soluble fibers such as galactomannans [36]. Soluble fibers have been reported to enhance glycaemic 2035 
control by inhibiting lipid and carbohydrate proteins in the digestive system [57-58].  2036 
 2037 
In conclusion, this set of data confirms the induction of total and phosphorylated protein and gene 2038 
expressions of GLUT2, IRβ, IRS1, Akt and GSK3α/β by 4-OH-lle under both conditions. The effect of 4-2039 
OH-lle is greater than MF with discernible relevance to the effect displayed during a chronic HG state. 2040 
Following an insulin resistant state and the insufficiency of insulin signalling components in the liver, this 2041 
effect of 4-OH-lle is significant. Hence, understanding the effect of 4-OH-lle relative to glucose sensing 2042 
and insulin signalling provides evidence for the use of 4-OH-lle in T2DM treatment. 2043 
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Abstract 2251 
Scope: In T2DM; defective insulin action and hyperglycaemia, lead to diabetic dyslipidemia. 2252 
Characteristic features include high plasma levels of triglycerides, LDLc and low HDLc. Diabetic 2253 
dyslipidemia is a risk factor for CVD. Our previous study demonstrated anti-diabetic effects of 4-2254 
hydroxyisoleucine - bioactive component of fenugreek seeds, in comparison to metformin. We evaluated 2255 
4-hydroxyisoleucine compared to metformin on the lipid profile and hepatic expression of PCSK9 and 2256 
PPARG in HepG2 cells and C57BL/6 mice.  2257 
Methods and results: Treatments were conducted over 72-hours (HepG2 cells) and 15-days (C57BL/6 2258 
mice) under normoglycaemic and hyperglycaemic conditions. Lipid profile analysis was conducted. 2259 
Protein expressions of PCSK9 and PPARG were determined by western blotting. mRNA levels of 2260 
PCSK9, SREBP1c, FAS, LDLr and Apo A1 were evaluated by qPCR. In both models, 4-OH-lle 2261 
increased SREBP1c and FAS expressions, PPARG protein expression and decreased PCSK9. 2262 
Conclusion: 4-OH-lle improved lipid homeostasis by regulating SREBP1c processing, PCSK9 and 2263 
PPARG expression.  2264 
 2265 
 2266 
 2267 
 2268 
 2269 
 2270 
 2271 
 2272 
 2273 
 2274 
 2275 
 2276 
 2277 
 2278 
 2279 
 2280 
 2281 
 2282 
 2283 
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Introduction 2285 
Type two diabetes mellitus (T2D) results from defective insulin signaling/resistance and leads to 2286 
increased blood glucose levels. T2D individuals present with dyslipidemia, characterized by elevated 2287 
triglycerides (TG), low high-density lipoprotein cholesterol (HDLc) and a predominance of small-dense 2288 
low-density lipoprotein (LDL) particles. These changes in the lipid profile are attributed to increased free 2289 
fatty acid (FFA) flux due to elevated blood glucose levels. Diabetic dyslipidemia is a risk factor for the 2290 
development of cardiovascular disease (CVD); this increases the risk of microvascular and macrovascular 2291 
complications, accompanied by morbidity and mortality (1). It is important to manage CVD risk factors in 2292 
T2D (1).  2293 
 2294 
The first-line drug therapy for the treatment of T2D is metformin (MF), which possesses anti-lipidemic 2295 
properties that include improved LDL, HDL and TG levels (2). Also, statins produce favourable changes 2296 
in altered lipid profiles via inhibition of HMGCoA reductase (3). However an optimum individualistic 2297 
regimen remains to be defined as intolerance and insufficiency is a common occurrence. Advancements 2298 
in lipid-lowering agents have focused on regulators of proprotein convertase subtilisin/kexin type 9 2299 
(PCSK9) and agonists of peroxisome proliferator-activated receptor gamma (PPARG). Studies have 2300 
reported PCSK9 as a circulating regulator of LDLc through its ability to induce degradation of the LDL 2301 
receptor (LDLr) in the lysosome of hepatocytes (4, 5). In T2D, elevated glucose levels cause a 2302 
concomitant rise in LDLc, whilst PCSK9 regulators shift LDLr traffic from degradation to recycling in 2303 
hepatic cells. In addition to LDLc clearance, there is the requirement for an associated rise in HDLc. 2304 
PPARG is responsible for mediating physiological effects on both glucose homeostasis and lipid 2305 
metabolism (6), and directly impacts on HDLc level (6, 7). Also, individuals with a dominant-negative 2306 
mutation in the PPARG gene showed severe hyperglycaemia, providing a genetic link between PPARG 2307 
and T2D (8). The disparity in lipid homeostasis in T2D, regulators of PCSK9 and agonists of PPARG 2308 
may contribute to its restoration.  2309 
 2310 
Nutritional supplements provide an opportunity for T2D individuals to normalize lipid levels. Plant 2311 
extracts are a potential source in reducing elevated lipid levels. Amongst these plants is Trigonella 2312 
foenum-graecum (an aromatic plant), commonly known as fenugreek (9), and the seeds possess anti-2313 
diabetic effects (10). The main biological content of fenugreek seeds is a branched-chain amino acid 2314 
derivative - 4-hydroxyisoleucine (4-OH-lle) which itself displays anti-diabetic effects. Among its 2315 
beneficial effects are regulation of blood glucose, plasma TGs, total cholesterol and FFA levels, and 2316 
improvement of liver function (11). A diabetic rat model showed that 4-OH-lle was well-tolerated in 2317 
control animals and improved HDLc levels (12). A dyslipidemic hamster model showed that 4-OH-lle 2318 
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significantly decreased plasma TG and increased HDLc levels (13). Similarly in C57BL/6 male mice 4-2319 
OH-lle reduced blood glucose, plasma insulin, TGs, total cholesterol and LDLc levels and raised plasma 2320 
HDLc levels (14). Previously, we showed that 4-OH-lle, MF and fenugreek seed extract (FSE) effectively 2321 
regulated insulin signaling both in vitro (15) and in vivo. The objective of this study was to investigate the 2322 
regulatory effect of 4-OH-lle in comparison to MF – on PCSK9 and PPARG signaling and the plasma 2323 
lipid profile, in hyperglycaemic induced HepG2 cells and C57BL/6 male mice. 2324 
 2325 
Materials and methods 2326 
Materials 2327 
4-hydroxyisoleucine (50118), MF (PHR1084) and streptozotocin (STZ) (S0130) were purchased from 2328 
Sigma Aldrich (St Louis, MO, USA). Whole fenugreek seeds were purchased from Agricol Niche Brands, 2329 
a South African seed company. A herbarium voucher of flowering material was lodged at the Ward 2330 
Herbarium (UDW-UKZN; N. Naicker 1). All other consumables were purchased from Merck (Darmstadt, 2331 
Germany), unless otherwise stated.   2332 
 2333 
Treatment preparation of stock solutions 2334 
Whole fenugreek seeds were crushed using a mortar and pestle, suspended in deionized water (1000 2335 
mg/mL), and placed on a stirrer at room temperature (RT) for 3 hour (hr). The aqueous solution was 2336 
transferred to a sterile conical tube and centrifuged (3600xg for 10min) at RT. Supernatant (FSE) was 2337 
removed, freeze-dried, and stored at -20oC. Metformin tablets were also crushed with a mortar and pestle 2338 
and suspended in 0.1M phosphate-buffered saline (PBS) (50mg/mL). The solution was then filter 2339 
sterilized (0.45mm filter). 4-hydroxyisoleucine was obtained in a liquid form, and treatments were 2340 
prepared from a stock solution (as per manufacture instructions). Subsequent treatments were prepared in 2341 
complete culture medium (CCM) for in vitro and in 0.1M PBS solution for in vivo.  2342 
 2343 
Cell culture and treatment preparation 2344 
HepG2 cells were cultured (37oC, 5% CO2) in 25cm3 flasks in complete CCM comprising Eagles 2345 
minimum essential medium, 10% foetal calf serum, 1% L-glutamine and 1% penstrepfungizone (Lonza 2346 
Biowhittaker; Basel, Switzerland). Cells were grown to 90% confluency prior to treatment for 72hr. Cells 2347 
were subject to normoglycaemic (NG; 5mM glucose) and hyperglycaemic (HG; 25mM glucose) 2348 
conditions. Treatments were replenished every 24hr. The methods used for the preparation of 4-OH-lle, 2349 
MF and FSE was as per the protocol followed by Naicker et al, 2016 (15). The optimized treatment 2350 
concentrations by Naicker et al, 2016 were used in this study which include; 4-OH-lle (100ng/ml), MF 2351 
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(2mM) and FSE (100ng/ml) (15).  All experiments were conducted in triplicate and repeated 2352 
independently 3 times. 2353 
 2354 
Animals 2355 
Six-week-old male C57BL/6 mice (n=40) were procured from the Biomedical Resource Unit at the 2356 
Westville Campus of the University of KwaZulu-Natal (UKZN), Durban, South Africa. Mice with a mean 2357 
body weight (BW) of 20 ± 2.99g were randomly divided into 2 groups: non-diabetic (NG) and diabetic 2358 
(HG). Each group were further subdivided into 4 groups of 5 mice each as follows: Control (C), 4-OH-lle, 2359 
MF and FSE. Mice were housed in polycarbonated cages in a humidity and temperature controlled room 2360 
(40-60% humidity, 23 ± 1oC) with a 12hr light dark cycle. The mice were fed a commercially available 2361 
pellet diet and normal drinking water ad libitum throughout the 15 day experimental period. The mice 2362 
were maintained according to the rules and regulations of the Experimental Animal Ethics Committee of 2363 
the UKZN (Ethical approval number: AREC/057/016). 2364 
 2365 
Induction of diabetes 2366 
Administration of a low single dose of STZ damages pancreatic β cells through alkylation of DNA by 2367 
causing partial destruction of these cells, resulting in hyperglycaemia. This process displays the 2368 
pathophysiological characteristics of T2D which include inadequate β-cell mass and β-cell dysfunction. 2369 
Type two diabetes was induced in all mice in the diabetic group (HG) by an intraperitoneal administration 2370 
of STZ (50mg/kg BW) dissolved in 0.1M citrate buffer (pH 4.4) following an overnight fast (12hr). The 2371 
optimal dosage of 50mg/kg was determined by preliminary investigation which included a range of STZ 2372 
concentrations (50mg/kg, 100mg/kg and 150mg/kg BW). Blood was collected from the tail vein, using a 2373 
glucometer (Accu-Chek®) to monitor and measure the fasting blood glucose over a 10 day period prior to 2374 
administration of treatment. Once a blood glucose of >7mmol/L and <16mmol/L was achieved and stable, 2375 
the treatment period was inducted.    2376 
 2377 
Treatment preparations 2378 
Preparation of treatments were guided by the protocol followed by Naicker et al, 2016 (15). The 2379 
concentration of 4-OH-lle (100mg/kg BW), MF (20mg/kg BW) and FSE (100mg/kg BW) were based on 2380 
previous animal studies which evaluated a range of concentrations and reported the outcomes of the range 2381 
which we based our optimal concentration (14, 16). Mice were treated once daily for the 15 day treatment 2382 
period via oral gavage.  2383 
 2384 
 2385 
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Animals post treatment 2386 
At the end of the treatment period, the mice were sacrificed using isoflurane. Blood samples were 2387 
collected using anticoagulant EDTA tubes, in order to measure blood glucose levels. The blood glucose 2388 
levels were measured at an accredited laboratory (AMPATH, Amanzimtoti, South Africa).  All mice 2389 
livers were harvested, rinsed twice in saline, dissected and then stored in Cytobuster (Novagen, 2390 
Darmstadt, Germany) and Qiazol (Qiagen; Hildenburg, Germany) at -80oC until analysis. 2391 
 2392 
Western blotting 2393 
Western blots were performed to quantify relative protein expression of PCSK9 and PPARG. Crude 2394 
protein was isolated using Cytobuster (Novagen, San Diego, CA, USA) supplemented with protease and 2395 
phosphate inhibitors (Roche: 04693124001 and 04906837001). HepG2 cells and mice liver samples 2396 
(homogenized) were incubated in Cytobuster for 10min on ice and then centrifuged (4oC, 12,000g). Crude 2397 
protein samples was quantified by the bicinchoninic acid assay and standardized to 1mg/mL. Samples 2398 
were boiled in Laemmli buffer [dH2O, 0.5M Tris–HCl (pH 6.8), glycerol, 10% SDS, β-mercaptoethanol, 2399 
and 1% bromophenol blue] for 5min. Samples were electrophoresed on a sodium dodecyl sulphate 2400 
polyacrylamide gel (4% stacking and 10% resolving) for 1Hr at 150V and transferred on to nitrocellulose 2401 
using the TransBlot Turbo Blotting System (Bio-Rad; Hercules, CA) using a preinstalled Standard SD 2402 
program. All membranes were blocked for 2hr in 3% BSA in Tween20-Tris-buffered saline (TTBS - 2403 
0.15M NaCl, 2.68M KCl, 24. 86M Tris, 500µl Tween20, pH 7.4) at RT on a shaker. Thereafter, the 2404 
membranes were incubated with primary antibody PCSK9 (ab125251, 1:5,000) and PPARG (ab, 1:5,000) 2405 
at 4oC overnight. The membranes were then equilibrated to RT on a shaker for 1hr, followed by 5 washes 2406 
(10min) with TTBS. Membranes were then probed with horseradish peroxidase conjugated-secondary 2407 
antibody [anti-rabbit 1:10,000 (CS7074)] for 1hr, followed by 5 washes (10min) with TTBS. 2408 
Chemiluminescent signal was detected using ECL Clarity Western detection reagent (Bio-Rad) and 2409 
captured on the Bio-Rad ChemiDoc Viewing System. Data were expressed as relative band density 2410 
(RBD) and expression of proteins was analyzed with the Bio-Rad ChemiDoc MP Imaging System with 2411 
Image Lab software. Membranes were quenched (5% H2O2 at 37oC for 30min) and proteins were 2412 
normalized against β-actin (A5316), 1:1,000. 2413 
 2414 
Quantitative PCR 2415 
The mRNA levels of genes regulating lipid homeostasis: PCSK9, LDLr, SREBP1c, FAS and ApoA1, was 2416 
determined by qPCR. Total RNA was isolated using extraction buffer (Qiazol) and an in-house protocol 2417 
(17). RNA was quantified using a spectrophotometer (Nanodrop2000, Biotech) and standardized to 2418 
1000ng/µl. Standardized RNA was reverse transcribed to complementary DNA (cDNA) using the 2419 
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iScriptTM cDNA Synthesis kit (Bio-Rad; 107-8890) as per the manufacturer’s instruction. A reaction 2420 
volume of 10μl was prepared consisting of 5X IQ™ SYBR® ssoAdvanced SYBR Green (Bio-Rad; 170-2421 
880), nuclease free water, 1μl cDNA template (1000ng/ml), and 1μl sense and anti-sense primer (Inqaba 2422 
Biotec™). The mRNA expression was normalized against a housekeeping gene (18S). Thermocycler 2423 
conditions were carried out using the CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad, 2424 
Hercules, CA) as follows:  initial denaturation (95°C, 10min), 40 cycles of denaturation [95°C, 15seconds 2425 
(s)], annealing and extension (72°C, 30s). Relative fold change was calculated using the method described 2426 
by Livak and Schmittgen, 2001 to calculate relative fold change (18). Primer sequences and annealing 2427 
temperatures are shown in Table 1 (supplementary data). 2428 
 2429 
Lipid profile and glucose analysis 2430 
Lipid profile analysis and measurement of glucose concentration was performed by an accredited 2431 
pathology laboratory (AMPATH laboratories, Amanzimtoti, South Africa). The supernatant from each 2432 
cell culture sample was lyophilized and reconstituted in 500µl of 0.1M phosphate buffer solution and sent 2433 
for analysis. And the plasma from each mouse sample was analyzed. Glucose and oral glucose tolerance 2434 
test analysis are shown in supplementary data (Appendix 3). 2435 
  2436 
Liquid chromatography–mass spectrometry  2437 
Liquid chromatography–mass spectrometry (LC-MS) is an analytic chemistry technique which combines 2438 
the physical separation capabilities of liquid chromatography (or HPLC) with the mass analysis 2439 
capabilities of mass spectrometry (MS). 1mg of crude FSE was weighed and dissolved in 10ml methanol 2440 
(MeOH). Each sample was vortexed and sonicated to allow for complete dissolution. The extract was 2441 
then subjected to solid phase extraction, using a Supelco C18 100mg solid phase cartridge. The extract 2442 
was eluted with MeOH. A 1:100 dilution of the sample was prepared using MeOH and injected into the 2443 
LC-MS. The instrumentation used was the Shimadzu 202 UFLC-MS, mobile A: 0.1% formic acid (FA) in 2444 
water and mobile phase B: 0.1% FA in acetonitrile. Separation was achieved using a YMC Triart C18 2445 
analytical column (4.6mm x 150mm), using a gradient elution method from 5% B to 95 B over 25min. 2446 
Data was collected at 265nm and analyzed using the Shimadzu Lab Solutions software (Supplementary 2447 
data Fig 2, 3, 4 and Table 2). 2448 
 2449 
Statistical analyses 2450 
Statistical analyses was performed using GraphPad Prism v5.0 software (GraphPad Software, Inc.). The 2451 
data was expressed as relative fold change to respective controls in the qPCR and western blotting 2452 
experiments. With regards to western blotting, the phosphorylated proteins were normalized against the 2453 
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total protein. Followed by the total protein against actin. Following each experiment in vitro and in vivo, 2454 
4-OH-lle was compared to MF and the untreated control. We then analyzed FSE in comparison to the 2455 
untreated control. Statistical comparisons for 4-OH-lle, MF and the untreated control were made using a 2456 
one-way analysis of variance (ANOVA), nonparametric test (Kruskal Wallis test) and a Dunn’s post-test; 2457 
and a non-parametric Mann-Whitney test was used for FSE and the untreated control. The data were 2458 
considered statistically significant with a value of p < 0.05. 2459 
 2460 
Results 2461 
4-OH-lle regulates protein expression of PCSK9 and gene expression of PCSK9 and LDLr under 2462 
NG and HG conditions, in vitro and in vivo 2463 
PCSK9 is an inhibitory enzyme which regulates the LDLr pool. The relative protein expression of PCSK9 2464 
in HepG2 cells was maintained by both treatments (Fig 1A). However, under HG conditions, 4-OH-lle 2465 
reduced the expression of PCSK9 0.8-fold (0.99±0.03RBD) compared to MF (Fig 1A). Similarly, in the 2466 
liver cells of C57BL/6 mice, the protein expression of PCSK9 was maintained by all treatments, under a 2467 
NG state (Fig 1B). However, under a HG state, 4-OH-lle (0.5-fold; 0.89±0.03RBD) and MF (0.8-fold; 2468 
0.99±0.03RBD) reduced its expression (Fig 1 C; D). These reductions in protein expression by 4-OH-lle 2469 
correlate with the decrease in mRNA levels of PCSK9 in both models (Fig 2). Under normal conditions in 2470 
vitro and in vivo (Fig 1A, C), metformin treatment increased the protein expression of PCSK9. Under a 2471 
hyperglycaemic condition in vitro (Fig 1B) metformin treatment had no effect compared to the untreated 2472 
control. However, under a hyperglycaemic condition in vivo, metformin treatment significantly reduced 2473 
the protein expression of PCSK9. The changes observed in protein expression correlated with the changes 2474 
in gene expression, under both conditions and models. Therefore, we can conclude that elevated glucose 2475 
levels could have an impact on the action of metformin on PCSK9. 4-OH-lle decreases the expression of 2476 
PCSK9, and thereby reduces its inhibitory effect on the LDLr. This will increase the LDLr pool and 2477 
consequently reduces the extracellular levels of LDLc. We then investigated the changes in mRNA 2478 
expression of LDLr. In vitro, 4-OH-lle significantly increased LDLr mRNA levels 1.8-fold compared to 2479 
MF 1.5-fold, under a HG state (Fig 2C). Whereas in vivo, 4-OH-lle elevated the gene expression under 2480 
both conditions (Fig 2E). To correlate these results, a lipid profile was analyzed on the supernatant of 2481 
each treatment (Fig 2D) and on the serum of treated mice (Fig 2F), to measure the extracellular levels of 2482 
LDLc. Following the reported changes in both protein and mRNA levels of PCSK9, these changes 2483 
translated into the reduced levels of LDLc (Fig 2 D, F). 2484 
 2485 
 2486 
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4-OH-lle regulates protein expression of PPARG and gene expression of Apo A1 under NG and HG 2487 
conditions, in vitro and in vivo 2488 
We evaluated the protein expression of PPARG by western blotting. In vitro, both treatments significantly 2489 
increased the protein expression of PPARG under both conditions (Fig 1). In vivo, 4-OH-lle (2.6-fold; 2490 
1.90±0.03RBD) elicited the highest response in elevating the expression of PPARG compared to MF (Fig 2491 
1). As previously mentioned, PPARG is responsible for regulating HDLc. Apolipoprotein A1 (Apo AI) is 2492 
a major constituent of HDLc that removes cholesterol from peripheral cells and transports it to the liver 2493 
for their ultimate removal. Therefore the effect of 4-OH-lle and MF on Apo AI mRNA levels was 2494 
investigated by qPCR. In vitro and in vivo, 4-OH-lle (2.6-fold; 1.7-fold) and MF (2.5-fold; 1.8-fold) 2495 
increased the gene expression of Apo AI under HG conditions (Fig 3 A, C). This increase in mRNA 2496 
content correlates with the increase in extracellular HDLc in both HepG2 cells (Fig 3 B) and C57BL/6 2497 
mice (Fig 3 D), under similar conditions. Subsequently, both the increase in protein expression of PPARG 2498 
and gene expression of Apo A1, positively contribute to the elevated levels of HDLc. 2499 
 2500 
2501 
Figure 1. Protein expression analysis of pro-protein convertase subtilisin/kexin type 9 (PCSK9) and 2502 
peroxisome proliferator-activated receptor gamma (PPARG) in 4-hydroxyisoleucine (4-OH-lle) and 2503 
metformin (MF) treated HepG2 cells (normoglycaemic –A, p=0.0272; hyperglycaemic – B, p=0.0313) 2504 
and mouse liver (normoglycaemic – C, p=0.0296; hyperglycaemic – D, p=0.0040). *P< 0.05 relative to 2505 
control 2506 
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2507 
Figure 2 4-hydroxyisoleucine (4-OH-Ile) and metformin (MF) treatments increase mRNA levels of 2508 
PCSK9 in HepG2 cells (A, p=0.0207) and mice liver samples (B, p=0.0335). LDLr mRNA was 2509 
significantly elevated in hyperglycaemic HepG2 samples treated with MF and 4-OH-Ile (C, p=0.0478) 2510 
with a concomitant decrease in extracellular LDLc concentration (D, p=0.0293). The in vivo data 2511 
substantiated this with significantly elevated LDLr transcripts (E, p=0.0255) and significantly reduced 2512 
plasma LDLc levels (F, p=0.0112) in both MF and 4-OH-Ile treatments under both conditions. *P< 0.05; 2513 
**P< 0.005 relative to control. 2514 
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 2515 
Figure 3 Quantitative PCR results show 4-hydroxyisoleucine (4-OH-Ile) and metformin (MF) increased 2516 
mRNA levels of SREBP1c (A; p=0.0143); and FAS (B; p=0.00513) in HepG2 cells. Extracellular 2517 
cholesterol levels were significantly reduced relative to the control under hyperglycaemic conditions (C, 2518 
p=0.0478) and TGs were significantly reduced by MF and 4-OH-Ile under both conditions (D, p=0.0441). 2519 
mRNA quantification in substantiated increased SREBP1c (E, p=0.0043) and FAS (F, p=0.0102) in the 2520 
presence of MET and 4-OH-Ile. Lipid profile analysis showed reduced plasma levels of cholesterol (G, 2521 
p=0.0121) and TGs (H, p=0.0231) of treated mice. *P< 0.05; **P< 0.005 relative to control. 2522 
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2523 
Figure 4 4-hydroxyisoleucine (4-OH-Ile) and metformin (MF) treatments relative to the untreated control 2524 
on the gene expression Apo A1 on HepG2 cells (A, p=0.0036) and mice liver (C, p=0.0272) under 2525 
normoglycaemic and hyperglycaemic conditions.  A lipid profile analysis was performed on the 2526 
supernatant of the treated HepG2 cells (B, p=0.0206) and serum (D, p=0.0336) of treated mice to assess 2527 
the extracellular HDLc levels, under normoglycaemic and hyperglycaemic conditions. *P< 0.05 relative 2528 
to control 2529 
 2530 
4-OH-lle regulates gene expression of SREBP1c and FAS under NG and HG conditions, in vitro and 2531 
in vivo 2532 
SREBP1c is a major transcription factor regulating the expression of LDLr. SREBP1c regulates FAS 2533 
which is responsible for TG production. We investigated the effect of 4-OH-lle and MF on the gene 2534 
expression of SREBP1c and FAS (in vitro and in vivo) using qPCR. In vitro, under both conditions, 4-OH-2535 
lle up-regulated the mRNA levels of SREBP1c (2.1 and 3.8-fold; Fig 4 A). Gene expression of FAS was 2536 
increased by 4-OH-lle under both conditions (NG: 2.5 and HG: 2.8-fold; Fig 4 B).  In vivo, both 4-OH-lle 2537 
(1.7-fold) and MF (1.8-fold) elevated mRNA levels of SREBP1c (Fig 4 E). Similarly, 4-OH-lle (NG: 1.6-2538 
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fold; HG: 1.7-fold) elevated the expression of FAS under both conditions (Fig 4 F). A lipid profile 2539 
measuring the extracellular levels of cholesterol (Fig 4 C, G) and TG (Fig 4 D, H) in the cell culture 2540 
supernatant (Fig 4 C, D) of each treatment and in the serum of treated mice (Fig 4 G, H) was determined. 2541 
4-OH-lle up-regulated SREBP1c which is responsible for cholesterol synthesis. This was confirmed by 2542 
the change in extracellular cholesterol levels. Increased mRNA levels of SREBP1c, which regulates FAS, 2543 
resulted in an increased FAS mRNA and extracellular TG levels. Triglyceride’s form a part of the VLDL 2544 
complex which in turn form LDL particles. These LDL particles form LDLc which is endocytosed by 2545 
LDLr.  2546 
 2547 
FSE regulates the protein expression of PSCK9 and PPARG and the gene expression of PCSK9, 2548 
Apo A1, SREBP1c and FAS, in vitro and in vivo 2549 
We also investigated the effect of FSE on the protein expression of PCSK9 and PPARG, gene expression 2550 
of PCSK9, LDLr, SREBP1c, FAS and Apo A1 and lipid profiles, both in vitro and in vivo. During both 2551 
conditions in vitro, FSE maintained the protein expression of PCSK9 (Fig 5A, B). However in vivo, FSE 2552 
increased the protein expression of PCSK9 (Fig 5C, D). Interestingly, FSE increased the gene expression 2553 
of PCSK9 under both conditions. However the gene expression of LDLr and the LDLc levels were also 2554 
increased. A potential explanation for this effect of FSE could be the cause of a contribution of other 2555 
compounds within the seed, as opposed to 4-OH-lle (an isolated compound). This reduction in PCSK9 2556 
expression correlated with the change in LDLr expression (Fig 6 C, E), followed by the concomitant 2557 
reduction in LDLc levels, both in vivo and in vitro (Fig 6 D, F). This effect of FSE (in vitro; 4.1-fold; in 2558 
vivo; 3.2-fold) was much greater in comparison to 4-OH-lle (in vitro; 1.8-fold; in vivo; 2.5-fold) under a 2559 
HG state. FSE also positively affected the protein expression of PPARG. In vitro FSE (2.5-fold; 2560 
1.90±0.03RBD) up-regulated the expression of PPARG under a HG state (Fig 5 A, B). The similar pattern 2561 
of expression was displayed in vivo, FSE increased PPARG expression by 1.9-fold (1.10±0.03RBD) (Fig 2562 
5 C, D). In vitro and in vivo, FSE increased the gene expression of Apo A1 2.2-fold and 3.9-fold 2563 
respectively, under a HG state (supplementary data, Fig1). This rise in expression translated to the 2564 
elevated HDLc levels measured in the HepG2 (supplementary data, Fig 1) and mice liver cells 2565 
(supplementary data, Fig 2). In comparison to 4-OH-lle, these responses were significant but not as great 2566 
as 4-OH-lle. With regards to the gene expression of SREBP1c and FAS, FSE again displayed its 2567 
stimulating affects as an increase in both genes are observed under both conditions, in both models 2568 
(supplementary data, Fig 2). Moreover, these changes in gene expression translated into the changes 2569 
observed in the cholesterol and TG levels, in vitro and in vivo (supplementary data). Similarly, FSE 2570 
elicited a significant response but not as great as 4-OH-lle. 2571 
 2572 
89 
 
2573 
Figure 5 Protein expression analysis of pro-protein convertase subtilisin/kexin type 9 (PCSK9) and 2574 
peroxisome proliferator-activated receptor gamma (PPARG) in fenugreek seed extract (FSE) treated 2575 
HepG2 cells (normoglycaemic –A, p=0.0142; hyperglycaemic – B, p=0.0021) and mouse liver 2576 
(normoglycaemic – C, p=0.0352; hyperglycaemic – D, p=0.0141). *P< 0.05 relative to control 2577 
 2578 
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2579 
Figure 6 Fenugreek seed extract treatment increase mRNA levels of PCSK9 in HepG2 cells (A, 2580 
p=0.0363) and mice liver samples (B, p=0.00412). LDLr mRNA was significantly elevated in 2581 
hyperglycaemic HepG2 samples treated with FSE (C, p=0.0223) with a concomitant decrease in 2582 
extracellular LDLc concentration (D, p=0.0360). The in vivo data substantiated this with significantly 2583 
elevated LDLr transcripts (E, p=0.0142) and significantly reduced plasma LDLc levels (F, p=0.0133) in 2584 
both MF and 4-OH-Ile treatments under both conditions. *P< 0.05 relative to control 2585 
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 2586 
Figure 7 Quantitative PCR results show fenugreek seed extract (FSE) increased mRNA levels of 2587 
SREBP1c (A; p=0.0412); and FAS (B; p=0.0021) in HepG2 cells. Extracellular cholesterol levels were 2588 
significantly reduced relative to the control under hyperglycaemic conditions (C, p=0.0312) and TGs 2589 
were significantly reduced by MF and 4-OH-Ile under both conditions (D, p=0.0122). mRNA 2590 
quantification in substantiated increased SREBP1c (E, p=0.0043) and FAS (F, p=0.0102) in the presence 2591 
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of MET and 4-OH-Ile. Lipid profile analysis showed reduced plasma levels of cholesterol (G, p=0.0121) 2592 
and TGs (H, p=0.0231) of treated mice. *P< 0.05 relative to control. 2593 
 2594 
2595 
Figure 8 Fenugreek seed extract treatment relative to the untreated control on the gene expression Apo A1 2596 
on HepG2 cells (A, p=0.0122) and mice liver (C, p=0.0272) under normoglycaemic and hyperglycaemic 2597 
conditions.  A lipid profile analysis was performed on the supernatant of the treated HepG2 cells (B, 2598 
p=0.0233) and serum (D, p=0.0332) of treated mice to assess the extracellular HDLc levels, under 2599 
normoglycaemic and hyperglycaemic conditions. *P< 0.05 relative to control 2600 
 2601 
Discussion 2602 
The role of 4-OH-lle as an anti-lipidemic alternative has been supported by improved lipid profiles (19). 2603 
We previously showed in an in vitro liver model, the reduction of extracellular glucose levels by 4-OH-2604 
lle, MF and FSE via induction of the insulin signaling pathway and subsequent GLUT2 recruitment. (15). 2605 
We also validated the above study in an in vivo mice model.  The present study consolidated our previous 2606 
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findings on 4-OH-lle, by investigating the effect of 4-OH-lle in comparison to MF and FSE on PCSK9 2607 
and PPARG signaling and related plasma lipid profiles in hyperglycaemic HepG2 cells and C57BL/6 2608 
male mice. 4-hydroxyisoleucine significantly improved the altered lipid profile, SREBP1c-FAS, PCSK9 2609 
and PPARG signaling in both models by effectively regulating altered lipid levels, enhancing SREBP1c-2610 
FAS and PPARG signaling and reducing PCSK9.  2611 
 2612 
An abnormal lipid profile is the hallmark abnormality of diabetic dyslipidemia. Studies have reported the 2613 
lipid lowering effect of fenugreek in reducing abnormal lipid levels. In human studies by Sharma et al, 2614 
1990 and Kassaian et al, 2009, both researchers concluded that the lipid lowering effect of fenugreek 2615 
seeds was attributed to 4-OH-lle (19, 29). In dyslipidemic hamsters’ 4-OH-lle decreased plasma TGs, 2616 
total cholesterol, and FFAs, accompanied with an elevation by 39% of the HDLc: TC ratio. Another study 2617 
by Haeri et al, 2009 (12) displayed improved liver function markers, decreased blood glucose and 2618 
restoration of blood lipid and uric acid levels following 4-OH-lle treatment (12). An important study by 2619 
Vijayakumar et al, 2010 (10) investigated the hypolipidemic effect of fenugreek seeds in 3T3-L1 and 2620 
HepG2 cells. They showed that the inhibition of fat accumulation and upregulation of LDLr, decreased 2621 
both TGs and LDLc (10). However no studies have reported the lipid lowering effects of 4-OH-lle on 2622 
both PCSK9 and PPARG in regulating lipid homeostasis. In our study, we compare the effect of 4-OH-lle 2623 
to MF and FSE on plasma lipoproteins and regulation of PCSK9 and PPARG under both normal and HG 2624 
conditions, in HepG2 cells and C57BL/6 male mice.  2625 
 2626 
In this study, we showed the potential of 4-OH-lle in activing SREBP1c gene expression. 2627 
Interestingly, 4-OH-lle elicited a more potent effect than MF under NG and HG conditions, in both 2628 
models. The activation of SREBP1c is largely regulated by insulin which plays a profound role in 2629 
insulin’s effect on the transcription of the hepatic gene FAS. The significance of this direct 2630 
communication of insulin with SREBP1c was supported by Azzout-Marniche et al, 2000 (20). This 2631 
interaction between insulin and SREBP1c is crucial for the genomic actions of insulin on both 2632 
carbohydrate and lipid metabolism (20). Furthermore, the results of Dif et al, 2006 strongly suggest that 2633 
SREBP1c transcription factors are the main mediators of insulin action on SREBP1c expression in human 2634 
tissues. Other studies are also in agreement of the imperative role of insulin on SREBP1c (21). Therefore, 2635 
we investigated the effect of 4-OH-lle in comparison to MF on SREBP1c mRNA expression. In both 2636 
models, we observed 4-OH-lle significantly increase SREBP1c with a profound effect during 2637 
hyperglycaemia (Fig 4). In addition, the transcript levels of FAS also increased, with 4-OH-lle inducing a 2638 
greater increase as compared to MF (Fig 4). During FA synthesis, both SREBP1c and subsequent FAS 2639 
activation is central to the formation of TGs (22, 23). Triglycerides form a major component of very-low 2640 
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density lipoprotein (VLDL) which serve as both energy sources and transporters of dietary fat (2). Again, 2641 
our results showed that 4-OH-lle preceded the effect of MF in regulating TG levels (Fig 4). Collectively 2642 
these findings validate the potential of 4-OH-lle in regulating SREBP1c and FAS activation during 2643 
chronic hyperglycaemia.  2644 
 2645 
The impact of SREBP1c activation is fundamental for the formation of lipoproteins (23). Following the 2646 
formation of TGs, their uptake into the cell stimulates VLDL assembly which is an attempt of the liver to 2647 
maintain lipid homeostasis (24). This is followed by the removal of TG remnants from VLDL particles, 2648 
resulting in particles with a higher cholesterol content – forming LDLc (25, 26). Several studies have 2649 
evaluated the role of LDLc in lipid homeostasis (27, 28). A study by Mohan et al, 2005 concluded that 2650 
LDL is associated with diabetes and a TG/HDL ratio ≥ 3.0 could serve as a marker of LDL (27). A patient 2651 
study supported recommendations for aggressive control of LDLc in diabetic individuals, with a target 2652 
level of <5.5mmol/L (29). In addition, studies have reported the use of PCSK9 regulators in controlling 2653 
LDLc levels (4). Seidah, 2009 reported Annexin A2 to specifically bind and inhibit PCSK9 (30). Another 2654 
study raised the possibility that pharmacologic inhibition of PCSK9 might lower LDLc levels in patients 2655 
with hypercholesterolemia (31). In the destructive hyperglycaemic environment 4-OH-lle down-regulated 2656 
the total protein expression of PCSK9 (Fig 1B, D). This effect translated into the observed reduction in 2657 
PCSK9 gene expression (Fig 1, 2). More importantly, we observed a concomitant rise in the transcript 2658 
levels of LDLr (Fig 1; 2). Our results infer the potential of 4-OH-lle in restoring lipid homeostasis which 2659 
is on par or even better than MF. 2660 
 2661 
Despite lowering LDLc levels, it is of utmost importance that lowered LDLc is accompanied by a 2662 
concomitant rise in HDLc. The term ‘good’ cholesterol is given to HDLc which is formed following the 2663 
removal of cholesterol from LDLc. The formation of HDLc is necessary for reverse cholesterol transport 2664 
which is accomplished by Apo A1, a major constituent of HDLc (32, 33). Apolipoprotein A1 functions to 2665 
remove cholesterol from peripheral cells and transports it to the liver for its removal from circulation (34). 2666 
The well-known transcription factor PPARG is responsible for positively contributing to the cholesterol 2667 
pool by elevating HDLc levels. Studies have suggested PPARG agonists might have therapeutic potential 2668 
in the treatment of diabetic dyslipidemia (35-37).  Our results are in agreement with these studies, as 4-2669 
OH-lle displayed a significant ability in increasing the protein expression of PPARG in both chronic 2670 
hyperglycaemic models (Fig 1). Furthermore, 4-OH-lle exhibited stronger potential than MF in increasing 2671 
the gene expression of Apo A1 (Fig 4). The outcome of this increase was validated by the elevated HDLc 2672 
levels, in both HG models (Fig 4). The increase in HDLc further exemplifies the potency of 4-OH-lle in 2673 
restoring an abnormal lipid profile. 2674 
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Following our promising results and the supporting literature, we further analyzed FSE under the same 2675 
parameters, in comparison to 4-OH-lle and MF. We observed FSE significantly decrease total protein 2676 
expression of PCSK9 and increase the total protein expression of PPARG (Fig 5). In addition, FSE 2677 
elevated the gene expression levels of PCSK9, LDLr, SREBP1c, FAS and Apo A1. These results 2678 
preceded the effect of MF but were similar to 4-OH-lle. Interestingly, 4-OH-lle could account for the 2679 
potency of FSE, as 4-OH-lle has been documented to be abundant in fenugreek seeds. Furthermore, 4-2680 
OH-lle is postulated to account for the seeds anti-diabetic and anti-lipidemic effects. Interestingly, our 2681 
study shows that 4-OH-lle is potent in its effect on both PCSK9 and PPARG expression and related lipid 2682 
factors as opposed to the independent effect of FSE. Studies have also reported diosgenin – a biologically 2683 
active steroid sapogenin as a possible mediator in the seeds effect to maintain glucose and lipid 2684 
homeostasis (38). Animal models have recently supported the role of diosgenin in reducing glycaemia in 2685 
a diabetic state by reducing the proteins involved in hepatic gluconeogenesis and glucose export. Also 2686 
soluble fibers such as galactomannans largely constitutes the fiber content of fenugreek seeds (39). 2687 
Studies reported that these fibers enhance glycaemic control by inhibiting lipid and carbohydrate proteins 2688 
in the digestive system (40).  2689 
 2690 
4-hydroxyisoelucine potentiates an anti-lipidemic response in hyperglycaemic HepG2 cells and C57BL/6 2691 
male mice. Collectively, the results show that the liver response to 4-OH-lle exposure augments PCSK9 2692 
and PPARG expression and the abnormal lipid profile. These results were particularly profound in a 2693 
hyperglycaemic state. Furthermore, the results provide substantial evidence for the use of FSE as a 2694 
possible lipid-lowering agent. This data may help develop a better understanding of the molecular and 2695 
biochemical interactions of both 4-OH-lle and FSE, associated with risks of diabetic dyslipidemia. This 2696 
has great importance in socio-economically challenged communities where T2D individuals are unable to 2697 
access healthcare facilities and natural products are first-line treatment.  2698 
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CHAPTER 5 2842 
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4-hydroxyisolecuine potentiates hepatic Nrf2-antioxidant response and mitochondrial maintenance 2844 
proteins during chronic hyperglycaemia in vitro and in vivo 2845 
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Abstract 2876 
During type 2 diabetes mellitus (T2D), defective insulin action and hyperglycaemia, initiate over-2877 
production of reactive oxygen species (ROS) and compromise mitochondrial integrity. This imbalance 2878 
causes oxidative stress (OS) contributing to diabetic complications. 4-hydroxyisoleucine (4-OH-lle) - the 2879 
bioactive component of fenugreek seeds, possesses anti-diabetic and anti-lipidemic effects. Our study 2880 
evaluated the effects of 4-OH-lle on hepatic Nrf2-mediated antioxidant response and mitochondrial 2881 
maintenance proteins (LonP1, SIRT3, PGC-1α), in vitro (HepG2 cells) and in vivo (C57BL/6 male mice). 2882 
In addition the effects of metformin and fenugreek seed extract (FSE) were also investigated. Treatments 2883 
included 4-OH-lle, metformin and FSE and were conducted over 72 hours (in vitro) and 15 days (in vivo) 2884 
under normoglycaemic and hyperglycaemic (in vitro: 25mM glucose; in vivo: 50mg/kg body weight 2885 
streptozotocin) conditions. In vitro GSH (GSH assay), MDA (TBARS) and protein carbonyl (protein 2886 
carbonyl assay) levels were measured. Protein expression of pNrf2/Nrf2, LonP1, SIRT3 and PGC-1α 2887 
were measured by western blotting. And mRNA levels of SIRT3, PGC-1α, SOD2 and GPx were 2888 
evaluated by qPCR. Thereafter, these results were validated using an in vivo diabetic mouse model.  2889 
In vitro, 4-OH-lle increased GSH concentrations and mitigated OS markers (MDA, protein carbonyl), 2890 
greater than metformin. Since 4-OH-lle enhanced the antioxidant status we validated the above regulatory 2891 
proteins both in vitro and in vivo. In both models, 4-OH-lle significantly increased mRNA levels of Nrf2 2892 
targets and mitochondrial maintenance genes and proteins, exceeding that of metformin. However, the 2893 
overall effect of 4-OH-lle was similar to FSE. In conclusion, 4-OH-lle improves the OS status in T2D by 2894 
regulating pNrf2, LonP1 and SIRT3 expression. This provides a possible novel therapeutic intervention 2895 
for the treatment of OS and associated diabetic complications.  2896 
 2897 
Keywords: type 2 diabetes mellitus, 4-hydroxyisoleucine, oxidative stress, hyperglycaemia, Nrf2, 2898 
mitochondrial proteins 2899 
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Introduction 2910 
During type two diabetes mellitus (T2D) compromised insulin signaling potentiates insulin resistance, 2911 
causing chronic hyperglycaemia [1]. Long term elevation in blood glucose levels initiates the over-2912 
production of reactive oxygen species (ROS) via attenuating endogenous antioxidant (AO) enzymes, 2913 
mitochondrial dysfunction, stimulation of protein kinase C (PKC) and generation of advanced glycation 2914 
end-products (AGEs) [2, 3]. The accumulation of ROS results in oxidative stress (OS) - a pathological 2915 
condition linked to the development and progression of cardiovascular disease (CVD) and diabetic 2916 
complications. Uncontrolled ROS production in T2D patients is central to the pathogenesis of micro- and 2917 
macro-vascular complications, and associated morbidity and mortality [1]. It is therefore critically 2918 
important in treating modifiable CVD risk factors in T2D individuals.  2919 
 2920 
Improving endogenous cellular AO responses and detoxification systems would be beneficial in 2921 
attenuating CVD and diabetic complications. The transcription factor nuclear factor erythroid 2-related 2922 
factor 2 (Nrf2) functions as the principal regulator of the endogenous AO system, with secondary 2923 
functions in detoxification and mitochondrial homeostasis. This transcription factor is the first line of 2924 
defence against OS by mediating the transcription of cytoprotective and ROS detoxification genes. 2925 
Reduced Nrf2 expression has been reported in diabetic mice and humans - contributing to elevated OS, 2926 
endothethial dysfunction and insulin resistance [4, 5]. Acute hyperglycaemia has been associated with 2927 
increased Nrf2 function whereas chronic hyperglycaemia has resulted in reduced function of Nrf2 [4-6]. 2928 
This transcription factor is regulated through multi-signaling processes which involve cytosolic 2929 
regulation, nuclear translocation and export, and DNA binding [4, 7]. Studies have confirmed that the 2930 
diabetic milieu dysregulates several aspects of the Nrf2 signaling pathway [4, 7-9]. Therefore, targeting 2931 
Nrf2 may prove beneficial in counteracting the pathological effects of T2D. 2932 
 2933 
The relationship between diabetes and mitochondrial dysfunction is well-established [7, 10]. 2934 
Mitochondria generate low levels of superoxide anion radicals as by-products of the electron transport 2935 
chain during respiration [11]. At basal levels, ROS play a role in redox signaling; however, over-2936 
production of ROS leads to free radical interaction with cellular macromolecules, often resulting in 2937 
deleterious effects [11]. It is well-documented that mitochondria are one of the main endogenous 2938 
producers of ROS [7, 10]. In an attempt to counteract this ROS production, Nrf2 further extends its AO 2939 
effect to the mitochondria [7, 10]. It has been reported that Nrf2 affects availability of substrates for 2940 
mitochondrial respiration, leading to its effect on mitochondrial ROS production [7, 10]. Furthermore, 2941 
mitochondria possess its own maintenance pathways which include sirtuin 3 (SIRT3), peroxisome 2942 
proliferator-activated receptor gamma coactivator-1alpha (PGC-1α) and mitochondrial lon protease 1 2943 
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(LonP1). A well-characterized marker of oxidative damage includes lipid peroxidation which yields lipid 2944 
peroxy-radicals [12]. The metabolic alterations associated with T2D increases susceptibility to lipid 2945 
peroxidation, and is considered a driver of atherosclerotic progression [12]. Additionally, ROS interaction 2946 
with amino acid side chains, produces protein carbonyls and dysfunctional oxidatively-modified proteins 2947 
[12]. Hyperglycaemia elevates protein damage via protein glycosylation, resulting in the production of 2948 
AGEs. LonP1 is a mitochondrial protease, which proteolytically clears damaged proteins, which 2949 
preserves proteostasis under normal metabolic conditions, and avoids proteotoxicity during environmental 2950 
and cellular stress [13]. SIRT3 is a NAD-dependent deactylase, targeting proteins involved in energy 2951 
metabolism and the rate of ROS production [14]. SIRT3 serves to elevate cellular respiration and 2952 
attenuate ROS levels. More importantly, SIRT3 is essential for the induction of PGC-1α - a regulator of 2953 
mitochondrial ROS scavenging enzyme; superoxide dismutase 2 (SOD2) and transcriptional coactivator 2954 
driving mitochondrial biogenesis [15]. Initiation of PGC-1α expression in liver is a regulatory event 2955 
causing the activation of energy metabolic pathways which exert homeostatic control. However, elevated 2956 
glucose levels compromise the expression of PGC-1α. Consequently, in T2D attenuated LonP1, SIRT3 2957 
and PGC-1α levels further exacerbate mitochondrial dysfunction and OS.  2958 
 2959 
Metformin (MF) is the first-line drug therapy for treating T2D and demonstrates some AO activity [16-2960 
18]. Alternative therapeutic interventions, however, provide a cost effective and easily accessible means 2961 
of treating T2D. Trigonella foenum-graecum, frequently known as fenugreek, has been investigated as a 2962 
therapeutic intervention in diabetes [19, 20]. Documented effects of fenugreek have been attributed to the 2963 
seed of the plant which has a high content of a branched-chain amino acid derivative - 4-2964 
hydroxyisoleucine (4-OH-lle) [20, 21]. A study by Mohamad et al, 2004 observed increased SOD2 and 2965 
liver enzymes in rats treated with 4-OH-lle [22]. In cholesterol-fed rats, extracts of fenugreek seeds 2966 
reduced thiobarbituric acid-reactive substances (TBARS) and increased catalase and SOD2 in the liver 2967 
[23]. More importantly a study by Dutta et al, 2014 revealed that the 4-OH-lle rich fraction possesses AO 2968 
characteristics which is evident from its ability to scavenge toxic radicals in a chemically defined in vitro 2969 
system [24]. In our previous study, we investigated the effects of 4-OH-lle, MF and fenugreek seed 2970 
extract (FSE) on proteins and genes involved in regulating insulin signaling and dyslipidemia in vitro [25] 2971 
and in vivo (PHYMED-D-17-01253). These studies supported the use of 4-OH-lle and fenugreek seed as 2972 
a possible alternate therapy for reducing hyperglycaemia and improving an abnormal lipid profile. The 2973 
objective of our current study was to investigate the regulatory effect of 4-OH-lle in comparison to MF on 2974 
hepatic OS and mitochondrial maintenance proteins in hyperglycaemic HepG2 cells and C57BL/6 male 2975 
mice. 2976 
 2977 
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Materials and methods 2978 
Materials 2979 
4-OH-Ile (50118), MF (PHR1084) and streptozotocin (STZ) (S0130) were purchased from Sigma Aldrich 2980 
(St Louis, MO, USA). Whole fenugreek seeds were purchased from Agricol Niche Brands, a South 2981 
African seed company. A herbarium voucher of flowering material was lodged at the Ward Herbarium 2982 
(UDW-UKZN; N. Naicker 1). All other consumables were purchased from Merck (Darmstadt, Germany), 2983 
unless otherwise stated. 2984 
 2985 
Liquid chromatography–mass spectrometry (LC-MS) 2986 
LC-MS was used to separate multiple components and structurally identify individual components with 2987 
high molecular specificity, within a crude extract. 1mg of crude FSE was weighed and dissolved in 10ml 2988 
methanol (MeOH). Each sample was vortexed and sonicated to allow for complete dissolution. The 2989 
extract was then subjected to solid phase extraction, using a Supelco C18 100mg solid phase cartridge. 2990 
The extract was eluted with MeOH. A 1:100 dilution of the sample was prepared using MeOH and 2991 
injected into the LC-MS. The instrumentation used was the Shimadzu 202 UFLC-MS, mobile A: 0.1% 2992 
formic acid (FA) in water and mobile phase B: 0.1% FA in acetonitrile. Separation was achieved using a 2993 
YMC Triart C18 analytical column (4.6mm x 150mm), using a gradient elution method from 5% B to 95 2994 
B over 25min. Data was collected at 265nm and analyzed using the Shimadzu Lab Solutions software 2995 
(Graphs 2, 3, 4 and Table 2).  2996 
 2997 
Treatment preparation of stock solutions 2998 
Whole fenugreek seeds were crushed using a pestle and mortar, suspended in deionized water (1,000 2999 
mg/mL) and placed on a stirrer at room temperature (RT) for 3 hour (hr). The aqueous solution was 3000 
3001 
removed, freeze-dried and stored at -20oC. Metformin tablets were crushed with a pestle and mortar, 3002 
suspended in 0.1M phosphate-buffered saline (PBS) (50mg/mL) and filter sterilized (0.45-mm filter). 4-3003 
hydroxyisoleucine was obtained in a liquid form and treatments were prepared from a stock solution (as 3004 
per manufacturer’s instructions). Subsequent treatments were prepared in complete culture medium 3005 
(CCM) for in vitro and in 0.1M PBS solution for in vivo administration.  3006 
 3007 
Cell culture and treatment preparation 3008 
HepG2 cells were cultured (37oC, 5% CO2) in 25cm3 flasks in complete CCM comprising Eagles 3009 
minimum essential medium, 10% foetal calf serum, 1% L-glutamine and 1% penstrepfungizone (Lonza 3010 
Biowhittaker; Basel, Switzerland). Cells were grown to 90% confluency prior to treatment for 72hr. Cells 3011 
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were subject to normoglycaemic (NG; 5mM glucose) and hyperglycaemic (HG; 25mM glucose) 3012 
conditions and treatments were replenished every 24hr. The methods used for the preparation of 4-OH-lle, 3013 
MF and FSE were as per the protocol followed by Naicker et al, 2016 [25]. The optimized treatment 3014 
concentrations by Naicker et al, 2016 were used in this study which include; 4-OH-lle (100ng/ml), MF 3015 
(2mM) and FSE (100ng/ml) [25].  All experiments were conducted in triplicate and repeated 3016 
independently 3 times. The following spectrophotometric assay: TBARS, GSH and protein carbonyl 3017 
assay were only performed in vitro, these results prompted us to further investigate the protein and gene 3018 
expression in vitro and in vivo. 3019 
 3020 
TBARS 3021 
The TBARS assay determined extracellular levels of MDA – an end-product of lipid peroxidation in 3022 
HepG2 cells. The assay was conducted as the method previously described by Phulukdaree et al, 2010 3023 
[26]. The absorbance was measured at 532nm with a reference wavelength of 600nm using a Bio-Tek 3024 
µQuant spectrophotometer. The average of 3 replicates were calculated and divided by the absorption 3025 
coefficient, 156 mM-1 to determine the average concentration of MDA (µM). 3026 
 3027 
GSH Assay 3028 
The GSH-Glo™ Glutathione Assay (Promega, Madison, USA) was used to detect reduced GSH content 3029 
in HepG2 cells. For the detection of GSSG, a stronger thiol reductant, tris (2-carboxyethyl) phosphine 3030 
hydrochloride (TCEP), was used to release GSH bound to proteins, providing a reading for GSSG+GSH. 3031 
GSSG was calculated by subtracting the GSH quantification from GSSG+GSH. The assay was conducted 3032 
as per the method previously described by Nagiah et al, 2015 [27]. The plates were read on a Modulus™ 3033 
microplate luminometer (Turner Biosystems, Sunnyvale, CA) and GSH concentrations (µM) were 3034 
determined by extrapolation from the standard curve. 3035 
 3036 
Protein carbonyl assay 3037 
The protein carbonyl assay was used as a measure of oxidative damage to proteins in HepG2 cells. 3038 
Following treatment, cells were rinsed twice with PBS; 200µl of cell lysis buffer was added for 10min on 3039 
ice and then centrifuged (4oC, 12,000g). Crude protein samples were quantified by the bicinchoninic acid 3040 
assay and standardized to 2mg/mL in 200µl. For each sample, 200µl of protein was transferred to a 15ml 3041 
conical centrifuge tube. 800μl of 10mM DNPH in 2,5M HCl was added to 200μl of protein of each 3042 
sample, except the blank (800µl of 2.5M HCl). Samples were left for 1hr to incubate at room temperature 3043 
and vortexed every 15min. 1ml of 20% TCA was added to each sample, and left on ice for 10min. This 3044 
was followed by centrifugation for 10min at 4000xg for the collection of protein precipitates. Another 3045 
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wash was performed using 1ml of 10% TCA. Samples were then centrifuged at 2000g for 10min at RT. 3046 
To remove the free DNPH, the pellets were washed twice with 1ml of ethanol-ethyl acetate (1:1, v/v). The 3047 
final precipitates were dissolved in 500μl of 6M guanidine hydrochloride and left for 10min at 37°C with 3048 
general vortex mixing. Any insoluble materials were removed by additional centrifugation (2,000g, 3049 
10min, RT). Samples were plated at 100µl per well in triplicate and protein carbonyl concentration was 3050 
determined at an absorbance of 370nm. 3051 
 3052 
Animals 3053 
Six-week-old male C57BL/6 mice (n=40) were procured from the Biomedical Resource Unit at the 3054 
Westville Campus of the University of KwaZulu-Natal (UKZN), Durban, South Africa. Mice with a mean 3055 
body weight (BW) of 20 ± 2.99g were randomly divided into 2 groups: non-diabetic (NG) and diabetic 3056 
(HG). Each group were further subdivided into 4 groups of 5 mice each as follows: Control (C), 4-OH-lle, 3057 
MF and FSE. Mice were housed in polycarbonated cages in a humidity and temperature controlled room 3058 
(40-60% humidity, 23 ± 1oC) with a 12hr light dark cycle. The mice were fed a commercially available 3059 
pellet diet and normal drinking water ad libitum throughout the 15 day experimental period. The mice 3060 
were maintained according to the rules and regulations of the Experimental Animal Ethics Committee of 3061 
the UKZN (Ethical approval number: AREC/057/016). 3062 
 3063 
Induction of diabetes 3064 
Administration of a low single dose of STZ damages pancreatic β-cells through alkylation of DNA by 3065 
causing partial destruction of these cells, resulting in hyperglycaemia [28, 29]. This process displays the 3066 
pathophysiological characteristics of T2D which include inadequate β-cell mass and β-cell dysfunction. 3067 
Type two diabetes was induced in all mice in the diabetic group via intraperitoneal administration of STZ 3068 
(50mg/kg BW) dissolved in 0.1M citrate buffer (pH 4.4) following an overnight fast (12hr). The optimal 3069 
dosage of 50mg/kg was determined by preliminary investigation which included a range of STZ 3070 
concentrations (50mg/kg, 100mg/kg and 150mg/kg BW). Blood was collected from the tail vein, using a 3071 
glucometer (Accu-Chek®) to monitor and measure the fasting blood glucose over a 10 day period prior to 3072 
administration of treatment. Once a blood glucose of >7mmol/L and <16mmol/L was achieved and stable, 3073 
the treatment period was inducted.    3074 
 3075 
Treatment preparations 3076 
Preparation of treatments were guided by the protocol followed by Naicker et al, 2016 [25]. The 3077 
concentration of 4-OH-lle (100mg/kg BW), MF (20mg/kg BW) and FSE (100mg/kg BW) were based on 3078 
previous animal studies which evaluated a range of concentrations and reported the outcomes of the range 3079 
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which we based our optimal concentration [19, 30-33]. Mice were treated once daily for the 15 day 3080 
treatment period via oral gavage.  3081 
 3082 
Animals post treatment 3083 
At the end of the treatment period, mice were sacrificed using isoflurane. Blood samples were collected 3084 
using anticoagulant EDTA tubes, in order to measure blood glucose levels. The blood glucose levels were 3085 
measured at an accredited laboratory (AMPATH, Amanzimtoti, South Africa).  All mice livers were 3086 
harvested, rinsed twice in saline, dissected and stored in Cytobuster (Novagen, Darmstadt, Germany) and 3087 
Qiazol (Qiagen; Hildenburg, Germany) at -80oC until analysis. 3088 
 3089 
Glucose analysis 3090 
Glucose analysis was performed by an accredited pathology laboratory (AMPATH laboratories, 3091 
Amanzimtoti, South Africa). The supernatant from each cell culture sample was lyophilized and 3092 
reconstituted in 500µl of 0.1M PBS before analysis. Plasma isolated from each mouse was also analyzed 3093 
for glucose levels. Glucose and oral glucose tolerance test analysis are shown in Figure 1 (supplementary 3094 
data). 3095 
 3096 
Western blotting 3097 
Western blots were performed to quantify relative protein expression of pNrf2/Nrf2, SIRT3, PGC-1α and 3098 
LonP1. Crude protein was isolated using Cytobuster supplemented with protease and phosphate inhibitors 3099 
(Roche: 04693124001 and 04906837001). HepG2 cells and mice liver samples (homogenized) were 3100 
incubated in Cytobuster for 10min on ice and then centrifuged (4oC, 12,000g). Crude protein samples 3101 
were quantified by the bicinchoninic acid assay and standardized to 1mg/mL. Samples were boiled in 3102 
Laemmli buffer [dH2O, 0.5M Tris–HCl (pH 6.8), glycerol, 10% SDS, β-mercaptoethanol and 1% 3103 
bromophenol blue] for 5min. Samples were electrophoresed on a sodium dodecyl sulphate 3104 
polyacrylamide gel (4% stacking and 10% resolving) for 1hr at 150V and transferred on to nitrocellulose 3105 
using the TransBlot Turbo Blotting System (Bio-Rad; Hercules, CA) using a preinstalled Standard SD 3106 
program. All membranes were blocked for 2hr in 3% BSA in Tween20-Tris-buffered saline (TTBS - 3107 
0.15M NaCl, 2.68M KCl, 24.86M Tris, 500µl Tween20, pH 7.4) at RT on a shaker. Thereafter, the 3108 
membranes were incubated with primary antibody pNrf2 (CS8882, 1:5,000), SIRT3 (CSC73E7, 1:5,000), 3109 
PGC-1α (CS2178, 1:5,000) and LonP1 (Sigma HPA002192, 1:5,000) at 4oC overnight. The membranes 3110 
were then equilibrated to RT on a shaker for 1hr, followed by 5 washes (10min) with TTBS. Membranes 3111 
were then probed with horseradish peroxidase conjugated-secondary antibody [anti-rabbit 1:10,000 3112 
(CS7074)] for 1hr, followed by 5 washes (10min) with TTBS. Chemiluminescent signal was detected 3113 
108 
 
using ECL Clarity Western detection reagent (Bio-Rad) and captured on the Bio-Rad ChemiDoc Viewing 3114 
System. Data were expressed as relative band density (RBD) and expression of proteins was analyzed 3115 
with the Bio-Rad ChemiDoc MP Imaging System with Image Lab software. Membranes were quenched 3116 
(5% H2O2 at 37oC for 30min) and pNrf2 was normalized against total Nrf2 (ab31163, 1:5,000) and other 3117 
proteins were normalized against β-actin (A5316, 1:5,000).  3118 
 3119 
Quantitative PCR 3120 
The mRNA expression of SIRT3, PGC-1α, GPx and SOD2 was determined by qPCR. Total RNA was 3121 
isolated using Qiazol extraction buffer (Qiagen, Hilden, Germany) and an in-house protocol [34]. RNA 3122 
was quantified using a spectrophotometer (Nanodrop2000, Biotech) and standardized to 1,000ng/µl. 3123 
Standardized RNA was reverse transcribed to complementary DNA (cDNA) using the iScriptTM cDNA 3124 
Synthesis kit (Bio-Rad; 107-8890) as per the manufacturer’s instruction. A reaction volume of 10μl was 3125 
prepared consisting of 5X IQ™ SYBR® ssoAdvanced SYBR Green (Bio-Rad; 170-880), nuclease free 3126 
water, 1μl cDNA template (1,000ng/ml), and 1μl sense and anti-sense primer (Inqaba Biotec™). The 3127 
mRNA expression was normalized against a housekeeping gene (18S). Thermocycler conditions were 3128 
carried out using the CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad, Hercules, CA) as 3129 
follows: initial denaturation (95°C, 10min), 40 cycles of denaturation (95°C, 15sec), annealing and 3130 
extension (72°C, 30sec). Relative fold change was calculated using the method described by Livak and 3131 
Schmittgen, 2001 to calculate relative fold change [35]. Primer sequences and annealing temperatures are 3132 
shown in (Supplementary data, table 1). 3133 
 3134 
Statistical analyses 3135 
Following each experiment in vitro and in vivo, 4-OH-lle was compared to MF and the untreated control. 3136 
We then analyzed FSE in comparison to the untreated control. Statistical analyses were performed using 3137 
GraphPad Prism v5.0 software (GraphPad Software, Inc.). Statistical comparisons for 4-OH-lle, MF and 3138 
the untreated control were made using a one-way analysis of variance (ANOVA), nonparametric test 3139 
(Kruskal Wallis test) and a Dunn’s post-test; and a non-parametric Mann-Whitney test was used for FSE 3140 
and the untreated control. The data were considered statistically significant with a value of p < 0.05. 3141 
 3142 
Results 3143 
4-OH-lle regulates MDA, GSH and protein carbonyl levels under NG and HG conditions, in vitro 3144 
We first determined the effect of 4-OH-lle on OS markers (MDA and protein carbonyls) and cellular AO 3145 
content (GSH/GSSG). Figure 1A demonstrates OS induction as indicated by increased extracellular MDA 3146 
levels, under a HG state (0.38 ± 0.004). 4-OH-lle (0.13 ± 0.004) and MF (0.15 ± 0.004) significantly 3147 
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reduced the levels of MDA (Fig 1A). During hyperglycaemia, GSH levels are attenuated which is 3148 
observed in the hyperglycaemic control (4.0 ± 0.002) (Fig 1B). Again, both 4-OH-lle (NG: 30.0± 0.002; 3149 
HG: 18.0 ± 0.002) and MF (NG: 32.0 ± 0.001; HG: 27 ± 0.004) significantly increased GSH levels 3150 
compared to the untreated controls (Fig 1B). In addition, the levels of GSSG were reduced under both 3151 
conditions by 4-OH-lle (NG: 0.2 ± 0.006; HG: 1.3 ± 0.005) and MF (NG: 0.9 ± 0.005; HG: 1.5 ± 0.006) 3152 
compared to the untreated controls (NG: 2.9 ± 0.001, HG: 1.8 ± 0.017) (Fig 1C). Hyperglycaemia causes 3153 
the oxidation of proteins, forming protein carbonyls. We observed the rise in protein carbonyls in the 3154 
hyperglycaemic state (0.0000015 ± 0.005) (Fig 1D). However, as seen in figure 1D 4-OH-lle (NG: 3155 
0.0000008 ± 0.003; HG: 0.0000009 ± 0.002) and MF (NG: 0.0000006 ± 0.001; HG: 0.0000007 ± 0.004) 3156 
attenuated the protein carbonyl levels. 3157 
3158 
Figure 1. Intracellular reactive oxygen species measured as malondialdehyde (MDA) (A– 3159 
normoglycaemic, p=0.0024; hyperglycaemic, p=0.0012), GSH (B – normoglycaemic, p=0.0424; 3160 
hyperglycaemic, p=0.0232), GSSG (C– normoglycaemic, p=0.0121; hyperglycaemic, p=0.0242), and 3161 
protein carbonyl (D– normoglycaemic, p=0.0420; hyperglycaemic, p=0.0112) levels in HepG2 cells 3162 
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treated with metformin (MF) and 4-hydroxyisoleucine (4-OH-lle) at 72h, *P<0.05; **P<0.05 relative to 3163 
control. 3164 
 3165 
4-OH-lle regulates protein expression of pNrf2/Nrf2 and gene expression of SOD2 and GPx under 3166 
NG and HG conditions, in vitro and in vivo 3167 
The changes in MDA and GSH levels observed in vitro prompted further investigation of the 3168 
transcriptional regulation of the cellular AO response. In vitro, 4-OH-lle elevated the expression of pNrf2 3169 
(NG: 2.2-fold, 1.40±0.03RBD; HG: 2.5-fold, 1.38±0.02RBD) (Fig 2A, B). This was validated in vivo; 3170 
where we observed 4-OH-lle increase the expression of pNrf2 (NG: 2-fold, 1.40±0.02RBD; HG: 2.3-fold, 3171 
1.38±0.01RBD) (Fig 2C, D). Increased pNrf2 is indicative of nuclear translocation and activation of Nrf2, 3172 
followed by binding to the ARE; inducing transcription of various antioxidant genes. This was evidenced 3173 
by increased SOD2 (Table 1) and GPx (Table 1) transcript levels in 4-OH-lle treatments. In both HG in 3174 
vitro and in vivo models 4-OH-lle increased SOD2 gene expression 2.4-fold (Table 1) and 2.2-fold (Table 3175 
1), respectively. Likewise, 4-OH-lle increased GPx gene expression 2.5-fold (Table 1) and 2.6-fold (Table 3176 
1). 3177 
3178 
Figure 2. Phosphorylated (p) Nuclear factor erythroid 2-related factor 2 (Nrf2) and total Nrf2 expression 3179 
in 4-hydroxyisoleucine (4-OH-lle) and metformin (MF) treated HepG2 cells (normoglycaemic –A, 3180 
p=0.0112; hyperglycaemic – B, p=0.0113) and mouse liver (normoglycaemic – C, p=0.0164; 3181 
hyperglycaemic – D, p=0.0011). *P< 0.05 relative to control. 3182 
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Table 1. Gene expression of SIRT3, PGC-1α, SOD2 and GPx following 4-OH-lle and MF treatment in 3183 
vitro and in vivo, under NG and HG conditions 3184 
Normoglycaemic Hyperglycaemic 
         Gene 
In vitro 
SIRT3 PGC-
1α 
SOD2 GPx SIRT3 PGC-1α SOD
2 
GPx 
Control 1 1 1 1 1 1 1 1 
4-OH-lle 1.2* 1.5* 1.2* 1.3* 1.8* 1.6* 2.4* 2.4* 
MF 1.3* 1.6* 1.3* 1.2* 2.0* 1.4* 2.6* 2.5* 
         
In vivo         
Control 1 1 1 1 1 1 1 1 
4-OH-lle 1.2* 1.45* 1.2* 1.1* 1.7* 1.6* 2.4* 2.3* 
MF 1.4* 1.4* 1.3* 1.2* 1.8* 1.5* 2.1* 2.0* 
  3185 
4-OH-Ile and MF treatments increase mRNA levels of SIRT3, PGC-1α, SOD2 and GPx in HepG2 cells 3186 
and mice liver samples.  SIRT3 (p=0.00132), PGC-1α (p=0.00133), SOD2 (p=0.00331) and GPx 3187 
(p=0.00012) mRNA was significantly elevated in hyperglycaemic HepG2 samples treated with MF and 4-3188 
OH-Ile. The in vivo data substantiated this with significantly elevated SIRT3 (p=0.00112), PGC-1α 3189 
(p=0.00211), SOD2 (p=0.00221) and GPx (p=0.00122) in both MF and 4-OH-Ile treatments under both 3190 
conditions. *P< 0.05 relative to control. 3191 
 3192 
4-OH-lle regulates protein expression of LonP1, SIRT3 and PGC-1α and mRNA expression of 3193 
SIRT3 and PGC-1α under NG and HG conditions, in vitro and in vivo 3194 
We evaluated the effects of 4-OH-lle and MF on protein expression of LonP1, SIRT3 and PGC-1α as an 3195 
assessment of mitochondrial stress. We proposed oxidized protein levels diminished following the 3196 
elevation of LonP1 in vitro; (NG: 2.3-fold, 1.28±0.02RBD; HG: 2.8-fold, 1.58±0.01RBD) (Fig 3A, B) 3197 
and in vivo; 1.7-fold (NG: 1.40±0.03RBD) (Fig 3C) and 2.2-fold (HG: 1.27±0.02RBD) (Fig 3D). This 3198 
effect was quantified in vitro as seen via the reduction in protein carbonyl levels (Fig 1D). Next, the 3199 
activation of mitochondrial regulatory proteins were confirmed in vitro, via the increased protein 3200 
expression of both SIRT3 (NG: 2-fold, 1.38±0.02RBD; HG: 2.8-fold, 1.58±0.02RBD) and PGC-1α (NG: 3201 
1.9-fold, 1.08±0.02RBD; HG: 3-fold, 1.70±0.02RBD) (Fig 3A, B). These results were validated by the 3202 
observed increases in vivo, (Fig 3C, D). SIRT3 increased by 1.6-fold (NG: 0.90±0.02RBD) (Fig 3C) and 3203 
1.9-fold (HG: 1.00±0.02RBD) (Fig 3D) whilst PGC-1α expression increased by 2.4-fold (NG: 3204 
2.40±0.02RBD) (Fig 3C) and 2.8-fold (HG: 1.57±0.02RBI) (Fig 3D). Furthermore, these observed 3205 
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changes in protein expression were accompanied by a concomitant rise in mRNA expression of both 3206 
SIRT3 and PGC-1α (Table 1). In both models, the expression of these genes were more prominent in a 3207 
HG condition. In vitro 4-OH-lle increased SIRT3 by 1.7-fold and PGC-1α by 1.55-fold (Table 1); and in 3208 
vivo 4-OH-lle elevated SIRT3 by 1.7-fold and PGC-1α by 1.5-fold (Table 1). Again, the anti-diabetic drug 3209 
MF failed to exceed the effects of 4-OH-lle on both SIRT3 and PGC-1α. 3210 
3211 
Figure 3. Protein expression analysis of Sirtuin 3 (SIRT3), peroxisome proliferator-activated receptor 3212 
gamma coactivator 1-alpha (PGC-1α) and mitochondrial lon protease 1 (LonP1) in 4-hydroxyisoleucine 3213 
(4-OH-lle) and metformin (MF) treated HepG2 cells (normoglycaemic –A, p=0.0242; hyperglycaemic – 3214 
B, p=0.0323) and mouse liver (normoglycaemic – C, p=0.0269; hyperglycaemic – D, p=0.0030). *P< 3215 
0.05 relative to control 3216 
 3217 
FSE regulates protein expression of pNrf2/Nrf2, LonP1, SIRT3 and PGC-1α and gene expression of 3218 
SIRT3, PGC-1α, SOD2 and GPx under NG and HG conditions, in vitro and in vivo 3219 
We also investigated the effect of FSE on GSH, MDA and protein carbonyl levels in vitro. We observed 3220 
that FSE possesses the ability to regulate markers of OS as efficiently as 4-OH-lle (Fig 4). Consequently, 3221 
in vitro and in vivo we investigated the phosphorylated and total protein expression Nrf2. pNrf2 increased 3222 
1.3-fold (NG: 1.01±0.03RBD) (Fig 5A) and 2.3-fold (HG: 1.50±0.02RBD) (Fig 5B) in vitro and 2.2-fold 3223 
(NG: 1.70±0.04RBD) (Fig 5C) and 1.4-fold (HG: 0.90±0.03RBD) (Fig 5D) in vivo. In vitro, 4-OH-lle 3224 
elevated total protein expression of Nrf2 (NG: 1.4-fold, 1.40±0.01RBD; HG: 1.5-fold, 1.38±0.02RBD) 3225 
and in vivo (NG: 1.5-fold, 1.40±0.04RBD; HG: 1.2-fold, 1.38±0.02RBD) expression of Nrf2 (Fig 5). 3226 
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Following the effects of 4-OH-lle, we can conclude that FSE is also a substantial regulator of this major 3227 
transcription factor. 3228 
 3229 
LonP1 displayed a 1.4-fold (NG: 1.01±0.02RBD) (Fig 6A) and 1.9-fold (HG: 1.50±0.02RBD) (Fig 6B) 3230 
increase in vitro and 2.1-fold (NG: 1.01±0.02RBD) (Fig 6C) and 1.2-fold (HG: 0.90±0.02RBD) (Fig 6D) 3231 
rise in vivo. However, in both models these effects did not exceed 4-OH-lle but were potent in eliciting a 3232 
response to the extract. In vitro, FSE significantly up-regulated the total protein expression of SIRT3 by 3233 
2.2-fold (NG: 1.18±0.03RBD) (Fig 6A) and 2.5-fold (HG: 1.28±0.02RBD) (Fig 6B). Also, under a HG 3234 
condition, FSE significantly increased the total protein expression of PGC-1α 2.6-fold (2.00±0.02RBD) 3235 
(Fig 6B) which exceeded the effects of 4-OH-lle. In vivo, FSE displayed the similar changes in protein 3236 
expression; NG: 1.8-fold (1.90±0.02RBD) (Fig 6C) and HG: 1.65-fold (1.60±0.02RBD) (Fig 6D). 3237 
Interestingly, FSE continued to display its efficacy via the marked increase in SIRT3 and PGC-1α.  3238 
 3239 
The gene expression of SOD2, GPx, SIRT3 and PGC-1α was increased by FSE under both conditions 3240 
(Table 2). In vitro, FSE (2.1-fold) displayed an increase in gene expression of SIRT3 (Table 2) which 3241 
surpassed the effect of 4-OH-lle. Also FSE (1.8- and 1.75-fold) increased PGC-1α and SOD2 gene 3242 
expression, respectively (Table 2). In vivo, the similar increases were observed following treatment with 3243 
FSE - SIRT3 increased 1.9-fold, PGC-1α; 2.1-fold and SOD2; 2.6-fold. In vitro, exceeding the effects of 3244 
4-OH-lle, FSE increased GPx gene expression 2.4-fold (in vitro; HG) (Table 2) and 2-fold (HG; in vivo) 3245 
(Table 2). 3246 
 3247 
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3248 
Figure 4. Intracellular reactive oxygen species measured as GSH (A – normoglycaemic, p=0.0124; 3249 
hyperglycaemic, p=0.0132), GSSG (B– normoglycaemic, p=0.0221; hyperglycaemic, p=0.0142), 3250 
malondialdehyde (C– normoglycaemic, p=0.0034; hyperglycaemic, p=0.0022) and protein carbonyl (D– 3251 
normoglycaemic, p=0.0320; hyperglycaemic, p=0.0212) levels in HepG2 cells treated with fenugreek 3252 
seed extract (FSE) at 72h, *P<0.05; **p<0.05 relative to control. 3253 
 3254 
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3255 
Figure 5. Phosphorylated (p) Nuclear factor erythroid 2-related factor 2 (Nrf2) and total Nrf2 expression 3256 
in fenugreek seed extract (FSE) treated HepG2 cells (normoglycaemic –A, p=0.0212; hyperglycaemic – 3257 
B, p=0.0213) and mouse liver (normoglycaemic – C, p=0.0164; hyperglycaemic – D, p=0.0011). *P< 3258 
0.05 relative to control 3259 
 3260 
3261 
Figure 6. Protein expression analysis of Sirtuin 3 (SIRT3), peroxisome proliferator-activated receptor 3262 
gamma coactivator 1-alpha (PGC-1α) and mitochondrial lon protease 1 (LonP1) in fenugreek seed extract 3263 
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(FSE) treated HepG2 cells (normoglycaemic –A, p=0.0231; hyperglycaemic – B, p=0.0233) and mouse 3264 
liver (normoglycaemic – C, p=0.0269; hyperglycaemic – D, p=0.0030). *P< 0.05 relative to control 3265 
 3266 
Table 2. Gene expression of SIRT3, PGC-1α, SOD2 and GPx following FSE treatment in vitro and in 3267 
vivo, under NG and HG conditions 3268 
Normoglycaemic Hyperglycaemic 
         Gene 
In vitro 
SIRT3 PGC-
1α 
SOD2 GPx SIRT3 PGC-1α SOD
2 
GPx 
Control 1 1 1 1 1 1 1 1 
FSE 1.9* 1.5* 1.1* 1.1* 2.1* 1.8* 1.8* 2.5* 
In vivo         
Control 1 1 1 1 1 1 1 1 
FSE 2.2* 1.7* 2.5* 1.3* 2.0* 2.1* 2.7* 2.0* 
 3269 
FSE treatment increased mRNA levels of SIRT3, PGC-1α, SOD2 and GPx in HepG2 cells (A-D) and 3270 
mice liver samples (E-H). SIRT3 (p=0.00121), PGC-1α (p=0.00132), SOD2 (p=0.00231) and GPx 3271 
(p=0.00112) mRNA was significantly elevated in hyperglycaemic HepG2 samples treated with FSE. The 3272 
in vivo data substantiated this with significantly elevated SIRT3 (p=0.00312), PGC-1α (p=0.00311), 3273 
SOD2 (p=0.0321) and GPx (p=0.00322) in both MF and 4-OH-Ile treatments under both conditions. *p< 3274 
0.05 relative to control 3275 
 3276 
Discussion 3277 
In our previous investigations we proved the salient role of 4-OH-lle as a promising therapeutic 3278 
intervention for T2D therapy, via the regulation of insulin signaling and dyslipidemia. Following these 3279 
favourable effects on two critical pathways related to diabetic complications, prompted us to evaluate OS 3280 
and mitochondrial health. Compelling evidence proposes that prolonged OS plays a causal role in the 3281 
pathogenesis of T2D; and improving endogenous cellular AO responses and detoxification will reduce 3282 
OS and attenuate diabetic complications. The major regulator of cellular redox status – Nrf2 has been 3283 
implicated in mitigating the features of diabetic milieu. Therefore, our study investigated the regulatory 3284 
effect of 4-OH-lle in comparison to MF on hepatic OS and mitochondrial maintenance pathways in 3285 
hyperglycaemic human liver (HepG2) cells and C57BL/6 male mice. We observed the protective effects 3286 
of 4-OH-lle via Nrf2 induction and mitochondrial maintenance proteins; LonP1, SIRT3 and PGC-1α. 3287 
 3288 
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Hyperglycaemic-induced ROS production is the main risk factor contributing to OS and subsequent CVD 3289 
and diabetic complications. Studies have reported the AO effect of fenugreek in reducing ROS levels. A 3290 
study by Mohamad et al, 2004 observed SOD2 and liver enzyme levels similar to the normoglycaemic 3291 
control group in fenugreek seed treated rats [22]. Ravikumar and Anuradha, 1999 displayed that 3292 
interrupted free radical metabolism in diabetic animals was regulated by dietary fenugreek seed 3293 
supplementation [36]. Another study investigated the AO activities of fenugreek seeds extracts in 3294 
cholesterol-fed rats and observed a decrease in TBARS and rise in catalase and SOD2 expression [23]. 3295 
Additionally Dixit et al, 2005 revealed substantial AO potential of germinated fenugreek seeds which is 3296 
due to the presence of flavonoids and polyphenols [37]. The bioactive component of fenugreek seeds, 4-3297 
OH-lle, independently possesses AO activity as shown by Dutta et al, 2014. This study evidenced that 4-3298 
OH-lle scavenges hydroxyl, superoxide anion, hydrogen peroxide and DPPH radicals, reduced lipid 3299 
peroxidation and protein carbonyl levels and concomitantly amplified GSH levels, in a chemically 3300 
defined in vitro system [24]. Other substituents of fenugreek seeds, trigonelline and diosgenin, display 3301 
similar effects and are identified as potent activators of the AO transcriptional regulator, Nrf2 [38]. This 3302 
central role player in endogenous AO response has yet to be investigated in relation to 4-OH-lle.  3303 
 3304 
Nrf2 is deemed the master regulator of the endogenous AO response; it enables cells to adapt to an 3305 
oxidative environment via the induction of cytoprotective genes. Nrf2 is positioned in the cytoplasm 3306 
where it is linked to a negative regulator Kelch-like ECH-associated protein 1 (Keap1) [39]. Following 3307 
exposure to OS, Nrf2 gains protein stability (via phosphorylation) and escapes Keap1-mediated 3308 
repression; translocating into the nucleus. This dissociation from Keap1 causes the phosphorylation and 3309 
activation of Nrf2. Within the nucleus, pNrf2 initiates the antioxidant response element (ARE); a 3310 
regulatory sequence involved responsible for transcriptional activation of genes coding for AO enzymes. 3311 
These include cytoprotective genes SOD2 and GPx which are involved in the synthesis of GSH. Cell 3312 
culture studies demonstrated the activation of Nrf2 in response to hyperglycaemic induced-oxidative and 3313 
chemical stress [40, 41]. Other studies also reported the decrease of Nrf2 in both diabetic mice and T2D 3314 
individuals; contributing to increased OS, endothelial dysfunction, insulin resistance and microvascular 3315 
complications [4-6]. Our study was the first to demonstrate the AO response of 4-OH-lle via the induction 3316 
of pNrf2 in both hyperglycaemic Hepg2 cells and the liver of C57BL/6 male mice. Furthermore, the 3317 
induction of pNrf2 by 4-OH-lle exceeded the effects of MF and FSE. This result was validated by the 3318 
increase in transcript levels of SOD2 and GPx, with 4-OH-lle inducing a greater response as compared to 3319 
MF and FSE (Fig 4). During OS, both SOD2 and GPx activation is central to the synthesis of GSH [42, 3320 
43]. Glutathione forms a major component of the AO response which functions to alleviate OS by directly 3321 
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quenching free reactive radicals [43]. To further confirm the above response, our results showed that 4-3322 
OH-lle preceded the effect of MF and FSE in regulating GSH (Fig 1).  3323 
 3324 
Protein kinase pathways are implicated in transducing OS signals to gene expression facilitated through 3325 
the ARE. Hyperglycaemia causes chronic elevation of diacylglycerol (DAG); a secondary messenger that 3326 
activates proteins involved in a multiplicity of signaling cascades [2]. In T2D, DAG levels are elevated in 3327 
non-vascular tissues, such as the liver which is responsible for activating protein kinase C (PKC) [2]. The 3328 
initiation of PKC is of great value as evidence proves the involvement of PKC in phosphorylation of Nrf2 3329 
on Ser40, promoting its dissociation from Keap1 [2]. Furthermore, phosphatidylinositol 3-kinase and its 3330 
downstream target protein kinase B (Akt) have been associated with activation of the ARE in hepatoma 3331 
cells [44]. Our previous study on insulin signaling evaluated Akt signaling and provided evidence on the 3332 
elevating effect of 4-OH-lle on hepatic Akt (Submitted for publication). Both PKC and Akt activation 3333 
comprise the group of biochemical pathways proposed in linking the adverse effects of hyperglycaemia 3334 
with diabetic complications. Another cellular mechanism includes the activation of AGE pathway. 3335 
Elevated ROS causes the formation of oxidatively damaged proteins, forming protein carbonyls [45]. 3336 
Protein carbonyls are by-products of glycosylated proteins which ultimately form the toxic compounds - 3337 
AGEs. Previous studies support the worsening effect of AGEs on metabolic control in T2D [3, 46, 47].  3338 
An important study by Sampath et al, 2017 confirmed the reduction of AGEs via Nrf2 [48]. In addition to 3339 
Nrf2-regulated AO response, mitochondria possess LonP1 which enable cells to effectively remove 3340 
damaged proteins. We showed 4-OH-lle significantly potentiated the protein expression of LonP1 in both 3341 
chronic hyperglycaemic models (Fig 3). To further support this finding in vitro, we showed the ability of 3342 
4-OH-lle to attenuate the levels of protein carbonyls (Fig 1). 3343 
 3344 
Hyperglycaemia induced OS coupled with insulin resistance causes a decline in mitochondrial function. 3345 
Mitochondria produce ATP via oxidative phosphorylation. However, this process is linked to the 3346 
production of ROS. Mitochondria possess their own maintenance proteins - SIRT3 and PGC-1α, enabling 3347 
these organelles to alleviate the effects of OS. In addition to these proteins, Nrf2 also plays a functional 3348 
role in counterbalancing mitochondrial produced ROS via SOD2, GPx and GSH. SIRT3 is a NAD+-3349 
dependent protein deacetylase which is located and exerts its function in the mitochondria. Among the 3350 
SIRTs located in the mitochondria, SIRT3 is responsible for regulating mitochondrial function via 3351 
deacetylation of mitochondrial proteins [49]. SIRT3 induction is regulated by caloric restriction and stress 3352 
which is central to the effect of SIRT3 on the transcription of PGC-1α [14]. Studies provide substantial 3353 
evidence for the communication between SIRT3 and PGC-1α, which is imperative for the AO response 3354 
and regulation of mitochondrial biogenesis [50]. Our results clearly displayed the interaction between 3355 
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SIRT3 and PGC-1α. More importantly, we further exemplify the AO potency of 4-OH-lle by displaying 3356 
its ability in significantly up-regulating the protein and gene expression of both SIRT3 and PGC-1α (Fig 3357 
3). It is of greater significance that we observed these effects in a chronic glucose condition which 3358 
surpassed the effects of MF and FSE. 3359 
 3360 
Following our favourable results and the supporting literature, we evaluated FSE under the same 3361 
parameters, in comparison to 4-OH-lle and MF. We observed FSE significantly increase the 3362 
phosphorylated and total protein expression of Nrf2 as well as the total protein expression of LonP1, 3363 
SIRT3 and PGC-1α (Fig 6, 7). In addition, FSE elevated the transcript levels of SOD2, GPx, SIRT3 and 3364 
PGC-1α. These results surpassed the effect of MF but were similar to 4-OH-lle. 4-OH-lle could account 3365 
for the potency of FSE, as 4-OH-lle has been documented to be abundant in fenugreek seeds, and 3366 
suggested to account for the seeds anti-diabetic and anti-lipidemic effects. An important study by 3367 
Mayakrishnan et al, 2015 found both trigonelline and diosgenin to exhibit protective effects via a 3368 
substantial decrease in serum enzymes, liver TGs, expression of liver ER stress marker proteins and 3369 
elevated liver glycogen content and AOs [38]. Therefore, the effects observed by FSE may also be due to 3370 
the culminated effect of these active compounds in the seed. Interestingly, our study was the first to show 3371 
that 4-OH-lle is potent in stimulating the Nrf2-AO response and detoxification system. 3372 
 3373 
Oxidative stress has been implicated as a contributor to the onset and progression of CVD and associated 3374 
diabetic complications. The consequence of an oxidative environment is the development of 3375 
compromised AO defence mechanisms and mitochondrial dysfunction, which ultimately leads to a 3376 
diabetic disease state. 4-hydroxyisoelucine potentiates an AO response in hyperglycaemic HepG2 cells 3377 
and C57BL/6 male mice. Collectively, the results show that 4-OH-lle exposure augments the expression 3378 
of Nrf2, LonP1, SIRT3 and PGC-1α, particularly in a hyperglycaemic state. Furthermore, the results 3379 
provide significant evidence for the use of FSE as a possible AO agent. This data may help develop a 3380 
better understanding of the molecular and biochemical interactions of both 4-OH-lle and FSE, associated 3381 
with risks of elevated ROS production and diabetic complications. This is importance in socio-3382 
economically challenged communities where T2D individuals are diagnosed with CVD, unable to access 3383 
healthcare facilities and natural products serve as first-line therapy. 3384 
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6.1 Synthesis  3552 
Diabetes mellitus significantly contributes to the morbidity and mortality rates, resulting in negative 3553 
socio-economic impacts. Type 2 diabetes mellitus, a subtype of DM, is progressively observed among 3554 
children, teenagers and younger adults (WHO, 2016). The epidemic of T2D is attributed to a multifaceted 3555 
collection of genetic and molecular systems interacting within a complex social framework that controls 3556 
behaviour and environmental influences (WHO, 2016). T2D is characterized by hyperglycaemia, insulin 3557 
resistance and relative lack of insulin production. These disturbances negatively impact the normal 3558 
physiological, molecular and biochemical activities of the body (Ashcroft & Rorsman, 2012). The 3559 
treatment approach for T2D comprises both self-care and anti-diabetic drugs. Unfortunately, the lack of 3560 
complying with self-care recommendations and the associated unwanted side effects of anti-diabetic 3561 
drugs such as MF, demands the need for new therapeutic interventions. This study investigated the anti-3562 
hyperglycaemic, anti-lipidaemic and anti-oxidative effect of 4-OH-lle in comparison to MF, and FSE in a 3563 
hyperglycaemic in vitro and in vivo model. It was observed that 4-OH-lle and FSE improved 3564 
compromised insulin signalling and glucose sensing, the altered lipid profile, and an imbalance in OS.  3565 
 3566 
4-OH-lle up-regulated the proteins and genes pertinent to insulin signalling and glucose sensing. IRβ and 3567 
IRS1 are important proteins in initiating the insulin signalling cascade (Guo, 2014). 4-OH-lle displayed 3568 
the greatest effect in elevating the phosphorylated and total protein and mRNA expression of IRβ and 3569 
IRS1, in both models. This elevation translated to the phosphorylation and activation of Akt and 3570 
subsequent increase in GSK3α/β activity. The dominant effect of 4-OH-lle was further observed in the 3571 
increased mRNA levels of GS and GK; which in turn regulate the conversion of excess glucose into 3572 
glycogen. The entry of glucose into the cell is essential for regulating excess glucose levels (Cho, 3573 
Thorvaldsen, Chu, Feng, & Birnbaum, 2001). We showed that 4-OH-lle possesses the strongest potential 3574 
in regulating glucose entry into the cell via the up-regulation of the protein and mRNA expression of 3575 
GLUT2. This was further supported by the reduction in glucose levels. Therefore, this study provides 3576 
evidence that 4-OH-lle elicited a stronger response than both MF and FSE in regulating the specific 3577 
proteins and genes compromised during a hyperglycaemic state. 3578 
 3579 
Insulin signalling plays a principal role in regulating lipid metabolism (Mullugeta, Chawla, Kebede, & 3580 
Worku, 2012). In T2D, defective insulin signaling alters the lipid profile resulting in diabetic 3581 
dyslipidaemia (Tangvarasittichai, 2015). The levels of TGs are controlled by SREBP1c and FAS (Horton, 3582 
Goldstein, & Brown, 2002), which were elevated by 4-OH-lle. This change in gene expression correlated 3583 
with the regulation of both TG and cholesterol levels. Furthermore, 4-OH-lle down-regulated protein and 3584 
gene expression of PCSK9 and up-regulated the protein expression of PPARG, which are crucial in 3585 
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restoring LDLc and HDLc levels, respectively (Amy C. Burke, 2017; Gervois, Torra, Fruchart, & Staels, 3586 
2000). The effect of 4-OH-lle on PCSK9 was validated by the increase in LDLr and reduction in LDLc, 3587 
whereas the effect of 4-OH-lle on PPARG was validated via the elevation in gene expression of ApoA1 3588 
and HDLc levels. Together, these results show that 4-OH-lle in comparison to MF, and FSE efficiently 3589 
restores the lipid profile via the regulation of PCSK9 and PPARG; which were posed as possible targets 3590 
for the treatment of diabetic dyslipidaemia (Gervois et al., 2000; Horton, Cohen, & Hobbs, 2007). 3591 
Therefore, in regulating both insulin signalling and dyslipidaemia, 4-OH-lle possesses the ability to 3592 
control the progression of CVD that may present in T2D. 3593 
 3594 
In addition, hyperglycaemic-induced OS is a major risk factor for the onset and progression of CVD and 3595 
diabetic complications (John W Baynes, 1991, J W Baynes & Thorpe, 1999).  4-OH-lle induced the AO 3596 
response via pNrf2 and subsequent increase in SOD2, GPx and GSH levels. In T2D over and above 3597 
hyperglycaemic-induced ROS, mitochondria are also responsible for an increase in ROS production 3598 
(Brownlee, 2001). Mitochondrial ROS is reduced by the activity of pNrf2 as well as its own maintenance 3599 
proteins (Dinkova-Kostova & Abramov, 2015; Giralt & Villarroya, 2012; Pomatto, Raynes, & Davies, 3600 
2017). Further, 4-OH-lle increased the activities of these proteins which include LonP1, SIRT3, and 3601 
PGC-1α. The elevation of these proteins is essential in attenuating mitochondrial dysfunction present in 3602 
T2D (Dinkova-Kostova & Abramov, 2015; Giralt & Villarroya, 2012; Pomatto et al., 2017). The results 3603 
further exemplify the potency of 4-OH-lle in comparison to MF, and FSE, by inducing the Nrf2-AO 3604 
response in a chronic hyperglycaemic state, attenuating OS and the accompanying risk of developing 3605 
CVD and diabetic complications.  3606 
 3607 
6.2 General conclusions 3608 
During T2D, insulin signalling, dyslipidaemia, and OS have been implicated as major contributors to the 3609 
onset and development of CVD and diabetic complications. The consequences of defective insulin 3610 
signalling promote dyslipidaemia and an oxidative environment. This gives rise to the development of an 3611 
abnormal lipid profile and compromised AO defence mechanisms and mitochondrial dysfunction, 3612 
ultimately causing a diabetic disease state. The data provides evidence on the potency of 4-OH-lle in 3613 
regulating insulin signalling, lipid metabolism, and OS, in both hyperglycaemic HepG2 cells and 3614 
C57BL/6 male mice. Collectively, the results show that the hepatic response to 4-OH-lle augments the 3615 
expression of specific proteins, genes and, related factors, altered in T2D. Furthermore, the results 3616 
provide substantial evidence for the use of FSE as a possible therapeutic intervention, as the seed extract 3617 
also elicited potent responses, although not as potent as 4-OH-lle. 3618 
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The data assists in developing a better understanding of the molecular and biochemical interactions of 3619 
both 4-OH-lle and FSE. This has a great impact on socio-economically challenged communities where 3620 
T2D individuals are diagnosed with CVD and/or other diabetic complications but are unable to access 3621 
healthcare facilities. In addition, these affected individuals have access to natural products which possess 3622 
invaluable medicinal properties.  3623 
 3624 
6.3 Implications for further research 3625 
Future studies to extend on the current findings would be to investigate the effects of 4-OH-lle and FSE in 3626 
other organ systems such as the pancreas and skeletal muscle since these organs play a central role in 3627 
regulating insulin production and glucose utilization. Furthermore, the pathways investigated in this study 3628 
coupled with existing literature, could provide substantial evidence for the possible initiation of a clinical 3629 
trial for the use of 4-OH-lle and FSE as possible anti-diabetic therapy.  3630 
 3631 
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CHAPTER 7 3684 
APPENDICES 3685 
 3686 
Appendix 1: Animal ethics approval 3687 
 3688 
 3689 
 3690 
 3691 
 3692 
 3693 
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Appendix 2: Supplementary data for chapter 3 (Table numbers correlate with chapter 3) 3694 
The term control refers to the group of mice which were untreated during the experimental period. These 3695 
mice were maintained under the same conditions but were not treated with metformin, 4-3696 
hydroxyisoleucine or fenugreek seed extract. Following the methods of our study there were two 3697 
experimental arms (normoglycaemic and hyperglycaemic) – each arm had an untreated group of mice. 3698 
 3699 
Table 1 Absolute oral glucose tolerance test values (mmol) following treatment of mice with fenugreek 3700 
seed extract (FSE), 4-hydroxyisoleucine (4-OH-lle), and metformin (MF)  3701 
Time of 
measurement 
Normoglycaemic state (Glucose in mmol/L) 
Control (untreated) 
 
FSE (100mg/kg BW) MF (20mg/kg BW) 4-OH-lle 
(100mg/kg BW) 
0 min 4.80 4.40 4.30 4.00 
30 min 4.90 4.50 4.20 4.20 
60 min 5.00 4.50 4.30 4.10 
90 min 4.90 4.40 4.23 4.15 
120 min 4.95 5.00 4.25 4.00 
Time of 
measurement 
Hyperglycaemic state (Glucose in mmol/L) 
Control (untreated) 
 
FSE (100mg/kg BW) MF (20mg/kg BW) 4-OH-lle 
(100mg/kg BW) 
0 min 13.9 10.90 10.00 9.00 
30 min 14.8 10.50 9.80 10.20 
60 min 14.8 10.00 9.60 9.80 
90 min 14.8 9.90 9.70 10.10 
120 min 15.1 10.10 9.65 9.50 
 3702 
 3703 
 3704 
 3705 
 3706 
 3707 
 3708 
 3709 
 3710 
 3711 
 3712 
 3713 
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Table 2 Blood glucose measurements (mmol/L) at day 0, 3, and 10 of the ten day induction period of 3714 
the hyperglycaemic group of mice 3715 
All mice were labeled 1 to 20 by an ear piecing, to ensure the same mice were treated within the same group 3716 
 Day 0  
(glucose in mmol/L) 
Day 3 
(glucose in mmol/L) 
Day 10 
(glucose in mmol/L) 
Mice    
C 1 5.6 7.8 13.5 
2 4.3 6.5 14.4 
3 4.2 6.5 13.9 
4 4.1 6.3 14.0 
5 5.5 7.7 13.9 
FSE 6 4.3 6.5 14.2 
7 4.4 7.8 14.6 
8 3.9 6.9 13.8 
9 4.5 7.4 13.9 
10 4.6 7.3 14.9 
MF 11 4.3 7.9 14.3 
12 5.0 8.9 15.1 
13 4.7 7.9 14.6 
14 5.3 8.0 15.5 
15 4.9 8.5 15.2 
4-OH-lle 16 5.1 9.0 15.3 
17 4.8 6.9 14.5 
18 5.0 7.7 14.9 
19 4.8 8.5 15.7 
20 4.3 8.4 13.9 
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Table 3 Glucose measurements of each mouse per a treatment group (control, fenugreek seed extract 3717 
metformin and 4-hydroxyisoleucine) under both conditions on day 0, 3, 6, 9, 12 and 15 3718 
 3719 
All mice were labelled 1 to 40 by an ear piecing, to ensure the same mice were treated within the same group. The glucose was 3720 
measured with a glucometer on day 0, 5, and 10. On day 15, the glucose levels were measured by the accredited laboratory 3721 
 Day 0 
(glucose in mmol/L) 
Day 5 
(glucose in mmol/L) 
Day 10 
(glucose in mmol/L) 
Day 15 
(glucose in mmol/L) 
Mice     
Normoglycaemic     
Control 1 5.1 5.0 5.1 5.0* 
2 4.8 4.2 4.2 4.8* 
3 5.0 4.9 4.9 4.7 
4 4.8 4.9 4.9 5.0* 
5 4.3 4.2 4.7 4.8 
FSE 6 4.3 4.2 4.5 4.5 
7 5.0 4.5 4.8 4.6* 
8 4.7 4.5 4.4 4.7* 
9 5.3 4.8 4.6 4.8* 
10 4.9 4.5 4.5 4.9 
MF 11 4.7 4.9 4.8 4.1 
12 4.3 4.3 4.1 3.9* 
13 4.2 4.2 4.0 3.8* 
14 4.3 3.8 4.0 3.9* 
15 4.8 5.0 4.9 4.7 
4-OH-lle 16 4.7 4.2 4.0 3.9* 
17 4.5 4.3 4.2 3.9* 
18 3.5 3.8 3.7 3.6 
19 4.9 4.3 4.3 4.0* 
20 5.2 4.5 4.3 4.2 
Hyperglycaemic      
Control 21 13.5 13.8 14.2 14.3* 
22 14.4 14.5 14.6 14.9* 
23 13.9 13.3 13.8 13.2 
24 14.5 14.2 14.5 14.2 
25 13.9 13.9 13.8 14.9* 
FSE 26 14.9 12.1 10.9 9.9* 
27 14.6 12.0 11.7 9.9* 
28 14.9 12.0 10.5 9.9* 
29 13.9 11.4 11.5 9.7 
30 12.9 10.5 10.0 9.9 
MF 31 14.3 12.1 11.4 9.0 
32 15.1 11.0 10.6 8.9 
33 14.6 12.5 9.0 10.0* 
34 15.5 12.5 12.0 10.3* 
35 15.2 12.9 11.5 10.4* 
4-OH-lle 36 15.3 9.9 8.7 8.0 
37 14.5 9.5 9.1 8.9* 
38 14.9 10.2 9.4 9.0 
39 15.7 10.9 9.5 8.7* 
40 13.9 10.0 8.9 8.7* 
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mentioned in the methods and materials section. *Indicates these mice were chosen for the qPCR and western blot validation 3722 
(based on blood glucose values). 3723 
 3724 
 3725 
Table 4 Mouse primer sequences and annealing temperatures (Ta) for qPCR 3726 
3727 
Primer Sense Anti-sense Ta 
IRβ 5’TTTGTCATGGATGGAGGCTA3’ 5’CCTCATCTTGGGGTTGAACT3’ 53 
IRS-1     5’CTTCTCAGACGTGCGCAAGG3’ 5’GTTGATGTTGAAACAGCTCTC3’ 53 
GLUT2 5’GGCTAATTTCAGGACTGGTT3’ 5’TTTCTTTGCCCTGACTTCCT3’ 53 
Akt 5’ATCCCCTCAACAACTTCTCAGT3’ 5’CTTCCGTCCACTCTTCTCTTTC3’ 55 
GSK-3α/β 5’GCATTTATCATTAACCTAGCACCC3’ 5’ATTTTCTTTCCAAACGTGACC3’ 51 
GS 5’CCAGCTTGACAAGTTCGACA3’ 5’CCAGCTTGACAAGTTCGACA3’ 55 
Gck 5’CCAGGACCCTCAGTGACTTC3’ 5’AAAAGCCTGGAGTTGAAAGC3’ 59 
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Appendix 3: Supplementary data for chapter 4 (Table and figure numbers correlate with chapter 3728 
4) 3729 
 3730 
 3731 
Figure 1 Average concentrations (mean+SD) of blood glucose levels in the serum of mice, and oral 3732 
glucose tolerance test at day 15 of experimental period; blood glucose levels were measured at 0, 30, 60, 3733 
90 and 120min time intervals following an overnight fast, following treatment with metformin (MF), 3734 
fenugreek seed extract (FSE) and 4-hydroxyisoleucine (4-OH-lle), compared to the relative control (C). 3735 
Average blood glucose (A) normoglycaemic (p=0.00231) and (B) hyperglycaemic (p=0.0245). Oral 3736 
glucose tolerance test (C) normoglycaemic (p=0.0154) and (D) hyperglycaemic (p=0.0021). 3737 
 3738 
 3739 
 3740 
 3741 
 3742 
 3743 
 3744 
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Table 1 Absolute oral glucose tolerance test values (mmol) following treatment of mice with fenugreek 3745 
seed extract (FSE), 4-hydroxyisoleucine (4-OH-lle), and metformin (MF)  3746 
Time of 
measurement 
Normoglycaemic state (Glucose in mmol/L) 
Control (untreated) 
 
FSE (100mg/kg BW) MF (20mg/kg BW) 4-OH-lle 
(100mg/kg BW) 
0 min 4.80 4.40 4.30 4.00 
30 min 4.90 4.50 4.20 4.20 
60 min 5.00 4.50 4.30 4.10 
90 min 4.90 4.40 4.23 4.15 
120 min 4.95 5.00 4.25 4.00 
Time of 
measurement 
Hyperglycaemic state (Glucose in mmol/L) 
Control (untreated) 
 
FSE (100mg/kg BW) MF (20mg/kg BW) 4-OH-lle 
(100mg/kg BW) 
0 min 13.9 10.90 10.00 9.00 
30 min 14.8 10.50 9.80 10.20 
60 min 14.8 10.00 9.60 9.80 
90 min 14.8 9.90 9.70 10.10 
120 min 15.1 10.10 9.65 9.50 
 3747 
 3748 
Table 2 Area under the curve (AUC) values for the OGTT at day 15 of experimental period for 3749 
normoglycaemic group 3750 
Area under curve (AUC) Control FSE MET 4-OH-lle 
AUC 1 (30-0 min) 217.5 ± 50* 199.5 ± 21# 192 ± 47+ 183 ± 24+ 
AUC 2 (60-30 min) 222 ± 34* 202.5 ± 72# 190.5 ± 24+ 187.5 ± 48+ 
AUC 3 (90-60 min) 223.5 ± 61* 201 ± 45# 192.45 ± 13+ 185.25 ± 23+ 
AUC 4 (120-90 min) 221.25 ± 19* 207 ± 35# 190.65 ± 175+ 184.5 ± 25+ 
Total AUC 884.25 ± 124 810 ± 264 765.6 ± 119 740.25 ± 249 
Data are shown as mean ± SD of 5 animals; *, #, + Values with different superscript letters within a row are significantly 3751 
different from each group of animals (Tukey’s multiple range posthoc test, p < 0.05). FSE: fenugreek seed extract, 3752 
MET: Metformin, 4-OH-lle: 4-hydroxyisoleucine 3753 
 3754 
 3755 
 3756 
 3757 
 3758 
 3759 
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Table 3 Area under the curve (AUC) values for the OGTT at day 15 of experimental period for 3760 
hyperglycaemic group 3761 
Area under curve (AUC) Control FSE MET 4-OH-lle 
     
AUC 1 (30-0 min) 639 ± 29* 484.5 ± 17# 447 ± 33+ 423 ± 17+ 
AUC 2 (60-30 min) 666 ± 54* 465 ± 89# 438 ± 55+ 453 ± 18+ 
AUC 3 (90-60 min) 666 ± 45* 448.5 ± 16# 433.5 ± 12+ 445.5 ± 19+ 
AUC 4 (120-90 min) 670.5 ± 34* 448.5 ± 10# 435.75 ± 11+ 445.5 ± 15+ 
Total AUC 2641.5 ± 163* 1846.5 ± 257# 1754.25 ± 175+ 1767 ± 138 
 
Data are shown as mean ± SD of 5 animals; *,#,+ Values with different superscript letters within a row are significantly 3762 
different from each group of animals (Tukey’s multiple range posthoc test, p < 0.05). FSE: fenugreek seed extract, 3763 
MET: Metformin, 4-OH-lle: 4-hydroxyisoleucine 3764 
 3765 
 3766 
 3767 
 3768 
 3769 
 3770 
 3771 
 3772 
 3773 
 3774 
 3775 
 3776 
 3777 
 3778 
 3779 
 3780 
 3781 
 3782 
 3783 
 3784 
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Table 4 Blood glucose measurements (mmol/L) at day 0, 3, and 10 of the ten day induction period of 3785 
the hyperglycaemic group of mice 3786 
All mice were labeled 1 to 20 by an ear piecing, to ensure the same mice were treated within the same group 3787 
 Day 0  
(glucose in mmol/L) 
Day 3 
(glucose in mmol/L) 
Day 10 
(glucose in mmol/L) 
Mice    
C 1 5.6 7.8 13.5 
2 4.3 6.5 14.4 
3 4.2 6.5 13.9 
4 4.1 6.3 14.0 
5 5.5 7.7 13.9 
FSE 6 4.3 6.5 14.2 
7 4.4 7.8 14.6 
8 3.9 6.9 13.8 
9 4.5 7.4 13.9 
10 4.6 7.3 14.9 
MF 11 4.3 7.9 14.3 
12 5.0 8.9 15.1 
13 4.7 7.9 14.6 
14 5.3 8.0 15.5 
15 4.9 8.5 15.2 
4-OH-lle 16 5.1 9.0 15.3 
17 4.8 6.9 14.5 
18 5.0 7.7 14.9 
19 4.8 8.5 15.7 
20 4.3 8.4 13.9 
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Table 5 Glucose measurements of each mouse per a treatment group (control, fenugreek seed extract 3788 
metformin and 4-hydroxyisoleucine) under both conditions on day 0, 3, 6, 9, 12 and 15 3789 
 3790 
All mice were labelled 1 to 40 by an ear piecing, to ensure the same mice were treated within the same group. The glucose was 3791 
measured with a glucometer on day 0, 5, and 10. On day 15, the glucose levels were measured by the accredited laboratory 3792 
 Day 0 
(glucose in mmol/L) 
Day 5 
(glucose in mmol/L) 
Day 10 
(glucose in mmol/L) 
Day 15 
(glucose in mmol/L) 
Mice     
Normoglycaemic     
Control 1 5.1 5.0 5.1 5.0* 
2 4.8 4.2 4.2 4.8* 
3 5.0 4.9 4.9 4.7 
4 4.8 4.9 4.9 5.0* 
5 4.3 4.2 4.7 4.8 
FSE 6 4.3 4.2 4.5 4.5 
7 5.0 4.5 4.8 4.6* 
8 4.7 4.5 4.4 4.7* 
9 5.3 4.8 4.6 4.8* 
10 4.9 4.5 4.5 4.9 
MF 11 4.7 4.9 4.8 4.1 
12 4.3 4.3 4.1 3.9* 
13 4.2 4.2 4.0 3.8* 
14 4.3 3.8 4.0 3.9* 
15 4.8 5.0 4.9 4.7 
4-OH-lle 16 4.7 4.2 4.0 3.9* 
17 4.5 4.3 4.2 3.9* 
18 3.5 3.8 3.7 3.6 
19 4.9 4.3 4.3 4.0* 
20 5.2 4.5 4.3 4.2 
Hyperglycaemic      
Control 21 13.5 13.8 14.2 14.3* 
22 14.4 14.5 14.6 14.9* 
23 13.9 13.3 13.8 13.2 
24 14.5 14.2 14.5 14.2 
25 13.9 13.9 13.8 14.9* 
FSE 26 14.9 12.1 10.9 9.9* 
27 14.6 12.0 11.7 9.9* 
28 14.9 12.0 10.5 9.9* 
29 13.9 11.4 11.5 9.7 
30 12.9 10.5 10.0 9.9 
MF 31 14.3 12.1 11.4 9.0 
32 15.1 11.0 10.6 8.9 
33 14.6 12.5 9.0 10.0* 
34 15.5 12.5 12.0 10.3* 
35 15.2 12.9 11.5 10.4* 
4-OH-lle 36 15.3 9.9 8.7 8.0 
37 14.5 9.5 9.1 8.9* 
38 14.9 10.2 9.4 9.0 
39 15.7 10.9 9.5 8.7* 
40 13.9 10.0 8.9 8.7* 
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mentioned in the methods and materials section. *Indicates these mice were chosen for the qPCR and western blot validation 3793 
(based on blood glucose values). 3794 
 3795 
 3796 
Table 6. Primer sequences and annealing temperatures for qPCR 3797 
Primer Primer Type Ta (°C) Primer Sequence 
Human    
SREBP1c Sense 58 5’-GTGGCGGCTGCATTGAGAGTGAAG-3’ 
 Antisense  5’-AGGTACCCGAGGGCATCCGAGAAT-3’ 
FAS Sense 58 5’-CAAGAACTGCACGGAGGTGT-3’ 
 Antisense  5’-AGCTGCCAGAGTCGGAGAAC-3’ 
LDLR Sense 58 5’-CCCCGCAGATCAAACCCCCACC-3’ 
 Antisense  5’-AGACCCCCAGGCAAAGGACACGS-3’ 
ApoA1 Sense 58 5’-AGACAGCGGCAGAGACTATGTGTC-3’ 
 Antisense  5’-ACCTTCTGGCGGTAGAGCTC-3’ 
PCSK9 Sense 58 5’- CCAAGATCCTGCATGTCTTCC-3; 
 Antisense  5’- AACTTCAAGGCCAGCTCCAG-3’ 
β-Actin Sense  5’-TGACGGGTCACCCACTGTGCCCAT-3’ 
 Antisense  5’-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’ 
18S Sense  5’-ACAGGGACAGGATTGACAGA-3’ 
 Antisense  5’-CAAATCGCTCCACCAACCTAA-3’ 
Mice    
SREBP1c Sense  5’- ATCGGCGCGGAAGCTGTCGGGGTAGCGTC-3’ 
 Antisense 62 5’- ACTGTCTTGGTTGTTGATGAGCTGGAGCAT-3’ 
FAS Sense 55 5’ ATCGGCGCGGAAGCTGTCGGGGTAGCGTC-3’ 
 Antisense  5’- AGAGACGTGTCACTCCTGGACTT-3’ 
LDLr Sense 61 5’- GAAGTCGACACTGTACTGACCACC-3’ 
 Antisense  5’- CTCCTCATTCCCTCTGCCAGCCAT-3’ 
PCSK9 Sense 58 5’- TGCTCCAGAGGTCATCACAG-3’ 
 Antisense  5’- GTCCCACTCTGTGACATGAAG-3’ 
Ta - annealing temperature 3798 
 3799 
 3800 
 3801 
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Table 7 Absolute lipid profile values (mmol/L) for each experimental group, in vitro and in vivo at day 0 3802 
and day 15 of the experimental period  3803 
In vitro Control 
(untreated) 
Glucose in 
mmol/L 
FSE 
(100mg/kg 
BW) 
MF 
(20mg/kg 
BW) 
4-OH-lle 
(100mg/kg 
BW) 
Normoglycaemic Day 15 Day 15 Day 15 Day 15 
LDLc 2.6 2.13 2.17 2.07 
HDLc 1.23 1.17 1.21 1.18 
TC 4.12 4.23 4.4 4.33 
TG 0.90 0.37 0.5 0.43 
Hyperglycaemic 
 
LDLc 3.10 2.09 2.08 2.08 
HDLc 0.87 1.08 1.4 1.18 
TC 5.61 4.57 4.57 4.25 
TG 1.43 0.8 0.7 0.83 
 
  
 
 
In vivo 
Normoglycaemic 
 
LDLc 0.58 0.48 0.48 0.07 
HDLc 1.40 2.1 2.17 2.5 
TC 3.50 3.6 3.8 2.12 
TG 0.21 0.13 0.17 0.07 
Hyperglycaemic     
LDLC 0.70 0.60 0.6 0.09 
HDLc 1.33 2.08 2.23 2.43 
TC 4.93 4.26 4.73 4.25 
TG 0.35 0.08 0.08 0.08 
 3804 
Table 1 Concentration of glucose in the cell supernatant following incubation with fenugreek seed extract 3805 
(FSE), 4-hydroxyisoleucine (4-OH-lle), insulin and metformin for 72 hours. 3806 
Normoglycaemic state Hyperglycaemic state 
Treatment (ng/ml) Glucose mmol/L) Treatment (ng/ml) Glucose (mmol/L) 
Control (0) 5.0*** Control (0) >28 (read too high)*** 
Metformin (100) 2.9*** Metformin (100) 20.0*** 
FSE (100) < 1.7 (read too low)*** FSE (100) 18.5*** 
4-OH-lle ( 100) 2.4*** 4-OH-lle ( 100) 22.4*** 
 3807 
 3808 
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Appendix 4: Supplementary data for chapter 5 (Table numbers correlate with chapter 5) 3809 
 3810 
 3811 
Figure 1 Average concentrations (mean+SD) of blood glucose levels in the serum of mice, and oral 3812 
glucose tolerance test at day 15 of experimental period; blood glucose levels were measured at 0, 30, 60, 3813 
90 and 120min time intervals following an overnight fast, following treatment with metformin (MF), 3814 
fenugreek seed extract (FSE) and 4-hydroxyisoleucine (4-OH-lle), compared to the relative control (C). 3815 
Average blood glucose (A) normoglycaemic (p=0.00231) and (B) hyperglycaemic (p=0.0245). Oral 3816 
glucose tolerance test (C) normoglycaemic (p=0.0154) and (D) hyperglycaemic (p=0.0021). 3817 
 3818 
Table 1 Concentration of glucose in the cell supernatant following incubation with fenugreek seed extract 3819 
(FSE), 4-hydroxyisoleucine (4-OH-lle), insulin and metformin for 72 hours. 3820 
Normoglycaemic state Hyperglycaemic state 
Treatment (ng/ml) Glucose mmol/L) Treatment (ng/ml) Glucose (mmol/L) 
Control (0) 5.0*** Control (0) >28 (read too high)*** 
Metformin (100) 2.9*** Metformin (100) 20.0*** 
FSE (100) < 1.7 (read too low)*** FSE (100) 18.5*** 
4-OH-lle ( 100) 2.4*** 4-OH-lle ( 100) 22.4*** 
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Table 2 Absolute oral glucose tolerance test values (mmol) following treatment of mice with fenugreek 3821 
seed extract (FSE), 4-hydroxyisoleucine (4-OH-lle), and metformin (MF)  3822 
Time of 
measurement 
Normoglycaemic state (Glucose in mmol/L) 
Control (untreated) 
 
FSE (100mg/kg BW) MF (20mg/kg BW) 4-OH-lle 
(100mg/kg BW) 
0 min 4.80 4.40 4.30 4.00 
30 min 4.90 4.50 4.20 4.20 
60 min 5.00 4.50 4.30 4.10 
90 min 4.90 4.40 4.23 4.15 
120 min 4.95 5.00 4.25 4.00 
Time of 
measurement 
Hyperglycaemic state (Glucose in mmol/L) 
Control (untreated) 
 
FSE (100mg/kg BW) MF (20mg/kg BW) 4-OH-lle 
(100mg/kg BW) 
0 min 13.9 10.90 10.00 9.00 
30 min 14.8 10.50 9.80 10.20 
60 min 14.8 10.00 9.60 9.80 
90 min 14.8 9.90 9.70 10.10 
120 min 15.1 10.10 9.65 9.50 
 3823 
 3824 
Table 3 Area under the curve (AUC) values for the OGTT at day 15 of experimental period for 3825 
normoglycaemic group 3826 
Area under curve (AUC) Control FSE MET 4-OH-lle 
AUC 1 (30-0 min) 217.5 ± 50* 199.5 ± 21# 192 ± 47+ 183 ± 24+ 
AUC 2 (60-30 min) 222 ± 34* 202.5 ± 72# 190.5 ± 24+ 187.5 ± 48+ 
AUC 3 (90-60 min) 223.5 ± 61* 201 ± 45# 192.45 ± 13+ 185.25 ± 23+ 
AUC 4 (120-90 min) 221.25 ± 19* 207 ± 35# 190.65 ± 175+ 184.5 ± 25+ 
Total AUC 884.25 ± 124 810 ± 264 765.6 ± 119 740.25 ± 249 
Data are shown as mean ± SD of 5 animals; *, #, + Values with different superscript letters within a row are significantly 3827 
different from each group of animals (Tukey’s multiple range posthoc test, p < 0.05). FSE: fenugreek seed extract, 3828 
MET: Metformin, 4-OH-lle: 4-hydroxyisoleucine 3829 
 3830 
 3831 
 3832 
 3833 
 3834 
 3835 
 3836 
143 
 
Table 4 Area under the curve (AUC) values for the OGTT at day 15 of experimental period for 3837 
hyperglycaemic group 3838 
Area under curve (AUC) Control FSE MET 4-OH-lle 
     
AUC 1 (30-0 min) 639 ± 29* 484.5 ± 17# 447 ± 33+ 423 ± 17+ 
AUC 2 (60-30 min) 666 ± 54* 465 ± 89# 438 ± 55+ 453 ± 18+ 
AUC 3 (90-60 min) 666 ± 45* 448.5 ± 16# 433.5 ± 12+ 445.5 ± 19+ 
AUC 4 (120-90 min) 670.5 ± 34* 448.5 ± 10# 435.75 ± 11+ 445.5 ± 15+ 
Total AUC 2641.5 ± 163* 1846.5 ± 257# 1754.25 ± 175+ 1767 ± 138 
 
Data are shown as mean ± SD of 5 animals; *,#,+ Values with different superscript letters within a row are significantly 3839 
different from each group of animals (Tukey’s multiple range posthoc test, p < 0.05). FSE: fenugreek seed extract, 3840 
MET: Metformin, 4-OH-lle: 4-hydroxyisoleucine 3841 
 3842 
 3843 
 3844 
 3845 
 3846 
 3847 
 3848 
 3849 
 3850 
 3851 
 3852 
 3853 
 3854 
 3855 
 3856 
 3857 
 3858 
 3859 
 3860 
 3861 
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Table 5 Blood glucose measurements (mmol/L) at day 0, 3, and 10 of the ten day induction period of 3862 
the hyperglycaemic group of mice 3863 
All mice were labeled 1 to 20 by an ear piecing, to ensure the same mice were treated within the same group 3864 
 Day 0  
(glucose in mmol/L) 
Day 3 
(glucose in mmol/L) 
Day 10 
(glucose in mmol/L) 
Mice    
C 1 5.6 7.8 13.5 
2 4.3 6.5 14.4 
3 4.2 6.5 13.9 
4 4.1 6.3 14.0 
5 5.5 7.7 13.9 
FSE 6 4.3 6.5 14.2 
7 4.4 7.8 14.6 
8 3.9 6.9 13.8 
9 4.5 7.4 13.9 
10 4.6 7.3 14.9 
MF 11 4.3 7.9 14.3 
12 5.0 8.9 15.1 
13 4.7 7.9 14.6 
14 5.3 8.0 15.5 
15 4.9 8.5 15.2 
4-OH-lle 16 5.1 9.0 15.3 
17 4.8 6.9 14.5 
18 5.0 7.7 14.9 
19 4.8 8.5 15.7 
20 4.3 8.4 13.9 
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Table 6 Glucose measurements of each mouse per a treatment group (control, fenugreek seed extract 3865 
metformin and 4-hydroxyisoleucine) under both conditions on day 0, 3, 6, 9, 12 and 15 3866 
 3867 
All mice were labelled 1 to 40 by an ear piecing, to ensure the same mice were treated within the same group. The glucose was 3868 
measured with a glucometer on day 0, 5, and 10. On day 15, the glucose levels were measured by the accredited laboratory 3869 
 Day 0 
(glucose in mmol/L) 
Day 5 
(glucose in mmol/L) 
Day 10 
(glucose in mmol/L) 
Day 15 
(glucose in mmol/L) 
Mice     
Normoglycaemic     
Control 1 5.1 5.0 5.1 5.0* 
2 4.8 4.2 4.2 4.8* 
3 5.0 4.9 4.9 4.7 
4 4.8 4.9 4.9 5.0* 
5 4.3 4.2 4.7 4.8 
FSE 6 4.3 4.2 4.5 4.5 
7 5.0 4.5 4.8 4.6* 
8 4.7 4.5 4.4 4.7* 
9 5.3 4.8 4.6 4.8* 
10 4.9 4.5 4.5 4.9 
MF 11 4.7 4.9 4.8 4.1 
12 4.3 4.3 4.1 3.9* 
13 4.2 4.2 4.0 3.8* 
14 4.3 3.8 4.0 3.9* 
15 4.8 5.0 4.9 4.7 
4-OH-lle 16 4.7 4.2 4.0 3.9* 
17 4.5 4.3 4.2 3.9* 
18 3.5 3.8 3.7 3.6 
19 4.9 4.3 4.3 4.0* 
20 5.2 4.5 4.3 4.2 
Hyperglycaemic      
Control 21 13.5 13.8 14.2 14.3* 
22 14.4 14.5 14.6 14.9* 
23 13.9 13.3 13.8 13.2 
24 14.5 14.2 14.5 14.2 
25 13.9 13.9 13.8 14.9* 
FSE 26 14.9 12.1 10.9 9.9* 
27 14.6 12.0 11.7 9.9* 
28 14.9 12.0 10.5 9.9* 
29 13.9 11.4 11.5 9.7 
30 12.9 10.5 10.0 9.9 
MF 31 14.3 12.1 11.4 9.0 
32 15.1 11.0 10.6 8.9 
33 14.6 12.5 9.0 10.0* 
34 15.5 12.5 12.0 10.3* 
35 15.2 12.9 11.5 10.4* 
4-OH-lle 36 15.3 9.9 8.7 8.0 
37 14.5 9.5 9.1 8.9* 
38 14.9 10.2 9.4 9.0 
39 15.7 10.9 9.5 8.7* 
40 13.9 10.0 8.9 8.7* 
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mentioned in the methods and materials section. *Indicates these mice were chosen for the qPCR and western blot validation 3870 
(based on blood glucose values). 3871 
 3872 
 3873 
Table 7 Primer sequences and annealing temperatures for qPCR 3874 
Primer Primer Type Ta (°C) Primer Sequence 
Human    
SIRT3 Sense 50 5’-GTGGCGGCTGCATTGAGAGTGAAG-3’ 
 Antisense  5’-AGGTACCCGAGGGCATCCGAGAAT-3’ 
PGC1α Sense 50 5’-CAAGAACTGCACGGAGGTGT-3’ 
 Antisense  5’-AGCTGCCAGAGTCGGAGAAC-3’ 
SOD2 Sense 57 5’-CCCCGCAGATCAAACCCCCACC-3’ 
 Antisense  5’-AGACCCCCAGGCAAAGGACACGS-3’ 
GPx Sense 53 5’-AGACAGCGGCAGAGACTATGTGTC-3’ 
 Antisense  5’-ACCTTCTGGCGGTAGAGCTC-3’ 
β-Actin Sense  5’-TGACGGGTCACCCACTGTGCCCAT-3’ 
 Antisense  5’-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’ 
18S Sense  5’-ACAGGGACAGGATTGACAGA-3’ 
 Antisense  5’-CAAATCGCTCCACCAACCTAA-3’ 
Mice    
SIRT3 Sense 55 5’- TACAGGCCCAATGTCACTCA -3’ 
 Antisense  5’- ACAGACCGTGCATGTAGCTG -3’ 
PGC1α Sense 55 5’- GCAACATGCTCAAGCCAAAC -3’ 
 Antisense  5’- TGCAGTTCCAGAGAGTTCCA -3’ 
SOD2 Sense 53 5’- ATTAACGCGCAGATCATGCA -3’ 
 Antisense  5’- TGTCCCCCACCATTGAACTT -3’ 
GPx Sense 53 5’- GGTTCGAGCCCAATTTTACA -3’ 
 Antisense  5’-ACCTTCTGGCGGTAGAGCTC-3’ 
β-Actin Sense  5’-TGACGGGTCACCCACTGTGCCCAT-3’ 
 Antisense  5’-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’ 
18S Sense  5’-ACAGGGACAGGATTGACAGA-3’ 
 Antisense  5’-CAAATCGCTCCACCAACCTAA-3’ 
Ta - annealing temperature 3875 
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Appendix 5: Liquid chromatography–mass  3876 
 3877 
Figure 1 LCMS displaying molecular weight more than 200g/mol of compounds present in the fenugreek 3878 
seed 3879 
 3880 
 3881 
 3882 
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 3883 
Figure 2 LCMS displaying molecular weight less than 200g/mol of compounds present in the fenugreek 3884 
seed 3885 
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 3886 
Figure 3 Duplication of LCMS displaying molecular weight less than 200g/mol of compounds present in 3887 
the fenugreek seed 3888 
 3889 
 3890 
 3891 
 3892 
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Table 1 Molecular weight per LCMS of compounds present in fenugreek seed extract 3893 
Compound present in fenugreek seed Reported molecular 
weight (g/mol) 
Molecular weight per LCMS 
(g/mol) 
4-hydroxyisoleucine 147.174 148.17 
Betain 117.148 115.21 
Diosgenin 414.62 421.04 
Inositol 180.16 189.12 
Saponin 634.851 648.78 
Trigonelline 137.136 148.17 
Vicenin 594.522 553.85 
Vitamin A 286.4516 287.07 
Vitamin B 1355.37 1365.28 
Vitamin D 384.648 371.09 
Vitexin 432.38 431.06 
 3894 
 3895 
 3896 
 3897 
 3898 
 3899 
 3900 
 3901 
 3902 
 3903 
 3904 
 3905 
 3906 
 3907 
 3908 
 3909 
 3910 
 3911 
 3912 
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Appendix 6 3913 
Validation of qPCR data 3914 
Chapter 3: Insulin signalling 3915 
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Figure 1 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3919 
on the gene expression of insulin receptor β (P=0.0051) on mice liver under normo- (white) and 3920 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  3921 
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Figure 2 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3925 
on the gene expression of insulin receptor substrate 1(P= 0.0051) on mice liver under normo- (white) and 3926 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  3927 
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Figure 3 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3930 
on the gene expression of glucose transporter 2 (P= 0.0059) on mice liver under normo- (white) and 3931 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  3932 
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Figure 4 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3936 
on the gene expression of sterol regulatory element binding protein 1c (P= 0.0078) on mice liver under 3937 
normo- (white) and hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  3938 
 3939 
 3940 
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Figure 5 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3944 
on the gene expression of protein kinase B (P= 0.0051) on mice liver under normo- (white) and 3945 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  3946 
 3947 
GSK-3αβ 3948 
Control Metformin 4-OH-lle
0
1
2
3
**
R
e
la
ti
v
e
 F
o
ld
 C
h
a
n
g
e
 3949 
Figure 6 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3950 
on the gene expression of glycogen synthase kinase 3α/β (P= 0.0059) on mice liver under normo- (white) 3951 
and hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  3952 
 3953 
 3954 
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Figure 7 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3957 
on the gene expression of glycogen synthase (P= 0.0059) on mice liver under normo- (white) and 3958 
hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  3959 
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Figure 8 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3963 
on the gene expression of glucokinase (P= 0.0059) on mice liver under normo- (white) and 3964 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  3965 
 3966 
 3967 
 3968 
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Figure 9 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated control 3971 
on the gene expression of insulin receptor β (P= 0.0059) on mice liver under normo- (white) and 3972 
hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  3973 
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Figure 10 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 3977 
control on the gene expression of insulin receptor substrate (P= 0.0059) on mice liver under normo- 3978 
(white) and hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  3979 
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156 
 
Control FSE
0
1
2
3
4
R
e
la
ti
v
e
 F
o
ld
 C
h
a
n
g
e *
 3983 
Figure 11 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 3984 
control on the gene expression of glucose transporter 2 (P= 0.0059) on mice liver under normo- (white) 3985 
and hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  3986 
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Figure 12 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 3990 
control on the gene expression of sterol regulatory element binding protein 1c (P= 0.0059) on mice liver 3991 
under normo- (white) and hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  3992 
 3993 
 3994 
 3995 
Akt  3996 
157 
 
Control FSE
0
1
2
3
4
R
e
la
ti
v
e
 F
o
ld
 C
h
a
n
g
e
*
 3997 
Figure 13 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 3998 
control on the gene expression of protein kinase B (P= 0.0059) on mice liver under normo- (white) and 3999 
hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  4000 
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Figure 14 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4004 
control on the gene expression of glycogen synthase kinase-3α/β (P= 0.0059) on mice liver under normo- 4005 
(white) and hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  4006 
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Figure 15 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4011 
control on the gene expression of glycogen synthase (P= 0.0059) on mice liver under normo- (white) and 4012 
hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  4013 
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Figure 16 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4017 
control on the gene expression of glucokinase (P= 0.0059) on mice liver under normo- (white) and 4018 
hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  4019 
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 4022 
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Figure 17 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4026 
control on the gene expression of proprotein convertase subtilisin/kexin type 9 (P= 0.0059) on mice liver 4027 
under normo- (white) and hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  4028 
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Figure 18 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4032 
control on the gene expression of low density lipoprotein receptor (P= 0.0059) on mice liver under 4033 
normo- (white) and hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  4034 
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Figure 19 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4039 
control on the gene expression of fatty acid synthase (P= 0.0059) on mice liver under normo- (white) and 4040 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  4041 
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Figure 20 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4045 
control on the gene expression of apolipoprotein A1 (P= 0.0059) on mice liver under normo- (white) and 4046 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  4047 
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Figure 21 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4053 
control on the gene expression of proprotein convertase subtilisin/kexin type 9 (P= 0.0059) on mice liver 4054 
under normo- (white) and hyperglycaemic (grey) conditions. *P< 0.005 relative to control.  4055 
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Figure 22 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4059 
control on the gene expression of low density lipoprotein receptor (P= 0.0059) on mice liver under 4060 
normo- (white) and hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  4061 
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Figure 23 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4067 
control on the gene expression of fatty acid synthase (P= 0.0059) on mice liver under normo- (white) and 4068 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  4069 
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Figure 24 Metformin (MF) and 4-hydroxyisoleucine (4-OH-Ile) treatments relative to the untreated 4073 
control on the gene expression of apolipoprotein A1 (P= 0.0059) on mice liver under normo- (white) and 4074 
hyperglycaemic (grey) conditions. **P< 0.005 relative to control.  4075 
 4076 
 4077 
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Validation of western blot data 4079 
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 4081 
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 4083 
Figure 1 Protein expression analysis of glucose transporter 2 in metformin, 4-hydroxyisoleucine (4-OH-4084 
lle) and fenugreek seed extract (FSE) treated mouse liver (p=0.0067), under normal and hyperglycaemic 4085 
conditions. *P< 0.05 relative to control, **P< 0.05 relative to control 4086 
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Chapter 4: Lipid metabolism  4109 
 4110 
 4111 
Figure 2 Protein expression analysis of proprotein convertase subtilisin/kexin type 9 in metformin, 4-4112 
hydroxyisoleucine (4-OH-lle) and fenugreek seed extract (FSE) treated mouse liver (p=0.0010), under 4113 
normal and hyperglycaemic conditions. *P< 0.05 relative to control, **P< 0.05 relative to control 4114 
 4115 
 4116 
 4117 
Figure 3 Protein expression analysis of peroxisome proliferator-activated receptor gamma in metformin, 4118 
4-hydroxyisoleucine (4-OH-lle) and fenugreek seed extract (FSE) treated mouse liver (p=0.0048), under 4119 
normal and hyperglycaemic conditions. *P< 0.05 relative to control, **P< 0.05 relative to control 4120 
